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Skeletal muscle plays a key role in the metabolic response to injury and
sepsis and in the negative nitrogen balance often associated with these conditions.
The intra-muscular concentration ofglutamine, a "non-essential" amino acid, shows
a marked fall as a result of trauma or surgery and a close relationship has been
demonstrated between muscle protein synthesis and breakdown, and the
intramuscular concentration ofglutamine. Provision of extra glutamine to the post¬
operative patient as the dipeptide L-Alanyl-L-Glutamine (Ala-Gin) results in
improved whole body nitrogen balance. In the present studies the acute effects and
the possible mechanisms of action of this dipeptide on muscle protein balance have
been studied in 15 healthy post-absorptive subjects and in 16 intensive care unit
patients who had undergone major elective abdominal surgery.
Whole body and skeletal muscle protein turnover were investigated using
primed, constant infusions of the stable isotope tracers L-[l-13C]leucine and L-
[lsN]phenylalanine, with determination of plasma leucine-C flux and 13C02
production, assay of L-[l-13C]leucine incorporation into mixed anterior tibial muscle
protein sampled by biopsy and arteriovenous forearm exchange of L-
[15N Iphenylalanine with net release of 3-methylhistidine from forearm tissues to
assess muscle mixed protein turnover and myofibrillar protein breakdown
respectively.
Parenteral administration of the dipeptide Ala-Gin increased plasma and
intramuscular glutamine concentrations in healthy subjects and in post-operative
patients. In healthy postabsorptive subjects, mixed muscle protein synthesis was
increased with 110 significant effect on mixed muscle protein breakdown or on
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whole-body protein turnover, although small reductions were observed in whole-
body flux of leucine and phenylalanine. The increased glutamine availability in
muscle per se appeared to stimulate muscle protein synthesis, calculated on the
basis of the enrichments of plasma a-ketoisocaproate. Since Ala-Gin infusion does
not appear to alter whole-body protein turnover it is likely that in the absence of
availability of dietary amino acids, skeletal muscle protein synthesis is increased
by glutamine at the expense of non-muscle protein, as the muscle free amino acid
pool could not sustain such an increase for more than a few minutes.
In post-operative patients receiving a standard non-glutamine containing
amino acid mixture used in conventional total parenteral nutrition (TPN), short-
term Ala-Gin supplementation acutely increased mixed muscle protein synthesis,
as determined by L-[l-13C]leucine incorporation into M. tibialis anterior and by L-
[15NJphenylalanine arteriovenous forearm exchange, although the absolute values
observed for protein synthesis were lower than in the post-absorptive healthy
subjects. There was no significant effect of Ala-Gin dipeptide supplementation on
muscle protein breakdown, or whole-body kinetics although the whole-body flux of
both leucine and phenylalanine were slightly lower with Ala-Gin supplementation.
Albumin synthesis was increased by Ala-Gin supplementation.
These results suggest that increased glutamine provision, as the dipeptide
Ala-Gin, has a small anabolic effect on skeletal muscle in healthy post-absorptive
man. In patients undergoing major elective surgery, short-term glutamine
dipeptide supplementation of conventional TPN results in a marked acute anabolic
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1.1 Early Observations of Injury in Man
The danger of injury, either of an accidental nature or that inflicted
deliberately, has always been present in man's environment and methods for
treating the wounded probably have a history as long as that of mankind.
However, attempts to understand the mechanisms by which critical illness
produced tissue loss were only begun in the nineteenth century and detailed
investigations were not undertaken till the third decade of the present century. In
1887 Bernard (Burns, 1988) noted that haemorrhage caused a rise in blood sugar,
and shortly after this in 1899 Crile (Burns, 1988) published an experimental study
of shock, in which for the first time, arterial vasoconstriction and consequent
reduced tissue perfusion was identified as a common feature of injury. Evidence
to link the circulatory abnormality with a metabolic lesion was produced by Cannon
and Bayliss in 1919 (Burns, 1988) who used the Van Slyke apparatus to show that
fixed acids (such as lactic acid) accumulated in the blood of soldiers with low blood
pressure. In 1918 Dale and Richards (Burns, 1988) were studying the effects of
tourniquet removal from injured limbs. They noted an improved survival if
amputation was carried out before the tourniquet was removed and they concluded
from this that a major factor in injury was the release of toxic materials into the
systemic circulation from the wound.
Although increased losses of urinary nitrogen in man had been observed
during disease and following trauma by Vogel in 1884 and by Malcolm in 1893,
respectively (Clague, 1981), the implication of this loss for protein metabolism only
became apparent in the nineteen thirties. Cuthbertson (1932), from simple
observations and careful analyses on injured individuals, was able to characterise
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the major sources and composition of this nitrogen loss. He and his colleagues
found that the metabolic response to injury appeared to be subdivided into two
phases, described as 'ebb' and 'flow', the latter being associated with increased
metabolism and the net loss of nitrogen from the body (Cuthbertson, 1942). This
loss appeared to be related to the severity of the injury (Cuthbertson, 1932), the age
of the patient (Cuthbertson, 1932), the pre-injury nutritional status of the
individual (Calloway et al., 1955) and nutritional intake following trauma
(Cuthbertson, 1936). Administration of extracts of endocrine glands (Cuthbertson
et al., 1942) or hormonal involvement (Johnston, 1967) could also modify the
nitrogen loss, which was thought to arise from increased muscle protein catabolism
(Cuthbertson, 1930). The metabolic response to trauma and the factors which
modulate its extent are discussed later in this chapter.
1.2 Early observations on the relationship between injury and nutrition
In 1936, Studley described the effect of antecedent malnutrition upon the
outcome of (surgical) injury: in patients undergoing surgery for peptic ulcer, those
who had lost a substantial amount of weight pre-operatively had a much higher
mortality than those of normal weight (Allison, 1986). In 1945 Munro and
Chalmers (Munro and Chalmers, 1945) published a study on rats, describing the
metabolic response to fracture at different levels of protein intake. The animals
were divided into three groups: one group was given a high protein intake; a second
group was given a low protein intake and a third group was given a protein-free
diet for 12 days before being subjected to fracture of the hind limb. The rise in
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nitrogen excretion post injury was less as protein intake fell. That this difference
depended upon the food intake before the fracture was shown by a second study in
which the low and high protein intake groups were switched at the time of fracture.
Their nitrogen excretion still did not reach that of the group which had been given
the high protein intake throughout.
These early observations have provided insight into the relationship between
injury and nutritional state. More recent research has been directed towards three
major issues: firstly, variations in the metabolic response under different conditions
and identification of the mediators which control the metabolic response; secondly,
a better understanding of the abnormal protein metabolism seen after injury with
exploration of the possibilities for its modulation if this were demonstrated to be
desirable; thirdly, a clearer understanding of the type and quantity of energy
required by stressed individuals. Consideration of the first and second of these
areas forms the basis for the remaining part of this chapter.
1.3 The metabolic response to trauma
1.3.1 Introduction
Of the two main phases of the metabolic response to injury (Cuthbertson,
1930; Table 1.1) the early ebb phase is characterised by hypovolaemia and
subsequent sympathetic and adrenal response, whilst during the later flow phase
the injury results in loss of protein at an accelerated rate.
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1.3.1.1 The ebb phase
Hypovolaemia, characterised in the clinical situation by a patient who is
pale, clammy and tachycardic, plays a major role in the ebb phase which lasts until
circulating volume is restored. The importance of the brain in the generation of the
early endocrine response to injury has been demonstrated by Hume and Egdahl
Table 1.1. Metabolic response to Injury - ebb and flow phases, (after
Cuthbertson).
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(Hume and Egdahl, 1959). In an experiment in which they disconnected a limb
from the body of an anaesthetised animal, leaving only the sciatic nerve and the
femoral vessels, the level of corticosteroids in adrenal venous blood was found to
rise immediately in response to a burn injury to the isolated limb. This response
did not occur when the sciatic nerve was divided. Hume and Egdahl also
demonstrated that the early hormonal response to injury did not occur unless the
central nervous system was intact. Thus pain, hypovolaemia, acidosis and hypoxia
initiate the neural afferent signals to the brain and after processing in the
hypothalamus, leads to increased activity of the sympatho-adrenal system which
is accompanied by release of adrenocorticotrophic hormone (ACTH) and growth
hormone (GH) from the anterior pituitary and anti-diuretic hormone (ADH) from
the posterior pituitary. ACTH release results in a rise in plasma Cortisol and the
renin-angiotensin system is activated (Hill, 1992). The resulting vasoconstriction
decreases renal blood flow, glomerular filtration rate, sodium excretion (hence
sodium and water retention) and urine production. Fluid retention extends beyond
the ebb phase but diuresis occurs within the first 72 hours in most cases. Plasma
insulin levels may be variable but they are relatively low in relation to the usually
high glucose concentration.
1.3.1.2 The flow phase
The duration of the flow phase is proportional to the severity of the injury
and it is followed by a third, anabolic, phase during which the protein and energy
stores lost in the early post-injury period begin to be repleted. The flow phase is
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characterised by degradation of muscle protein to release amino acids such as
glutamine and alanine. The later amino acid in particular undergoes de-amination
and through the process of gluconeogenesis supplies glucose which is essential for
the brain and healing tissues in particular. In severely injured patients and in
severe sepsis the flow phase is associated with an increased metabolic rate but the
rise is small or negligible in patients undergoing elective surgical procedures (Hill,
1992). The patient's energy requirements during this phase are mostly met by fat
oxidation. The plasma concentrations of the counter regulatory stress hormones
glucagon, catecholamines and Cortisol fall during this period. The plasma insulin
concentration rises during the flow phase to reach its maximum value.
Paradoxically loss of lean tissue is also maximal at this time and the apparent
resistance to the usual anabolic effects of insulin are poorly understood.
1.3.2 Cytokines and the metabolic response to trauma
Recent studies have highlighted the possible role of cytokines or cell
mediators released from the site of the wound (Fong and Lowry, 1990). These may
have local as well as systemic effects. Interleukin-1, interleukin-2, interleukin-6,
tumour necrosis factor (TNF) and interferon y are important mediators of the
integrated metabolic response (Cruickshank et al., 1990). At least two of these
cytokines, TNF and interleukin-2, are post-inflammatory circulating signals that
are probably involved in the metabolic response in serious sepsis. Endotoxin, a
lipopolysaccharide found on the cell wall of gram-negative bacteria, is a potent
stimulus for the production of TNF. TNF infusion replicates many of the clinical
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and metabolic features of sepsis, including fever, hypotension, anorexia,
hyperglycaemia and a negative nitrogen balance (Tracey et al., 1986; Michie et al.,
1988a, 1988b, 1988c and 1990). Its effects also include muscle proteolysis,
increased amino acid uptake by the liver and increased lipolysis. Interleukin-1 has
been called proteolysis inducing factor and also is a principal inducer of acute
phase protein synthesis. Interleukin-2 and interleukin-6, in addition to their
metabolic effects are also stimulators of the immune system. Interleukin-2 is a
growth factor for activated T cells and it activates cytotoxic T cells. Interleukin-6
plays a role in the differentiation of B cells into plasma cells, T cell activation and
is a growth factor for eosinophils (Flechner, 1994).
1.4 Neuroendocrine Responses to Injury
1.4.1 The Afferent Limb of the Neuroendocrine Response to Injury
It is well established that the neuroendocrine response to sepsis and trauma
effects many of the observed changes in metabolism (Figure 1.1). Trauma in all its
forms may result in activation of a number of different afferent pathways. The
neuroendocrine response to trauma can be blocked by division of the nerves to the
area being traumatised. Conscious perception of pain is not necessary for this
neuroendocrine response but the central nervous connections to the hypothalamus
are essential (Hume and Egdahl, 1959). Although reception of pain at the site of
injury and afferent impulses related to changes in effective circulating blood volume
play the overriding roles in the early neuroendocrine response to trauma, as injury
12
Figure 1.1 An overview of the important hormonal regulatory factors in the
regulation of metabolism in septic and injured patients. FFA = free
fatty acids. (Adapted from Douglas and Shaw, 1989)
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progresses, other stimuli such as acidosis, hypoxia, hypercapnia, changes in body
temperature as well as the release of local factors from injured tissues may all
contribute to the overall response.
1.4.2 The Efferent Limb of the Neuroendocrine Response to Injury
The best known neuroendocrine response to injury is the increase in ACTH
secretion and the resultant increase in adrenocortical secretion of glucocorticoid
hormones (Ganong, 1986). The mechanism by which increased plasma
glucocorticoids exert a protective effect is still poorly understood, although the
increase is clearly important, for in its absence the level of tolerance to stress is
reduced and relatively mild noxious stimuli can lead to death (Ganong, 1983a,
1983b). Sympathetic output is also increased by injury resulting in stimulation of
an increased output of adrenal medullary hormones. It has been postulated that
one of the reasons why the increase in glucocorticoid secretion can be life-
preserving is that it maintains the responsiveness of vascular smooth muscle to the
constrictor action of catecholamines (Ramey and Goldstein, 1957). This hypothesis
has not been proven however. Stressful stimuli, in particular any significant
decrease in extracellular fluid volume, also stimulate the secretion of vasopressin
(Ganong, 1983a, 1983b). Vasopressin contributes to the maintenance of
extracellular fluid volume by retaining water although this contribution is modest
since up to two-thirds of the retained water enters cells. Vasopressin also produces
vasoconstriction. Many stressful stimuli also increase circulating glucagon levels
by stimulation of the sympathetic nerves to the pancreas and the (3-adrenergic
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receptors in the pancreatic islet cells (Unger and Orci, 1981).
1.5 Factors Modifying the Response to Injury
A variety of factors may modify the endocrine-metabolic response to trauma
and some have relevance in the clinical situation.
1.5.1 General Anaesthesia
Although general anaesthesia limits the immediate perception of injury, the
processing of noxious stimuli to the hypothalamus is not interrupted, thus there is
no significant alteration of the stress response (Oyama, 1983).
1.5.2 Afferent Neurogenic Blockade: Regional Anaesthesia
In 1910, Crile (cited by Kehlet and Schulze, 1986) demonstrated that
blockage of nociceptive stimuli by a peripheral nerve block may ameliorate the
response to injury and further evidence for this was provided in a series of studies
by Hume and Egdahl (Hume and Egdahl, 1959) demonstrating the importance of
the central nervous system in mediating the adrenocortical response to injury. In
recent years a number of studies have shown that blockage of afferent neurogenic
stimuli by regional anaesthesia (either spinal or epidural) with local anaesthetic
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agents may prevent or attenuate a predominant part of the endocrine-metabolic
response to elective surgical trauma particularly for operations performed on the
lower part of the body, where adequate afferent block was easier to achieve (Kehlet,
1982 and 1984).
1.5.3 Systemic opiate administration
The clinical use of'high'-dose opiate administration is limited because of the
concomitant depression of the respiratory system. The available data strongly
suggest that standard post-operative doses of morphine administered at 4-10 mg
every 4-6 hours or other opiates at equivalent doses have no significant effect on
the stress response (Kehlet, 1986).
1.5.4 Modulation of Anabolic/Catabolic Hormone Ratio
Since the endocrine response to injury is characterised by increased
secretion of catabolically active hormones (catecholamines, Cortisol and glucagon)
and impaired secretion or effect of anabolically acting hormones (insulin,
testosterone) theoretically it would seem possible to counter the net catabolic state
by blocking the action of catecholamines by pharmacological blockade or by
administration of anabolic hormones.
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1.5.5 Alpha-Adrenergic and Beta-Adrenergic Blockade
Administration of the alpha-adrenergic receptor blocker phentolamine has
only minor or no effect on various metabolic responses to surgical stress (Kehlet
and Schulze, 1986). Beta-adrenergic receptor blockade, however, with propranolol
reduced oxygen consumption levels in burns patients (Wilmore et al., 1974) and
following surgical stress, propranolol also reduced the trauma-induced increase in
plasma glucose, lactate and free fatty acids (Tsuji et al., 1980). However, no studies
are available on the influence of adrenergic blockade on the neuro-endocrine
response to elective surgery and on post-operative nitrogen balance.
1.5.6 Insulin
Insulin infusion at doses of 35 to 70 mU/kg/h during gynaecological surgery
caused decreases in plasma glucose, free fatty acids and beta-hydroxybutyrate and
raised blood lactate and growth hormone levels (Hall et al., 1983). Infusion of large
doses of insulin in a mixed group of catabolic patients with pronounced urinary
nitrogen excretion resulted in a significant reduction in the nitrogen loss (Woolfson
et al., 1979).
1.5.7 Growth Hormone
Studies on patients with burn injuries (Wilmore et al., 1974; Soroff et al.,
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1967) as well as studies on post-operative patients (Ponting, 1988; Ward, 1987)
have shown that human growth hormone administration may result in a marked
increase in nitrogen retention. The mechanism, however, of this increased nitrogen
retention is yet unknown (Cameron et al., 1988) although various studies in both
man and in animals have raised the possibility that protein synthesis is increased
indirectly with this action being mediated by insulin-like growth factor 1 (IGF-1)
(Swenne and Hill, 1989; Bates and Holder, 1988; Schwartz, 1982; Fongetal., 1989).
1.5.8 Substrate Administration
Although the influence of nutritional support can alter several aspects of the
response to injury, in general, whereas provision of substrates may improve post-
injury catabolism it does not appear to do so to any major degree and the
fundamental neuro-endocrine and metabolic responses are not prevented (Kehlet
and Schulze, 1986).
1.5.9 Modulating the Response to Severe Injury
When injury is limited, as in uncomplicated elective surgery, the response
is slight and of shorter duration. In major accidental trauma, or in elective surgery
complicated by sepsis and major haemodynamic alterations, the neuroendocrine
response is enhanced and the metabolic effects such as the acute loss of lean tissue
mass may be substantial. Recent advances in molecular biology, in recombinant
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technology, by providing monoclonal antibodies to endotoxin (Ziegler et al., 1991)
and various cytokines such as TNF (Shimamoto et al., 1988), raise the prospect of
effective intervention in and modification of the metabolic response to trauma with
the possibility of realising significant benefits in the clinical field of patients being
treated in intensive therapy units.
1.6 Nitrogen Balance and Protein Turnover
1.6.1 Nitrogen Balance
The chemical measurement of nitrogen in food and excreta allowed
Boussingault to conduct detailed nitrogen studies on farm animals in 1842 (Holmes,
1984). It was almost a century later that Cuthbertson and co-workers
(Cuthbertson, 1932; Howard et al., 1944) and Moore and Ball (1952) demonstrated
that the increase in nitrogen excretion following injuiy was proportional to the
severity of that injury and that most of the extra nitrogen loss was in the form of
urea. Although studies of nitrogen balance give information on the net result of
protein synthesis and breakdown, the nitrogen balance method cannot be used in
assessing whole body protein turnover as no direct information is obtained on the
contributory processes of protein synthesis and protein breakdown (Bender, 1985).
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1.6.2 Proteins and Amino Acids
In a normal man of 70 kg body weight, body protein accounts for
approximately 10-11 kg and of this 1/2 to 2/3 is muscle (Cahill, 1970).
Approximately 45% of total body mass is represented by skeletal muscle (which also
represents 70% of lean body mass) and this tissue is composed of approximately
17% protein. In skeletal muscle 65% of its protein is in the form of the two
proteins of the contractile myofilaments, actin and myosin. Amino acids may be
present in skeletal muscle in either in the free amino acid pool or bound as protein
(Figure 1.2). Intracellular free amino acids are incorporated into protein by
protein synthesis. Amino acids may enter the free pool from the diet, from
breakdown of protein or from de novo synthesis (of the non-essential amino acids).
Skeletal muscle has an important mechanical role in the maintenance of
posture and in movement; it also has a vital metabolic role. Approximately 50%
of the body's free amino acid pool exists in skeletal muscle (Munro, 1970), making
it the largest reservoir of amino acids in the body. These amino acids are available
for a variety of metabolic processes. They may be used as:
1) Substrates for protein synthesis, either locally or in other tissues, and of
albumin and acute phase proteins which are important in the body's response
following injury.
2) Precursors for gluconeogenesis in maintaining glucose homeostasis (Cahill,
1970; Daniel et al., 1977); alanine and glutamine are the main gluconeogenic
amino acids and via the glucose-alanine cycle they effectively transport fuel from




Figure 1.2 Schematic representation of a two pool model of protein turnover.
D = diet; S = synthesis; B = breakdown; O = oxidation
LIVER BLOOD muscle
Figure 1.3 Schematic representation of Glucose - Alanine cycle. Adapted from
Felig, 1975.
21
3) Intermediary metabolites of branched chain amino acids which may act as
substrates for fatty acid synthesis.
4) Certain amino acids may act as substrate for further intermediary
metabolism. Glutamine is used by gut enterocytes in the synthesis of alanine
(Matsutaka et al., 1973), in the kidney for ammoniagenesis (Cahill, 1970) and as
a fuel for white cells and other rapidly turning over cells..
5) Amino acids may also have a buffering role in acid-based alternative e.g.
that occurring in starvation when there is no cation to accompany ketone,
bicarbonate, sulphate and phosphate excretion. Glutamine is metabolised by the
kidney to glutamate and the ammonium ion is excreted in the urine (Pitts et al.,
1965; Golden et al., 1982).
1.6.3 Free Amino Acid Pools and their Significance
Munro (1970) in his review of the role of free amino acids as "the units of
currency" of protein metabolism, has commented on the following features of free
amino acid pools:
1) Free amino acids account for only a small proportion (estimated at between
0.5% -1.0%) of the total amount of amino acids in the body.
2) Free amino-nitrogen is predominantly available in the form of four of the
eight non-essential or dispensable amino acids: alanine, glutamate,
glutamine and glycine.
3) Around 50% of the free pool of each amino acid is present in skeletal muscle
and indeed of all tissues muscle accounts for the largest proportion of the
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body's free pool.
4) The concentrations of the non-essential free amino acids are higher within
cells than in plasma and this would suggest that the concentration
difference is maintained by a concentration mechanism which would be
energy dependent ( e.g. glutamine, using the sodium gradient) or binding-
dependent (e.g. taurine).
5) The relative amounts of the different free amino acids are unrelated to their
relative proportions in the protein bound amino acid pool, as well as to the
known requirements for essential amino acids. Branched chain amino acids
(BCAA) for example account for 20% of protein composition but only 1% of
the free amino acid pool in skeletal muscle.
A number of factors affect the free amino acid pool sizes and these include:
1) Dietary intake, the main factor causing substantial and frequent alterations
in the free amino acid pool.
2) Protein turnover, which does not make any net contribution in steady state
conditions but may contribute in situations where the rates of protein
synthesis and breakdown are not equal in magnitude.
3) Non-essential amino acids are synthesised de novo.
4) Transamination, for example of pyruvate to alanine and the amidation of
glutamate to glutamine are important in the transport of amino-nitrogen
from peripheral tissues (e.g. muscle) to liver (Felig et al., 1969; Felig and
Wahren, 1974). It is likely then that changes in the concentrations of these
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amino acids may reflect predominantly changes in the overall pattern of
amino acid oxidation or of gluconeogenesis.
5) The concentration of amino acids in intracellular pools will be affected by
the activity of the transport systems. For most amino acids the intracellular
concentration is higher than the plasma concentration and the rate of
exchange between intra- and extracellular pools is very rapid. For most
amino acids the turnover time in the intracellular pool is of the order of a
30 minutes to 2 hours.
6) Of all the components of inflow and outflow from the free amino acid pool
it appears that the rates of oxidation and transport are the most closely
regulated.
1.6.4 Amino Acid Patterns
The plasma amino acid concentration in man and the ratios of free to
protein-bound amino acids in rat skeletal muscle are shown in Tables 1.2 and 1.3.
1.6.4.1 The Distribution of Free and Bound Amino Acids
There is no fixed relationship between the pattern of free amino acids in
plasma and those found bound within protein (Munro, 1970) and the ratios for the
essential amino acids vary over a twenty-fold range. When measuring protein
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Histidine 80 370 4.6
Isoleucine 60 110 1.8
Leucine 120 150 1.2
Lysine 180 1150 6.4
Methionine 20 110 5.6
Phenylalanine 50 70 1.4
Threonine 150 1030 6.8
Valine 220 260 1.2
Dispensable
Alanine 330 2340 7.3
Arginine 80 510 6.5
Asparagine 50 470 9.5
Citrulline 30 40 1.6
Cysteine 110 180 1.6
Glutamate 60 4380 74
Glutamine 570 19450 34
Glycine 210 1330 6.5
Ornithine 60 3000 5.1
Proline 170 830 4.9
Serine 120 980 6.9
Taurine 70 15440 220
Tyrosine 50 100 2.0
*Bergstrom et al., 1974.
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Table 1.3. Bound and Free Amino Acid Concentrations in Rat Muscle*.
Protein Free Ratio
(/xmol/g net weight) (Protein/Free)
Indispensable
Histidine 26 0.39 67
Isoleucine 50 0.16 306
Leucine 109 0.20 556
Lysine 58 1.86 31
Methionine 36 0.16 225
Phenylalanine 45 0.07 646
Threonine 60 1.94 31
Valine 83 0.31 272
Dispensable
Alanine 111 2.77 40
Arginine 67 0.25 269
Aspartate (+amide) 110 1.13 97
Glutamate (+amide) 148 9.91 15
Glycine 117 1.94 60
Serine 74 1.96 38
Tyrosine 36 0.14 226
*Fern, 1975.
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synthesis, this difference in composition between the free and bound pools has to
be considered: the free amino acid pool cannot be treated as a whole when using
a precursor pool to make calculations for protein synthesis. The amino acids used
for protein synthesis represent a selection of those in the free pool. During protein
synthesis the relative amounts of the amino acids used may vary markedly from
their relative distribution in the free pool. The differences in the patterns between
the free and the bound pool are maintained by a number of mechanisms. The
pattern of amino acids in a balanced diet is broadly similar to that in tissue
proteins and hence similar to the amino acid mixture being synthesised or derived
from it by its breakdown. In this situation the different pattern that can arise in
the free amino acid pool is likely to be due to differences in the relative rates of
disposal by oxidation or due to differences in transmembrane transport between
amino acids. Because of the values of their Michaelis constants, which are
relatively high, the activity of the oxidative enzymes is sensitive to substrate
concentration (Krebs, 1972). Therefore, if a substrate has a high steady state
concentration, e.g. lysine or threonine, this means that the activity of its oxidative
system must be relatively low. The under-representation of the branched chain
amino acids in the free amino acid pool may be explained by the high activity of
their oxidative enzymes.
1.6.4.2 Diet and the Free Amino Acid Pool
Diets which are deficient in protein can result in a reduction in the plasma
concentration of essential amino acids of up to 50% and this is accompanied by
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rises of a similar order in the concentration of the non-essential amino acids
(Lunn,1976). Starvation however produces changes in the plasma amino acid profile
which are opposite to protein deficiency with increases in the concentrations of the
essential amino acids and decreases in the concentrations of the non-essential
amino acids. The surprising rise in the concentrations of the essential amino acids
may be explained by their reduced uptake into protein and increased release from
protein breakdown (Millward et al., 1974). In man, the branched-chain amino acids
are particularly sensitive to dietary influence, showing the maximal fall amongst
all amino acids in response to protein deficiency and the greatest rise in their
concentration in muscle in response to fasting.
1.6.4.3 The Dynamic Behaviour of the Free Amino Acid Pool:
Turnover Rate
In the rat, the free amino acid pool has been calculated to turn over about
once every hour (Munro, 1970). In man, however, the total free essential amino
acid pool is smaller than its equivalent in the rat. It also turns over much more
slowly (Bergstrdm et al., 1974). There are differences in the turnover rates of
individual amino acids in man e.g. the half life of leucine is approximately 45
minutes and that of lysine 10 hours.
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1.6.4.4 Uptake of Amino Acids from the Free Amino Acid Pool
In man, the rate of uptake of most amino acids into muscle is proportional
to their concentration in plasma (Banos et al., 1973; Lundholm et al., 1987). If
cardiac output in adult man is assumed to be 5 1/min and only free amino acids in
plasma are taken into account (i.e. ignoring amino acids in red cells) then the total
amount of amino acids circulated to the tissues is of the order of 100 mmol/kg/day.
This is approximately 8 times the rate at which these amino acids are taken up
into protein. In certain situations however there may be a smaller margin of
safety. For instance it is possible that amino acid delivery might limit rates of
protein synthesis in man with the amino acid having the smallest ratio of delivery
to incorporation into protein possibly constraining protein synthesis under
conditions of high amino acid demand e.g. during growth spurts or periods of tissue
repair after injury, particularly if dietary amino acid intake was concurrently
reduced. Taking leucine as an example, the concentration of which in blood is 0.12
mmol/1, if blood flow to total body muscle is approximately 1 1/min and protein
synthetic rate is approximately 1.5%/day (Halliday et al., 1988) then the total blood
leucine delivery (170 mmol) is about 3.4 times the total amount of leucine which
is incorporated into protein daily. It seems possible therefore that under certain
conditions of low protein intake, catch-up growth or repair following injury, the
supply of amino acids to a tissue might limit the rate of protein synthesis. If
similar calculations to that used in the example for leucine are applied to the
branched chain amino acids, histidine, methionine and glutamate, it can be
calculated that during tissue repair following injury these amino acids may also
limit the rate of protein synthesis.
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1.6.4.5 Concept of Protein Turnover
The term turnover is used to describe the process of renewal or replacement
of a given substance. The process itself may involve the production of newly formed
material, with the disappearance of some material already present, or it may
represent the exchange of material between two or more compartments. Whole
body protein turnover is the overall rate at which protein is synthesised or broken
down in the body and is the sum of all the individual proteins over the full range
from the fastest to the slowest. Generally smaller animals have higher rates of
protein turnover per kg body weight and within the same species the young of the
species have a higher rate than the old (Young et al., 1975). In the steady state,
protein synthesis and breakdown are equal and nitrogen balance is zero.
1.6.4.6 Methods of Assessing Protein Turnover
The main methods used in assessing protein turnover are:
1. 3-Methylhistidine: a) Assessment of the loss of this amino acid in urine and
thereby expression as the ratio of 3-methylhistidine/creatinine, is an index
of total myofibrillar protein breakdown in the whole-body (Ballard and
Tomas, 1983). b) 3-Methylhistidine release from peripheral tissues (of
forearm and leg), when measured and calculated as the product of the
arteriovenous difference and blood flow, may be a more specific way to
assess skeletal muscle myofibrillar protein breakdown (Rennie and
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Figure 1.4 Schematic representation of the exponential decay of specific activity
over time after administration of a single dose of a radioactive tracer.
Millward, 1983a).
3. Use of a single dose of an isotope labelled amino acid to assess turnover or
flux of the amino acid pool from the rate of dilution of the tracer (Figure
1.4); Henriques et al., 1955).
4. Estimation of protein turnover from dilution of [15N] in the end products of
metabolism i.e. in urea and ammonia, from labelled non-essential amino
acids such as [15N]glycine (Sprinson and Rittenberg, 1949; Olesen et al.,
1954).
5. Continuous infusion of a labelled amino acid to assess the flux or turnover
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of the amino acid in the free amino acid pool (Figure 1.5). (O'Keefe et al.,
1974; Matthews et al. 1980; Clarke and Bier, 1982).
5. Techniques using incorporation of labelled free amino acids into the protein-
bound amino acid pool within plasma or tissues in vitro or in vivo
(Schoenheimer et al., 1942; Halliday and McKeron, 1975; Rennie et al.,
1982a, 1982b).
6. The so-called 'flooding-dose' technique with the use of a single dose of tracer
combined with a large dose of non-labelled amino acid to flood the free
amino acid pool and thus label the intracellular amino acid pool
compartments with tracer to a similar extent as the accessible amino acid
in plasma (Garlick et al., 1989).
7. Use of techniques where arteriovenous phenylalanine tracer exchange is
measured simultaneously with amino acid balance to assess skeletal muscle
protein breakdown and synthesis (Gelfand and Barrett, 1987; Thomson et
al., 1989).
8. Measurement of tissue ribosome content to assess the capacity for protein
synthesis (Millward et al., 1973) or measurement of tissue polyribosomal
profile in biopsy samples to assess translational activity (Hammarqvist et
al., 1988; Wernerman et al., 1989). Both of these methods are indirect
assessments of protein synthesis.
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Figure 1.5 The upper panel shows a schematic representation of a continuous
infusion of a stable isotope labelled tracer. The lower panel shows
the incorporation of the tracer into muscle protein.
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1.7 Lean Body Mass: Maintenance, Growth and Wasting
1.7.1 Mechanisms of Growth in Lean Tissues
Growth occurs in lean tissues when the rate of protein synthesis exceeds the
rate of protein breakdown. In muscle, growth can be associated with increased
turnover where rates of protein synthesis and breakdown are both elevated but the
increase in the rate of protein synthesis is greater than that of the rate of protein
breakdown compared to the basal state (Figure 1.6).
1. During the rapid growth periods of immature animals, the rates of protein
breakdown are greater than those of adults of the species (Millward, 1980a;
Millward, 1980b). This increase in the rates of protein breakdown in the
muscles of immature animals may be related to remodelling of the tissue
(Millward, 1975; Maruyama, 1978).
2. An increase in protein breakdown can also occur in muscular hypertrophy
e.g. in cardiac muscle related to disease conditions such as systemic
hypertension and aortic stenosis, where there are increases in both protein
synthesis and breakdown (Gudbjarnason et al., 1964; Zak and Fischman,
1971).
3. During refeeding and recovery from malnourishment, studies in rats have
shown that there are increases in protein synthesis and breakdown (Young
et al., 1971).
It appears that most forms of rapid growth in skeletal muscle are
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Figure 1.6 Different patterns of muscle protein synthesis and breakdown
associated with a variety of conditions affecting muscle growth and
wasting.
associated with increases in protein breakdown. Tissue growth can also be
associated with a fall in the rate of protein breakdown. This has been
demonstrated in a rapidly growing strain of rat (Bates and Millward, 1978).
1.7.2 Mechanisms of Wasting in Lean Tissues
For wasting to occur in lean tissue, an imbalance must exist such that the
rate of protein breakdown exceeds the rate of protein synthesis and theoretically
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this situation may arise with differing combinations of changes in either process
(Figure 1.6). The idea of facilitative and adaptive responses in protein synthesis
and breakdown has been proposed by Millward and colleagues to explain the
different patterns of turnover (Millward et al., 1976; Rennie et al., 1983b). In
skeletal muscle for example, changes in protein mass may occur with alterations
in synthesis in an appropriate (i.e. the same) direction but with apparently
paradoxical changes in breakdown which would counteract the effect of the change
in synthesis. This situation occurs in starvation where the rates both of synthesis
and breakdown fall (Millward and Waterlow, 1978) or in hypertrophy induced by
work where they both increase (Laurent et al., 1978b). Millward has described
these changes as facilitative as they promote the modulation of muscle mass and
the changes in breakdown as adaptive as they limit the modulation process. In
skeletal and cardiac muscle it is synthesis which is regulated in physiological states
and possibly also in pathological states (i.e. facilitative). In other tissues such as
liver and gut breakdown appears to be facilitative (Garlick et al., 1973; Emeiy et
al., 1986).
Although there is no full picture of the abnormalities of protein synthesis
and breakdown occurring in different pathophysiological situations where muscle
wasting occurs in man, there is information available on the patterns of protein
turnover in muscle in a number of specific conditions. In patients suffering from
cardiac cachexia, for instance, muscle protein breakdown is increased (Morrison et
al., 1988a). However, in other conditions involving muscle wasting, muscle protein
breakdown is not increased and wasting occurs as a result of a decrease in protein
synthesis. This situation arises for example on the first postoperative day in
patients who have undergone abdominal surgery (Rennie et al., 1984); in patients
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SITES OF CHANGES SYNTHESIS BREAKDOWN
IN PROTEIN MASS
1. Muscle ^ \l/ *
2. Liver Tissue = *
3. Liver export *
4. Viscera *
Figure 1.7 Hypothetical contribution of different tissues to whole-
body protein turnover (after Rennie, 1985).
with Duchenne muscular dystrophy (Rennie et al., 1982a) and myotonic muscular
dystrophy (Halliday et al., 1985); in patients with thyrotoxicosis (Morrison et al.,
1988b) and in patients with emphysema (Morrison, et al., 1988a). In cachectic
cancer patients muscle wasting is associated with a reduction in protein synthesis
and also an accompanying reduction in muscle protein breakdown (Lundholm et al.,
1982).
There is only limited information available for man on the contributions of
various tissues to whole body protein turnover. Muscle probably contributes
around 25-50% of whole body protein turnover in man (Munro, 1970; Rennie et al.,
1982b), with the lower figure of 25%, calculated with amended technology
(Halliday, 1988) likely to be the better estimate than the earlier suggested figure
of 50%. As shown in Figure 1.7, hypothetical simultaneous changes may occur in
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different tissues which could be interpreted as an alteration in whole body protein
turnover as measured by plasma amino acid flux. It can also be seen that a rise
in liver turnover such as that which occurs during stress and following injury may
be sufficient to counteract or swamp changes in the opposite direction in muscle
when whole body turnover is measured, since liver turnover is more rapid than
skeletal muscle (Sakamoto et al., 1983; Emery et al., 1984). The identification of
the mechanisms involved in tissue wasting is not purely an academic exercise since
it should provide knowledge for future rational therapeutic intervention for chronic
wasting conditions (Rennie and Harrison, 1984).
Although physiologically important regulatory processes may adjust
homeostatically, there may also be catastrophic unphysiological changes which may
be produced by various humoral agents (Wilmore et al., 1974; Rodemann and
Goldberg, 1982; Wilmore et al., 1983), neural influences or their lack (Denny-
Brown, 1960; Aftinge7 al., 1981), toxins (Powanda, 1977) and cell-mediated factors
(Baracos et al., 1983). These factors may be particularly important in sudden acute
conditions of wasting rather than chronic. In addition to pathophysiological
modulation of the normal mechanisms of protein turnover i.e., synthesis and
breakdown, there are two additional processes of considerable importance for the
response of lean tissue to disease and injury. These are:
a) Impaired amino acid transport in muscle causing loss of the normal gradient
of amino acids between muscle and plasma and loss of the normal
concentrative function of amino acid transport in muscle (Wannemacher et
al., 1971; Banos et al., 1973; Muhlbacher et al., 1984).
b) Destructive processes resulting in breaching of the cell membrane, influx of
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calcium and phagocytic attack (Jackson et al., 1984). These processes are
more likely to be important during acute changes due to sepsis and trauma
but may also contribute to chronic wasting.
1.7.3 Physiological and Pathophysiological Modulation of Protein
Turnover
1.7.3.1 The Effects of Feeding and Fasting
A net uptake of amino acids occurs during feeding and a net release occurs
during fasting (.Elia and Livesey, 1983). Studies of incorporation of[l-i:iC|leucine
into quadriceps muscle in healthy man show that protein synthesis is greater
during feeding than during fasting (Rennie et al., 1982b; Halliday et al., 1988).
Similar results have also been obtained by in vivo studies in man using exchange
of [l-13C,I5N]leucine by forearm tissues (Cheng et al., 1985; Cheng et al., 1987).
These studies also showed that feeding resulted in an increase in leucine
deamination, reamination and oxidation and improved the net balance between
synthesis and breakdown but the results suggested that feeding had no effect on
the rate of mixed muscle protein breakdown. The lack of any effect of feeding on
muscle protein breakdown has also been demonstrated in studies of myofibrillar
protein breakdown, as assessed by the limb release of 3-methylhistidine, during
parenteral feeding (Tracey et al., 1988). The muscle biopsy and arteriovenous limb-
exchange based techniques are disadvantaged in theory by the possibility that
changes in the plasma concentration of the amino acid tracee, leucine, which occur
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during feeding might alter the tracer equilibrium between the accessible plasma
pool and that at the site of incorporation of precursor for protein synthesis within
cells. Increases in amino acid transport occurring at increased amino acid
concentration (Lundholm et al., 1987) result in increased tracer and tracee
exchange between plasma and the intracellular pool (Layman and Wolfe, 1987) and
a closer approximation by the plasma enrichment to the intracellular enrichment.
Estimates of intracellular amino acid metabolism during postabsorptive conditions,
tend therefore to be underestimated when the plasma amino acid enrichment or
specific activity is used as a basis for calculations but underestimated to a lesser
extent during feeding. It also follows that the tracer dilution technique used in
most studies tends to overestimate the increases in protein synthesis during
feeding. Where the keto acid of leucine, a-ketoisocaproic acid (uKIC), a measure
of intracellular labelling (Matthews et al., 1982; Schwenk et al., 1985a; Layman and
Wolfe, 1987; Horber et al., 1989), was used to define precursor pool enrichment in
the biopsy-based studies (Rennie etal., 1982b; Halliday et al., 1988), overestimation
of the effects of feeding on protein synthesis would occur to a much lesser extent.
Garlick and co-workers, using a flooding dose technique in an attempt to
minimise the differences in tracer enrichment between the plasma compartment
and the precursor pool for protein synthesis within the cell and thereby reduce the
uncertainty about precursor labelling, have reported higher fractional protein
synthesis rates in skeletal muscle in man (Garlick et al., 1989) than Halliday and
colleagues (Halliday et al., 1988). Garlick and colleagues found no significant effect
of feeding on muscle protein synthesis in man using the flooding dose technique
(Essen, 1991). It is possible that this discrepancy in the result obtained by the
flooding dose technique compared with the stimulation in protein synthesis seen
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with feeding when using the primed constant infusion method may be explained by
some independent effect, perhaps stimulatory (Buse, 1975; Tischler, 1982; Smith
et al., 1992), which the administration of large doses of leucine may have on protein
synthesis during these studies and which may mask any acute effects of feeding.
Mixed feeding has been shown to increase whole-body protein synthesis in
man by a number of authors (Garlick et al., 1980; Motil et al., 1981a; Motil et al.,
1981b; Clugston and Garlick, 1982; Rennie et al., 1982b; Clague et al., 1983;
McNurlan et al., 1987), although not by all (Young et al., 1987; Beaufrere et al.,
1989). Most of these authors have also reported a reduction in whole-body protein
breakdown with feeding (Motil et al., 1981a; Motil et al., 1981b; Clugston and
Garlick, 1982; Young et al., 1987; Tracey et al., 1988; Beaufrere et al., 1989) but
some authors reported no effect (Garlick et al., 1980 ; Rennie et al., 1982b; Clague
et al., 1983; Young et al., 1987). In some of these studies it is possible that
significant errors may have occurred because of the recycling of tracer. This
problem can lead to an underestimation of protein synthesis where synthesis was
measured sequentially following a period of fasting during prolonged tracer infusion
(Schwenk et al., 1985b). Failure to take into account metabolism of ingested
leucine or protein by gut and liver generally results in overestimates of the
reduction in protein breakdown during feeding. Prolonged fasting for a period of
four days has been shown to increase whole-body leucine flux or proteolysis (Jensen
et al., 1988) and to reduce skeletal muscle protein synthesis in man (Essen et al.,
1989). The effect of fasting in the long term is to reduce protein utilization as a
source of substrate for gluconeogenesis but such changes take about a week to
become apparent (Kettelhut et al., 1988).
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1.7.3.2 The Effect of Amino Acids
When mixed amino acids are infused in man, a net increased amino acid
uptake has been demonstrated in leg tissues and the splanchnic bed with estimated
uptake of the infused amino acid load being 25-30% and 65-70% respectively
(Gelfand et al., 1986). No account was taken in this study of release of keto-acids
and amino acid metabolites. Infusion of mixed amino acids has been reported to
increase whole-body protein synthesis (Castellino et al., 1987; Tessari et al., 1987;
Pacy et al., 1988a) although there is no consensus on the effect of mixed amino acid
infusion on whole-body protein breakdown. Two studies have demonstrated a
decrease in the latter and no change was reported in one study in which use was
made of a different kinetic model i.e. a double primary pool as opposed to a
reciprocal-pool model (Tessari et al., 1987). Infusion of branched-chain amino acids
was shown to have no effect on either net leg protein balance or myofibrillar
protein breakdown in healthy subjects and in patients with cardiac cachexia
(Morrison et al., 1988a). Branched-chain amino acids also had no effect on protein
synthesis assessed by ribosomal profile in man (Hammarqvist etal., 1988; Eriksson
et al., 1983), although paradoxically leucine injection is reported to increase the
proportion of muscle ribosomes as polyribosomes in fasted rats (Buse et al., 1979).
In in vitro studies on human muscle, a ten-fold increase in amino acid
concentrations alone resulted in an increase in protein synthesis (Lundholm and
Schersten, 1977). Also, complete mixtures of amino acids are reported to enhance
protein synthesis in cell-free systems (Tyobeka and Manchester, 1985). Leucine is
reported to stimulate rat muscle protein synthesis in vitro (Buse and Reid, 1975).
It is possible that the branched-chain amino acids and particularly leucine are
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responsible for the effect of amino acid mixtures on stimulation of muscle protein
synthesis and of reductions in muscle protein breakdown (Buse and Reid, 1975;
Fulks et al., 1975; Li and Jefferson, 1978; Adibi, 1980; May and Buse, 1989). The
mechanism or mechanisms by which such effects are mediated are not known as
the km for the charging of £RNA is likely to be much lower than the intracellular
concentration of amino acids so that the £RNA is always fully charged (Shenoy and
Roger, 1978; Flaim et al., 1982a, 1982b; Tyobeka and Manchester, 1985). The
observation of a reduction in ribosomal subunits during provision ofbranched-chain
amino acids (Li and Jefferson, 1978; Buse et al., 1979) appears to indicate an effect
of amino acids on the initiation of protein synthesis. In addition to an increase in
muscle protein synthesis, in vitro studies in rats demonstrate that mixtures of
amino acids reduce muscle protein breakdown (Fulks et al., 1975; Frayn and
Maycock, 1979).
1.7.3.3 Effects of Substrates
There is little information on the effects of different substrates on protein
turnover in man. Glucose infusion at a rate of 4 mg/kg/min is reported to reduce
whole-body protein breakdown in healthy man with no effect on protein synthesis
(Robert et al., 1984). In addition increases in plasma glucose and insulin
concentrations, there was a trend toward a fall in glucagon concentrations, so that
it is possible the effects of glucose provision were mediated indirectly by such
alterations in hormone levels. In another study, feeding large doses of energy
nutrients of either carbohydrate, fat or a mixture of both improved nitrogen balance
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and decreased leucine oxidation (Motil et al., 1981b). These induced a reduction in
protein breakdown but no alteration in protein synthesis. Experiments with rat
muscle in vitro have shown that low concentrations of glucose in the perfusing
media results in increased leucine oxidation compared to a period of glucose
replacement (Buse et al., 1972) and glucose alone has been reported to increase
muscle protein synthesis (Hedden and Buse, 1982).
The ketone body (3-hydroxybutyrate has been suggested to increase muscle
and whole-body protein synthesis and to reduce whole-body leucine oxidation in
man (Nair et al., 1988b). It is possible that these effects in fact resulted from
changes in acid-base homeostasis, a factor shown to have effects on protein
turnover and amino acid oxidation in dogs (Rodriguez et al., 1989). There is no
apparent effect of (3-hydroxybutyrate on whole-body protein breakdown (Miles et al.,
1983; Nair et al., 1988b).
Infusion of medium-chain triglycerides and long-chain triglycerides in man
improves the net amino acid balance across forearm suggesting either increased
protein synthesis or reduced proteolysis of skeletal muscle (Wicklmayr et al., 1987).
Increases in plasma fatty acid concentrations in dogs reduced whole-body leucine
flux and leucine oxidation and tended to reduce whole-body protein synthesis
(Tessari et al., 1986). Conversely, decreased plasma free fatty acid concentrations
increased whole-body leucine flux and oxidation and decreased whole-body protein
synthesis (Tessari et al., 1986).
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1.7.3.4 The Effect of Hormones
Information on the effect of hormones on protein turnover is relatively
sparse. The effects of insulin on protein turnover have been studied for some time.
Insulin acts on a membrane receptor which possesses intrinsic tyrosine kinase
activity (Kahn and White, 1988). The events within the cell which occur after
insulin binds are not clearly established but appear to result from phosphorylation
of intermediates. In young animals, provision of insulin stimulated muscle protein
synthesis (Jefferson, 1980; Kimball and Jefferson, 1988). This stimulation could
only be observed in vitro when substantial concentrations of amino acids were
made available in the incubation medium. In sheep, insulin alone did not
stimulate muscle protein synthesis (Oddy et al., 1987. Muscle protein breakdown
has been shown to be sensitive to insulin (Gelfand and Barrett, 1987; Bennet et al.,
1988; Arfvidsson et al., 1989) although recent evidence appears to suggest this
finding may be artefactual (Biolo et al., 1995). It has been suggested that the
provision of insulin alone effectively empties the pool of free amino acids in skeletal
muscle as documented in normal subjects and in patients with uraemia and
diabetes (Alvestrand et al. 1988; Bennet et al., 1990b) and the provision of small
amounts of amino acids is insufficient to provide enough substrate during insulin
infusion; only when amino acid concentrations are elevated to the extent seen after
a large meal will limbs of normal and diabetic subjects achieve net positive amino
acid balance by a process of inhibition of protein breakdown and stimulation of
protein synthesis (Bennet et al., 1990a; Bennet et al., 1990b). However, Biolo and
co-workers (1995), by simultaneous use of biopsy and arteriovenous exchange
techniques, have clearly demonstrated a stimulatory effect of insulin on skeletal
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muscle protein synthesis, with no effect on breakdown, in healthy post-absorptive
subjects.
Growth hormone has substantial influences on increases in lean body mass
during growth (Tanner et al., 1977) especially at puberty and excretion of 3-
methylhistidine in patients with pituitary lesions appears depressed. It also
improves post-operative nitrogen balance in man (Manson and Wilmore, 1986;
Ponting et al., 1988). In pharmacological doses in healthy man, growth hormone
decreases whole-body leucine oxidation and increases whole-body protein synthesis
but appears to have no effect on whole-body protein breakdown (Horber and
Haymond, 1989). In animal studies growth hormone appears to exert its overall
anabolic action on muscle protein turnover by increasing muscle protein synthesis
(Cameron et al., 1988).
The effects of growth hormone are predominantly mediated by the two
insulin-like growth factors I and II (IGF-I and IGF-II) (Salmon and Daughaday,
1957). It is also likely that the anabolic effect of growth hormone is mediated by
insulin-like growth factor I (Isgaard et al., 1989) and this factor is a potent
stimulator of protein synthesis in vitro (Froesch et al., 1985). In contrast,
intravenous infusion of IGF-I in rats appeared to depress whole-body protein
synthesis and breakdown and reduced the rates of protein synthesis in a number
of specific tissues (Jacob, 1989). These effects may have arisen from use of
supraphysiological doses, where the IGF-I was not associated with its specific
binding protein and a direct effect mediated via the insulin receptor may have
resulted. It has been shown that growth hormone has greater growth promoting
effects than IGF-I suggesting that additional factors other than IGF-I are
important in mediating the effects of growth hormone (Skottner et al., 1987).
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The glucocorticoids and Cortisol in particular, have a negative effect on
protein balance. In man short courses of Cortisol increase whole-body protein
breakdown (Beaufrere et al., 1989) and stimulate transfer of nitrogen from leucine
to alanine and to glutamine with a resultant increased synthesis of these
gluconeogenic amino acids (Simmons et al., 1984; Darmaun et al., 1988). In
patients however with hyperglucocorticoidaemia of longer duration from untreated
Cushing's syndrome, an increased whole-body protein breakdown was not observed
(Tessari et al., 1989). It is possible that these different effects of Cortisol in the
longer term are the result of adaptive mechanisms such as increased insulin
concentration and to a predominant action of glucocorticoids in impairing protein
synthesis. Animal studies show that corticosteroids may increase both myofibrillar
protein breakdown and decrease protein synthesis (Rannels and Jefferson, 1989;
Odedra et al., 1983; Kayali et al., 1987) but a study in man has shown no effect on
myofibrillar protein breakdown (Beaufrere et al., 1989). Glucocorticoids decrease
glutamine concentrations in plasma and muscle (Muhlbacher et al., 1984). This
may be the indirect mechanism by which they influence protein turnover as
glutamine itself has a role in regulating protein turnover in injury (Rennie et al.,
1986). In healthy man, infusion of adrenaline decreases muscle ribosome
concentration (Wernerman et al., 1989) and decreases whole-body protein
breakdown, leucine oxidation and stimulates de novo alanine synthesis (Miles etal.,
1984; Kraenzlin et al., 1989). These may be direct effects or possibly indirect
effects mediated by alterations in insulin concentration. Muscle protein breakdown
appears to be reduced by adrenaline (Kraenzlin et al., 1989).
Excessive thyroxine levels in man results in a depression of skeletal muscle
protein synthesis but an unaltered myofibrillar protein breakdown, as assessed by
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the increased arteriovenous net efflux of tyrosine and unaltered 3-methylhistidine
balance across the leg (Morrison et al., 1988b). Although Morrison and colleagues
did not demonstrate any significant effect of hypothyroidism on leg protein balance,
in animal studies this condition results in reduced protein synthesis by muscle
(Brown et al., 1981), corrected by treatment with triiodothyronine (Brown and
Millward, 1983).
In the insulin deficient state glucagon increases whole-body protein
breakdown and leucine oxidation in man (Nair et al., 1987). Although it has been
suggested that glucagon inhibits muscle protein synthesis in vivo, such an effect is
only seen at pharmacological doses (Preedy and Garlick, 1988). There is no effect
of glucagon on muscle ribosome concentration or on the proportion of ribosomes
found as polyribosomes in man (Wernerman et al., 1989).
In patients with myotonic dystrophy who are hypogonadal, testosterone
administration appears to increase muscle protein synthesis (Griggs et al., 1986).
However, although the same workers reported significant increases in lean body
mass and protein synthesis estimated from incorporation of [ 13C]leucine into muscle
protein sampled by muscle biopsy (Griggs et al., 1989), examination of the
individual values suggests that the response is very variable and only in one or two
subjects did large biological effects occur.
Tumour necrosis factor-a , a polypeptide hormone produced by lymphocytes
and macrophages, appears to increase skeletal muscle protein breakdown in cancer
patients, as assessed by net amino acid efflux from the limb, yet conversely
increases whole-body protein synthesis (Warren et al., 1987; Starnes et al., 1989).
In vitro studies have generally failed to confirm such an effect of increased muscle
protein breakdown (Evans et al., 1989), suggesting that the effects of tumour
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necrosis factor-a may be mediated indirectly, e.g by increases in Cortisol or
glucagon. There is generally thought to be no effect of interleukin-1 on protein
turnover but a related factor, interleukin-6, may have a stimulatory effect on
muscle protein breakdown (Evans et al., 1989).
1.7.3.5 Gender-related Differences in Protein Turnover
There are insufficient data available in the literature to determine whether
or not there are significant gender related differences in muscle protein synthesis
but 3-methylhistidine excretion studies do show a slight difference with the rate of
turnover being less in women than in men (Young and Munro, 1978). It is difficult
to interpret the fractional rates of protein turnover in relation to creatinine because
of sex hormone-influenced differences in creatinine metabolism, which will
inevitably affect the 3-methylhistidine/creatinine urinary ratio.
1.7.3.6 The Influence of Exercise and Immobility on Protein Turnover
It is well known that muscular contractile activity or the lack of it can
induce changes in muscle composition and muscle mass (Tucker et al., 1973;
Laurent et al., 1978a, 1978b; Watson et al., 1984). The relatively sparse
information available for man regarding the related changes in protein turnover
suggests that muscle protein synthesis is depressed during immobilisation (Gibson
et al., 1987) and that mild electrical stimulation at levels sufficient to produce only
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5% of maximum voluntary contraction for 1 ha day is sufficient to halt the loss of
muscle (Gibson et al., 1988). Electrical stimulation of muscle in paraplegic subjects
also increased the rate of muscle protein synthesis in 5 subjects out of 6 (Pacy et
al., 1988b).
1.7.3.7 General Anaesthesia
To enable accurate interpretation of results from studies in protein turnover
involving anaesthesia and surgery it is important to initially clarify the separate
effect of anaesthesia. Intravenous anaesthetics themselves initiate negligible
endocrine-metabolic changes compared to the effects of surgical trauma (Nistrup
et al., 1976; Oyama, 1980; Tarhan et al., 1971). The duration of anaesthesia itself
does not appear to contribute to the response of interleukin-6 observed in surgical
patients (Cruickshank et al., 1990). Thiopental combined with a low dose of
fentanyl blunts the stress response to endotracheal intubation (Dahlgren et al.,
1981; Giesecke et al., 1988). In itself, mechanical ventilation is known to initiate
an endocrine response, including a release of antidiuretic hormone in intensive care
patients (Hemmer et al., 1980). After the induction of neuroleptic anaesthesia the
exchange of free amino acids across a leg is unaltered (Stjernstrom et al., 1986).
Whole body protein synthesis and degradation are decreased by halothane, when
determined before surgery (Rennie and Maclennan, 1985). In contrast, enflurane
administration during the 2 hours before surgery does not affect whole body protein
synthesis or breakdown (Carli et al., 1989). The effects of different anaesthetic
agents on protein synthesis in human individual tissues have so far not been
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investigated. In animal experiments, halothane is the most frequently studied
anaesthetic agent, since it is easy to quantify and to use. In intubated,
mechanically ventilated dogs whole body protein synthesis was decreased by
halothane anaesthesia administered with nitrous oxide and oxygen (Horber et al.,
1988). In spontaneously breathing rats protein synthesis decreases in liver and
lung when halothane is given in 66% nitrous oxide or in 02-enriched air (f;O2=0.33).
Only protein synthesis in the lung is affected by fentanyl/midazolam with 21%
oxygen. Protein synthesis in skeletal and cardiac muscle is unaffected by
halothane and fentanyl/midazolam (Heys et al., 1989). Also, albumin synthesis
decreases when halothane in 40% oxygen is given to rats twice within 24 hours, but
is unaffected after a single session of halothane anaesthesia (Franks et al., 1988).
Thus, these studies in rats appear to indicate that the effect of anaesthesia is
dependant upon both the agent used and the tissue studied.
1.7.3.8 Surgical injury
Even though it has been accepted for a long time that surgical trauma
initiates loss of muscle protein (Cuthbertson, 1930), the catabolic effects have
mostly been characterised one or several days postoperatively. Metabolically, the
immediate perioperative period is recognised to be essential, since surgery rapidly
evokes an endocrine response with increased levels of stress hormones and an
augmentation of other active factors such as cytokines, which all might act as
regulators for protein catabolism (Cruickshank et al., 1990; Giesecke et al., 1988;
Rutberg et al., 1984). During surgery, an increase in the release of free amino
acids from the leg is observed, indicating net muscle protein catabolism
(Stjernstrom et al., 1986). Muscle protein synthesis decreases at 24 hours
postoperatively, as reflected by the configuration and size distribution of ribosomes
(Wernerman et al., 1986). At the same time the efflux of 3-methylhistidine from
the leg decreases markedly, indicating a fall in muscle protein degradation, and the
tyrosine efflux doubles, suggesting an even larger decrease in protein synthesis as
compared to degradation (Rennie et al., 1984). Also, the free amino acid
concentrations in muscle show a characteristic catabolic pattern during the first
post operative day (Essen et al., 1991), that further develops during the ensuing
two to three days (Vinnars et al., 1975). On the third postoperative day protein
synthesis is still decreased when reflected by the ribosome technique (Wernerman
et al., 1986). Several isotopic studies have elucidated the effect of surgery on whole
body protein metabolism. Immediately after surgery of moderate severity whole
body protein synthesis and degradation decrease (Carli et al. 1989). One to several
days after surgery of intermediate nature whole body protein synthesis decreases,
while protein degradation is either unaffected (Crane et al., 1977; Kien et al., 1978;
O'Keefe et al., 1974) or increased (Clague et al., 1983). Whole body protein
synthesis is shown to increase after surgery of moderate severity (Harrison et al.,
1989; Lowry et al., 1986) and after major trauma (Birkham et al., 1980; Birkham
et al., 1981). In major trauma, however, protein degradation increases even more
than protein synthesis (Birkhahn et al., 1980; Birkhahn, et al. 1981).
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1.7.4 The Effect of Intravenous Parenteral Nutrition
1.7.4.1 Parenteral Nutrition: a historical note
The concept of parenteral nutrition is not a new one. Milk was given
intravenously to combat the wasting associated with cholera by Hodder in Toronto
in 1873 (Johnston, 1978). In 1913 Henriques and Anderson (Johnston, 1978)
carried out the first successful experimental studies using goat muscle digested
with pancreatic extract and combined with glucose, sodium and potassium. They
were able to maintain a positive nitrogen balance in dogs for 6 days using this
mixture. The first step in clinical intravenous nutrition was the use of sterile
solutions of 5% dextrose during the First World War. By the late 1930's protein
hydrolysates were under extensive study by Elman (Johnston, 1978) and it was not
long until the first fat emulsions were being prepared for intravenous use. The
next major advance in intravenous nutrition was the demonstration by Dudrick in
1967 that the simultaneous administration to puppies of glucose and amino acids
with added vitamins and minerals as the sole source of nourishment allowed
normal muscular and skeletal growth to occur. The subsequent development of
total parenteral nutrition (TPN) as a practical clinical proposition came when safe
techniques were devised for the administration ofhypertonic nutrient solutions into
the superior vena cava (Dudrick et al., 1968). The clinical use of TPN has led to
significant advances in surgical practice with a growing appreciation of the
problems of malnutrition in surgical patients, their adverse effect on post-operative
recovery and how they may be successfully managed (Wilmore and Dudrick, 1968).
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1.7.4.2 Postoperative Nutrition
The postoperative period is often characterised by semistarvation due to
anorexia or to restricted nutritional intake for medical reasons. Various types of
artificial nutrition may be used to overcome this semistarvation and TPN is
recommended when the intestinal tract cannot be utilized for longer periods.
However, the efficacy of TPN in the post-traumatic period is not fully evaluated in
terms of clinical outcome or biochemical effects. Despite TPN, a negative nitrogen
balance is observed in normal nourished subjects after surgery of moderate severity
(Hammarqvist et al., 1989; Hammarqvist et al., 1991; Wernerman et al., 1987).
After major trauma the release of amino acids across the forearm as well as the
urinary excretion of 3-methylhistidine increases, in spite of postoperative TPN
(Finley et al., 1986). The effects of surgical trauma on the muscle free intracellular
amino acids and on the concentration and size distribution of ribosomes in muscle
are not reversed by postoperative TPN (Vinnars et al., 1980; Wernerman et al.,
1986). However, conventional TPN might be inadequate for the needs of the
traumatised patient. Studies on the effect of postoperative TPN on whole body
protein synthesis have given discordant results, showing either an increase (Clague
et al., 1983; Lowry et al., 1986; O'Keefe et al., 1981) or a decrease (Crane et al.,
1977; Kien et al., 1978). This may be due to differences in i) the severity of the
trauma ii) the nutritional status of the patients iii) the postoperative nutritional
regimens and iv) the methods used for the investigations.
Although initially the amino acid solutions used in TPN were made from
hydrolysed protein, reflecting the protein concentration, present-day practice
involves the use of crystalline amino acids made to a specific formulation which
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includes all the indispensable amino acids in appropriate amounts together with
a variety of dispensable amino acids. The so-called dispensable amino acids do, in
fact, appear to play a useful role in amino acid metabolism since growth in animals
deprived of them is less in their absence . Also, recently it has become obvious that
glutamine is one dispensable amino acid which may be less dispensable than
previously thought.
1.8.1 The Intracellular Glutamine Pool: Its Role in Health and Disease
In the early 1970's reliable data on intracellular concentrations of free amino
acids in human muscle tissue first became available (Bergstrom et al., 1974). Of
the total pool of free amino acids glutamine was found to constitute 61%, and its
intracellular concentration was in the order of 19.5 mmol/1 intracellular water. The
intracellular/extracellular transmembrane gradient of 34 indicated that the
diffusion of glutamine through the muscle fibre membrane is restricted. The
results of this early study confirmed previous findings in experimental animals
showing that the intracellular glutamine concentration is much higher than that
in the extracellular compartment (Herbert et al., 1966; Munro 1970). The data,
however, also emphasized the consistent differences in amino acid patterns found
between species.
Skeletal muscle is the main tissue site for glutamine synthesis and
glutamine is released continuously from it (Karl et al., 1976; Marliss et al., 1971).
The efflux of amino acids from muscle tissue increases following trauma.
Glutamine and alanine represent the major portion of the total amino acid release
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during stress (Aulick and Wilmore 1979; Clowes et al., 1980; Lund 1985). The
mechanisms underlying the diminished intracellular concentration of free
glutamine in muscle are not entirely understood. Accompanying trauma the
activity of glutamine synthetase in rat skeletal muscle increases, promoting an
elevated production of glutamine (Ardawi, 1988). An unchanged activity of
glutamine synthetase is reported in dogs during administration of corticosteroids,
that parallels an increased glutamine outflow from muscle and decreased glutamine
levels in skeletal muscle tissue (Muhlbacher et al., 1984). An increased outflow of
glutamine from skeletal muscle, which exceeds the rate of glutamine synthesis, is
a plausible explanation for the decreased concentration in muscle tissue. The non-
hepatic splanchnic organs, particularly the small intestine, show an increased
uptake of glutamine accompanying trauma (Clowes et al., 1980; Felig 1973).
Glutamine constitutes a carrier for amino acid and ammonium nitrogen as well as
carbon skeletons emanating from amino acid deamination in skeletal muscle. A
sodium dependent carrier mechanism for glutamine across the cell membrane has
been proposed (Hundal etal., 1987; Rennie et al., 1986). It has been suggested that
this transport mechanism is influenced by the hormonal environment and by
concentrations of electrolytes, branched chain amino acids and glutamine. The
intracellular influx of sodium may thus be linked with the efflux of glutamine and
lead to a decline in the intracellular glutamine concentration. This hypothetical
association is supported by observations of an increased concentration of sodium
in muscle after major trauma (Larsson et al., 1984) and also after cholecystectomy
(Stillstrom et al., 1987).
A fall in the intramuscular free glutamine concentration accompanies a
number of catabolic conditions including trauma, sepsis and elective surgery
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(Askanazi et al., 1978; Askanazi et al., 1980a; Milewsky et al., 1982; Essen et al.,
1988; Legaspi et al., 1988; Roth et al., 1982; Roth et al., 1985; Roth et al., 1987;
Vinnars et al., 1975; Vinnars et al., 1976; Wernerman et al., 1987). Following
surgical injury this fall is apparent on the first postoperative day (Essen et al.,
1988) and in many cases by the third or fourth postoperative day it is responsible
for a depression of up to 60% in the intramuscular free glutamine concentration
(Furst, 1984). It is of interest that while provision of large amounts of amino acids
normalized the non-essential amino acid pool, the intracellular free glutamine level
remained low (Furst et al., 1979). Thus, in patients receiving conventional TPN
with amino acids, the decrease in glutamine was accompanied by an accumulation
of the other non-essential amino acids. The uniform reduction of approximately 50-
60% in the muscle free glutamine pool is one of the most typical features of the
response to catabolism. The extent of the intracellular glutamine depletion seems
to be virtually obligatory, irrespective of the magnitude or severity of catabolism.
Depletion of this major intracellular non-essential nitrogen source might be a
limiting factor for optimum protein synthesis (Furst et al., 1987). Manipulations
of the free glutamine concentration in animal experiments lead to changes in
protein synthesis in skeletal muscle tissue. In vivo studies in rats show that there
is a good correlation between the rate of muscle protein synthesis and the
intramuscular free glutamine concentration (Jepson et al., 1988). Evidence to
suggest that this effect is a causal one has been provided by demonstration that
manipulation of intramuscular free glutamine concentration in the perfused rat
hind limb causes an increase in muscle protein synthesis (Maclennan et al., 1987).
In addition, muscle protein breakdown, as assessed by [15N]phenylalanine dilution,
may be depressed by increased glutamine availability although myofibrillar protein
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breakdown appears not to be, according to the extent of 3-methylhistidine release
(MacLennan et al., 1988). In dogs, following trauma, provision of large amounts
of amino acids with or without glutamine preserves the muscle free glutamine
concentration and improves nitrogen balance across skeletal muscle (Kapadia etal.,
1985). However, a supply ofglutamine together with elevated insulin levels in non-
traumatized animals does not influence the in vivo protein synthetic rate in muscle
(Garlick and Grant, 1988). A combined infusion of stress hormones simultaneously
decreases the concentrations ofpolyribosomes and free glutamine in skeletal muscle
in healthy volunteers (Wernerman et al., 1989; Wernerman et al., 1987).
Furthermore, administration of corticosteroids to animals increases the efflux of
glutamine from skeletal muscle (Muhlbacher et al., 1984) and stimulates the
uptake of glutamine from blood across the intestine (Souba et al., 1985a, 1985b).
An increased uptake of glutamine by the small intestine has also been
shown to occur intraoperatively (Felig et al., 1973; Lund, 1985). The small
intestinal mucosa is dependant on a continuous supply of glutamine as respiratory
fuel and for normal cell division (Souba et al., 1985; Windmueller and Spaeth,
1974). Of the glutamine consumed by the intestine in rats in normal conditions a
large part is metabolised in the intestinal lumen (Windmueller, 1975). If the
availability of glutamine is low, the mucosal barrier may become impaired
(Baskerville et al., 1980), and allow the entrance of endotoxins and bacteria
(Wilmore et al., 1988). In trauma, the increased extraction of glutamine from blood
by the splanchnic organs is paralleled by an increased glutamine efflux from
muscle tissue (Felig, 1975; Lund, 1985). This may constitute a pathophysiological
response in trauma in order to maintain normal intestinal epithelial structure to
serve as a barrier against bacterial migration (Wilmore et al., 1988). Animal
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experiments show that the administration of enteral nutrition prior to stress
inhibits the early corticosteroid response to bleeding (Ljungqvist et al., 1986). It
is possible therefore that following trauma, the intestine may be better supported
by adding glutamine or its analogues to conventional TPN.
1.8.2 The Effect of Nutrition on the Free Intracellular Glutamine Pool
In several studies, intramuscular free amino acids have been measured
following elective operations (Vinnars et al., 1975 and 1976; Askanazi et al., 1980b;
Vinnars et al., 1983) and after severe accidental injury and burns (Vinnars et al.,
1976; Furst et al., 1979). The effects of different parenteral nutrition regimens
with various amounts and proportions of amino acids were evaluated in the
immediate post-injury phase (Vinnars et al., 1983). The pattern of changes in
intracellular free amino acids after trauma (Askanazi et al., 1980a and 1980b) was
not significantly influenced by parenteral nutrition. Alterations in the individual
amino acid concentrations appeared not to be affected by the total amounts or
proportions of amino acids administered. Surprisingly, the high amounts of amino
acids given were not reflected in an increased free amino acid pool in muscle and,
importantly, the substantial decrease in muscle glutamine concentrations was
found in all patients in spite of such amino acid provision. The reason why the
intracellular glutamine pool is depleted in the catabolic state remains obscure.
Increased glutamine transport, due to accelerated gluconeogenesis in the liver may
serve as a possible explanation. Also, hormonal factors may have an important
role: in one study, intracellular amino acid measurements indicated that glucagon-
59
induced proteolysis in the liver is mediated by intracellular depletion of glutamine
(Schworer et al., 1979). Under normal conditions both liver and muscle release
glutamine while uptake by the kidney and gastrointestinal tract quantitatively
balances this release (Windmueller et al., 1974; Cahill et al., 1975; Windmueller
1974). More recent evidence suggests that in a post-injury state the liver switches
from glutamine release to glutamine balance or slight uptake (Souba et al., 1983).
The increased amount of glutamine released in a catabolic state is taken up by the
gut while kidney exchange remains unaltered. The gastrointestinal tract may
therefore be considered as an important regulator of amino acid flux following
injury (Souba et al., 1983; Souba et al., 1985) and glutamine might be contemplated
as an important and appropriate substrate not only for the skeletal muscle pool but
also for the gastrointestinal tract (Souba et al., 1985; Cersosimo et al., 1986).
1.8.3 Glutamine Supplementation of TPN
There appears to be sufficient evidence to suggest that glutamine
supplementation of parenteral solutions might be beneficial in the catabolic state.
However there has been concern regarding the inclusion of free glutamine in such
solutions because of its instability during storage and heat-sterilization (Meister,
1956; Stehle et al., 1984; Stehle et al., 1987). The possibility of substituting
currently available amino acid solutions with suitable di- and tripeptides has
recently become feasible (Fiirst, 1987). This has provided an opportunity for
supplying glutamine intravenously by means of infusing stable and soluble
glutamine-containing peptides.
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1.9.1 L-alanyl-L-glutamine Dipeptide Synthesis and Characterization
A dipeptide of glutamine, L-alanyl-L-glutamine (Ala-Gin) has been
synthesised by applying the N-carboxy anhydride method in the aqueous phase
(Stehle et al., 1982). The purity in the final product approached 100% and its
structure could be fully confirmed by field-desorption mass spectrometry and proton
magnetic resonance spectrometry (Stehle et al., 1982a; Stehle et al. 1982b). The
synthetic peptide Ala-Gin is highly soluble (568 g/1 H20; 20°C) and stable during
heat sterilization over a wide pH range. The solubility of Ala-Gin is 16-fold higher
than that known for the free amino acid glutamine (36 g/1 H20; 20°C). The stability
of Ala-Gin during storage and heat-sterilization has been investigated in some
depth, particularly in view of the reported instability of free glutamine (Meister,
1956; Stehle et al., 1984; Stehle et al., 1987). When Ala-Gin was heat-sterilized for
30 and 60 min at 120°C at various pH no liberation of ammonia or formation of
pyroglutamic acid or L-alanyl-L-glutamic acid was observed (Stehle et al. 1984;
Fiirst et al, 1987, Stehle et al., 1985). Thus, the synthetic dipeptide Ala-Gin
appears to be a stable compound suitable for the heat-sterilisation process which
would be required prior to considering its inclusion in future parenteral solutions.
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1.9.2 In Vivo Utilization of L-Alanyl-L-Glutamine: Animal Studies
Isotope studies with (Ala-[U14C]Gln) administration in the rat and dog
strongly indicate that the dipeptide is easily available and the constituent amino
acids are rapidly used for protein synthesis, preferentially in muscle tissue. In
catabolic rats, continuous TPN without inclusion ofAla-Gin resulted in a profound
decrease in tissue free glutamine levels compared with normal rats (Furst et al.,
1987). Inclusion of Ala-Gin in TPN was followed by an increase in the tissue free
glutamine pool, considerably in liver and markedly in muscle (Furst et al., 1987).
These findings indicate a preferential capacity of muscle tissue for uptake of Ala-
Gin and suggest subsequent utilization of the liberated free glutamine in this
tissue.
Synthesis of 14C-labelled Ala-Gin (Ala-[U14C]Gln) facilitated studies of in vivo
cleavage and subsequent utilization of the dipeptide in rats (Amberger et al., 1983a;
Amberger et al., 1983b; Amberger etal., 1984; Amberger et al., 1985). After a bolus
injection of Ala-Gin (Ala-[U14C]Gln) the course of labelling was followed in non¬
protein and protein fractions of plasma, liver, kidney and muscle specimens as well
as in the urine (Amberger et al., 1983a, 1983b). In a separate study the rate of
oxidation was determined by means of 14C02 expiration (Amberger et al., 1984).
The release of 14C02 peaked at 55 min after injection and declined rapidly during
the next two hours. The recovered radioactivity after three hours calculated as a
percent of injected dose was 49%. This result provided the first evidence for in vivo
utilization of the peptide Ala-Gin, suggesting that about 49% of released Gin was
available as an energy substrate.
In the liver and kidney non-protein fractions, the high initial labelling was
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followed by a subsequent rapid decline. In contrast, the initially moderate labelling
of the muscle non-protein fraction showed a progressive increase, suggesting a
continuous active transport of the label to this fraction. This enrichment of the
muscle free pool may have occurred as a result of redistribution of radioactivity
presumably arising from the plasma non-protein fraction or from other tissue pools.
The rapid decline of label in the liver and kidney non-protein fractions was
accompanied by an increase in the measured radioactivity in the corresponding
protein fractions (Amberger et al. 1983a, 1983b; Furst et al., 1987). Liver protein
displayed an initial high labelling, indicating a rapid uptake and subsequent
metabolism of the glutamine dipeptide in this tissue. Interestingly, the enrichment
of liver protein attained its maximum with a simultaneous rapid increase of the
label in plasma protein fractions. This observation may suggest liver-specific
synthesis of plasma proteins. A significant and steadily increasing incorporation
was apparent in the muscle protein fraction. This observation suggested not only
a high capacity of muscle tissue to take up the glutamine peptide but also indicated
an efficient subsequent intracellular utilization of the liberated free glutamine in
this tissue.
The relative distribution of the recovered label in the rat three hours after
injection is depicted in Table 1.4. 14C02 accounted for the main part of the
recovered label (49%). After this, however, muscle revealed the major portion of
the recovered radioactivity (33%) in comparison with other investigated tissues
(liver: 9%, plasma: 5.5% and kidney: 1%). Urinary loss of the label was lower than
3%.
These results are in good agreement with those obtained in dogs (Amberger
et al., 1985; Furst et al., 1987) and emphasise the predominant quantitative role
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of muscle in utilizing the dipeptide Ala-Gin. Indeed, the high percentage of
radioactivity found in muscle tissue is likely to reflect the greater proportion of
muscle mass compared with other organ tissues.
Since previous efforts to normalize the post-operative intra-cellular
glutamine pool by using alternative non-essential nitrogen sources have failed
(Vesterberg et al., 1985), the obvious question which arises is whether or not a
maintenance of the intracellular glutamine pool is feasible following parenteral
provision of glutamine or glutamine-containing peptides. Wilmore and his
colleagues (Kapadia et al., 1985; Johnson et al., 1986) infused amino acid solutions
with or without glutamine enrichment to dogs during standard surgical trauma or
during simulated stress. By replacing ample amounts of nitrogen as glutamine,
they were able to maintain muscle free intracellular glutamine concentration and
achieved a reduction in skeletal muscle amino acid efflux. Wilmore's studies raised
exciting prospects for applications in the clinical field. However, considering the
known instability of free glutamine (Meister 1956; Stehle et al., 1984; Stehle et al.,
1987) the scope for direct use of parenteral glutamine in TPN appeared to be
limited. Subsequent studies in which continuous TPN with and without inclusion
of the peptide Ala-Gin was given to catabolic rats (Furst et al., 1987) showed that
in comparison with normal rats, injury induced a profound decrease in tissue free
glutamine levels (plasma and liver -20%, muscle -45%) in animals receiving
nutrition without dipeptide supplementation. Addition of the dipeptide to TPN
significantly reduced the extent of the trauma-induced intracellular glutamine
deprivation. On the other hand, the efficacy of treatment was rather moderate in
the other tissues investigated. Thus, inclusion ofAla-Gin in the TPN resulted only
in a slight increase in plasma free glutamine, while the elevation in liver free
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Table 1.4 A comparison of recovered radioactivity in protein and non-protein
fractions of various organs (tissues), following injection of I4C-labelled L-Alanyl-L-
glutamine (Ala-[U14C]Gln) expressed as a percent of injected dose in rat and dog,
respectively.
Organ (tissue) Protein fraction Non-protein fraction
Rat Dog Rat Dog
Muscle 3.5 + 0.35 3.0 + 0.33 9.5 _+ 1.10 10.4 :+ 0.80
Liver 1.8 + 0.02 2.0 + 0.12 1.3 + 0.20 1.5 + 0.20
Kidney +1COo 0.02 0.5 + 0.03 0.2 + 0.02 0.3 + 0.03
Plasma 1.7 + 0.10 1.8 + 0.25 o CO 1+ 0.04 0.4 + 0.05
Mucosa N. D. 7.6 + 0.52 N. D. 0.6 + 0.06
Serosa N. D. +1o 0.30 N. D. 0.5 + 0.03
Pancreas N. D. 0.9 + 0.07 N. D. 0.2 + 0.01
N.D. = No data available
(From Fiirst et al., 1987)
glutamine pool was more apparent.
The results derived from isotope studies strongly indicate that the dipeptide
Ala-Gin is easily available and rapidly used for protein synthesis, preferentially by
muscle tissue. These findings in studies with continuous TPN offer firm evidence
that parenterally administered Ala-Gin provides free glutamine especially for
maintenance of the muscle free intracellular glutamine pool. Indeed, the discussion
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should perhaps be focused on whether or not a normalization of the intracellular
glutamine pool might promote protein synthesis during periods of catabolic stress:
Rennie and colleagues (Rennie et al., 1986; MacLennan et al., 1987) were able to
demonstrate a strong relationship between the synthetic rate of skeletal muscle
protein and the intracellular concentration of free glutamine. Thus, it appears that
maintenance of the muscle free glutamine pool might be a prerequisite for optimum
protein synthesis in the catabolic state (MacLennan et al., 1987).
1.9.3 Studies of L-Alanyl-L-Glutamine in Man
In considering results obtained from studies of glutamine metabolism in rats
and their possible relevance to man it should be borne in mind that there is a
marked difference in glutamine content between human and rat muscle. While
glutamine represents more than 50% of the intracellular amino acid pool in human
muscle, the major intracellular constituent in rat muscle is glycine (Fiirst, 1985).
Consequently, studies in man are necessary to demonstrate the influence of the
dipeptide Ala-Gin on nitrogen economy in the catabolic state in man.
Utilization of Ala-Gin in vivo has been evaluated in healthy human subjects
by kinetic studies and under conditions of continuous infusion of dipeptide
supplemented amino acid solution (Albers et al., 1986). The peptide elimination tV2
was 3.1+0.16 min and that for the liberated free amino acids glutamine and alanine
8.2+0.82 and 6.8+0.34 min, respectively. During infusion of an amino acid solution
supplemented with Ala-Gin and Gly-Tyr, the increments of plasma glutamine and
tyrosine were 33+2.2 % and 67+5.7 % over the initial values. No peptide could be
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detected in the urine. During the entire infusion period the dipeptide, though
detectable in plasma, revealed only trace concentrations, suggesting virtually
complete quantitative hydrolysis and utilization. In a subsequent study Brandl and
colleagues (Brandl et al., 1987) investigated in vivo utilization of a mixture of 5
glycyl-dipeptides and free amino acids administered to healthy volunteers over 12
hours. This study also demonstrated the efficient utilization of administered
dipeptides in healthy man. Finally, provision of glutamine as the dipeptide (Ala-
Gin) has been shown to increase glutamine availability, reduce post-operative
muscle loss of alanine and glutamine and whole-body N-excretion (Stehle et al.,
1989), although no data are currently available to explain the likely mechanisms
of this latter action in man.
1.10 Aim of the present studies
The aim of the studies detailed in this work was to clarify the role of the
amino acid glutamine, provided as the dipeptide L-alanyl-L-glutamine (Ala-Gin),
in modulating skeletal muscle and whole-body protein turnover in healthy
postabsorptive man, and in patients undergoing major elective surgery when
administered in supplementation to conventional non-glutamine containing
intravenous nutrition. There has been considerable interest in this area of research
during the last decade. To my knowledge however, no information is available on
the role of glutamine in modulating muscle and whole-body protein turnover in
healthy man. My initial hypothesis was that in healthy postabsorptive man, in
whom the intracellular glutamine pool is not depleted, glutamine provision would
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either have no significant effect, or possibly a small effect only, on muscle and
whole-body protein turnover. I therefore began by designing a protocol to
investigate the possible acute effects of parenteral glutamine provision, as the
dipeptide Ala-Gin, on muscle protein synthesis and breakdown and whole-body
protein turnover in healthy male postabsorptive subjects using standard stable
isotope tracer techniques.
A number of workers have elaborated various facets of glutamine's role in
maintaining skeletal muscle and whole-body protein and nitrogen balance in
disease states such as sepsis, trauma and surgical injury. It appears from this
body of work, undertaken mainly in animals but also to some extent in man, that
depletion of the intramuscular free glutamine pool, occurring following injuiy, is
associated with negative whole-body nitrogen balance and a reduction in skeletal
muscle protein synthesis as determined by indirect semi-quantitative methodology.
Provision of glutamine appears to reduce the extent of the post-injury depletion of
the intra-muscular free glutamine pool and also appears to reduce the extent of the
negative nitrogen loss. Although indirect methods of assessment, using the
concentration of intramuscular polyribosomes as an index of protein synthesis,
appear to indicate that this ameliorating effect of glutamine provision on post-
injury nitrogen balance may occur as a result of a stimulation of protein synthesis,
no direct evidence is available to explain the mechanisms of glutamine's action in
human subjects. In these studies I have therefore set out to directly measure,
using the same stable isotope methodology outlined above, the acute effects of
conventional TPN, supplemented by Ala-Gin, on muscle protein synthesis and
breakdown, and whole-body protein turnover, in patients undergoing elective major
upper gastrointestinal surgery. My hypothesis was that in contrast to conventional
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non-glutamine containing TPN provision, glutamine dipeptide supplementation in
these patients would replete the intramuscular free glutamine pool and improve
muscle protein balance. The study protocols were designed to make comparison
firstly with the effect on muscle protein synthesis and breakdown (in the same
patients) of provision of TPN supplemented by a control isonitrogenous solution of
the free amino acids alanine and glycine. Further comparison was made with a
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2.1 The Use of Stable Isotopes in the Measurement of Protein Turnover
The measurement of protein turnover in vivo was shown to be possible in
a series of pioneering experiments with 15N and 2H labelled amino acids initiated
in the 1930's (Schoenheimer and Rittenberg, 1938). In the last two decades, there
has been an increased impetus to investigate amino acid metabolism in vivo in man
because of the availability of a range of commercially-produced stable isotope-
labelled amino acids and the development of reliable and relatively inexpensive
mass spectrometers by which to measure their labelling of trace compounds. Stable
isotopes, as their name indicates, do not decay and do not release ionising
radiation. These factors are of great importance in allowing their safe application
in studies in neonates (Chien, 1991), children (Tomkins et al., 1983), women in
their reproductive years (living et al., 1986) and young healthy subjects in general
(Bennet et al., 1989). When analysing stable isotope samples to determine the
tracee molar enrichment only one measurement is required, whereas, the analysis
of samples to determine radioactive tracee specific radioactivity requires separate
measurements of radioactive and chemical concentrations, with the result that the
coefficient of variation of the latter analysis is likely to be greater. In normal
conditions, stable isotopes are administered as a tracer dose in <10% of the flux
and the widely held assumption underlying the use of compounds containing stable
isotopes that they behave exactly as the endogenous compound appears to be valid.
A minor disadvantage is that these isotopes are ubiquitous and basal or
background values (e.g. up to 1% for 13C must be measured and taken into account.
The stable isotopes most commonly used to investigate human protein metabolism
are 2H, 13C, 15N and lf!0. These stable isotopes have now been applied in a wide
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range of metabolic studies of carbohydrate (McMahon et al., 1989), fatty acids
(Wolfe et al., 1980) and protein metabolism (Bier, 1987; Halliday and Rennie, 1982;
Wolfe, 1992) in man. They enable both qualitative and quantitative investigation
of human metabolism at the whole body, tissue and substrate level.
2.2 L-[l-';!C]leucine as a Stable Isotope Tracer
Leucine represents approximately 8% of skeletal muscle protein (Sprinson
and Rittenberg, 1949). The choice of leucine for the primed constant infusion
method is theoretically sound because as opposed to other essential amino acids
that are metabolised primarily in the liver, leucine is catabolised primarily in
skeletal muscle, the body's principle protein reservoir (Young, 1970; Odessey and
Goldberg, 1972). In addition, leucine appears to have a regulatory effect on the
other two branched-chain amino acids, valine and isoleucine (Hambraeus et al.,
1976) and on muscle protein synthesis and degradation (Buse and Reid, 1975;
Walser, 1984). It is also the main source of the alpha-amino nitrogen of
gluconeogenic amino acids released from muscle (Odessey et al., 1974; Adibi, 1976).
Leucine is metabolised first by transamination to oc-ketoisocaproate which is a
reversible reaction and then by decarboxylation to isovaleryl-CoA and carbon
dioxide (Figure 2.1). The carbon dioxide is released into expired air after first
passing through the bicarbonate pool. In contrast to a 13C label placed elsewhere
in the leucine molecule, carboxyl-13C is removed at the time when leucine is first
irreversibly committed to oxidation, making L-[l-13C]leucine an optimal, non-
recycling tracer of the oxidation process of branched chain amino acids. The free
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Figure 2.1 Leucine intermediary metabolism.
tracer, both in plasma and in intracellular fluid, is diluted by non-essential
amino acids either released by protein breakdown or from the diet. The rates of
these metabolic processes can be determined by the measurement of the 13C
enrichment of plasma cx-ketoisocaproate and its oxidation product, carbon dioxide,
excreted in breath and by comparison with the rate of infusion of tracer. The
immediate metabolite of leucine, a-ketoisocaproate, is measured in preference to
leucine on the assumption that this provides a closer measure of the tracer
enrichment of leucine in the intracellular milieu (Matthews et al., 1982; Rennie
et al., 1982b; Schwenk et al., 1985a; Layman and Wolfe, 1987; Horber et al.,
1989.
77







Figure 2.2 Two pool model of protein turnover; D = Diet; S = Synthesis; B
Breadown; O = Oxidation.
78
2.3 Whole Body Amino Acid Kinetics
The methodological basis of most apHxoaches to calculating total protein
turnover is to measure the flux of an amino acid or of nitrogen (Waterlow and
Stephen, 1967; Picou and Taylor-Roberts, 1969). The term flux refers to the rate
of amino acid flow through the free amino acid pool into protein and other
metabolic pathways (Figure 2.2). Amino acids enter the pool from the diet and
from protein breakdown with additional (but quantitatively smaller) entry from de
novo synthesis of the non-essential amino acids. The amino acids leave the pool by
incorporation into protein (by protein synthesis), by oxidation and excretion and by
certain other metabolic pathways e.g. in the formation of nucleotides and
porphyrins.
The general procedure for measurement of flux is to label the free amino
acid pool and to determine the amount of the label at subsequent times in a pool
which can be sampled: for measurements of whole body turnover this would involve
sampling of blood or urine. Flux can be measured either by using a single dose
technique where a single injection of a radioactive tracer is given, knowing the
amount of tracer given and dividing by the integral of the specific activity-time
curve, or by using a constant infusion technique to attain plateau labelling by
tracer in the free amino acid pool. When a labelled compound is administered and
the specific activity in blood or urine is measured a specific activity-time curve is
obtained showing an exponential fall in specific activity with time (represented
schematically in Figure 1.4, Chapter 1, section 1.6.4.6). Stable isotope-labelled
amino acids ([15N [glycine, (Olesen et al., 1954) and radioactive-labelled amino acids
([14C]glycine, (Henriques et al., 1955) have been used in this way to measure flux.
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A simple two-pool model approach has been used in these studies to
determine whole-body amino acid and protein turnover (Matthews et al., 1980). In
this model the whole body is considered as comprising two pools, a plasma pool and
a protein pool. The flux (Q) for an amino acid is determined after a steady state
is attained during a primed constant infusion of tracer amino acid and knowing the
rate of infusion and measurement of the dilution of tracer in the plasma pool allows
the calculation of the amino acid flux. The constant infusion method has the
advantage that since the plateau is a straight line it can be defined by fewer points
than are necessary for the specific activity-time curve after a single dose of tracer.
Once the time required to reach the plateau value is known, no measurements need
be made until plateau has been achieved. An important point to make with regard
to the constant infusion method is that the plateau reached in this method is a
'pseudo'-plateau rather than a true plateau, in that the amino acids incorporated
into protein are not irretrievably lost to the amino acid pool but there is in fact a
slow return of tracer to it from the protein bound pool (by the process of protein
degradation) resulting in a gradual increase in the specific activity in the infused
pool. However, because of the much larger size of the protein bound pool in
relation to the free amino acid pool, this return of tracer has been calculated to be
slow enough such that a time of the order of 1000 hours would be required to
significantly alter the free amino acid pool (Aub and Waterlow, 1970). In most
experimental conditions therefore, where infusions last from 6-8 hours, the
deviation of the 'pseudo'-plateau from the true is likely to be negligible.
Under steady state conditions, for essential amino acids such as leucine, flux
may be calculated using the following equation:
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q-s+6-b+d
Where Q is the rate of leucine flux or turnover, S is the rate of protein
synthesis, O is the rate of amino acid oxidation (for leucine and valine, not
phenylalanine), B is the rate of amino acid supplied from protein breakdown and
D represents the dietary intake, all p.mol/kg/h. In the fasted or postabsorptive
state, dietary input is zero and therefore breakdown equals flux. If [l-13C]leucine
is used as tracer, the flux under steady state conditions may be calculated from the
Ll-13C]leucine infusion rate and the extent either of leucine's labelling, or that of
a metabolite (e.g. a-ketoisocaproate) taken to represent the precursor pool for
protein synthesis:
Q = i x [ ^ -1]ep
Where i is the rate of tracer infusion (/xmol/kg/h), Es is the enrichment of the
infusate (atom % excess or APE) and Ep is the plateau enrichment (APE) of the
pool chosen to represent the precursor for protein synthesis i.e. arterial, venous or
mixed venous plasma amino acid or a-ketoacid.
Plasma L-[l-13C]leucine enrichment is measured by gas chromatography-
mass spectrometry (Matthews et al., 1980). Leucine oxidation may be measured
in the whole body by means of collection of expired C02 with subsequent cryogenic
purification and measurement of 13C02 enrichment by isotope ratio mass
spectrometry (Halliday and Read, 1981). The rate of 13C02 released by leucine-
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tracer oxidation (p,mol/13C kg/h) is:
p Fco2 • Ecoz ^ . 60 . 41.6
13C02 w 10O . 0.95
where Fco2 is the C02 production rate (cm'Vmin1)
Exo2 is the 13C02 enrichment in expired air at isotopic steady state
(APE)
W, the patient's weight (kg).
The constants 60 min/h and 41.6 p,mol/cm (at S.T.P.) convert Fco2 to /xmol/h; the
factor 100 changes atom % excess (APE) from a percentage to a fraction; the factor
0.95 accounts for the fraction of 13C02 released by L-[l-13C]leucine oxidation, but
not released from the body bicarbonate pool into expired air (Issekutz et al., 1968;
James et al., 1976; Elia et al., 1992). The rate of leucine oxidation is:
C = F13 [- -] X 100
C02 E>
from which the rate of leucine incorporation into protein (i.e. synthesis) can be
calculated:
S = Q - C
82
Finally, the rate of leucine release from the protein is the difference between
leucine turnover and dietary intake:
B - Q - D




2.3.1 Assumptions Required for the two Pool Model of Leucine
Metabolism
The assumptions required for the two pool model of leucine metabolism are:
1. Tracer (i.e. labelled) amino acid and unlabelled amino acid are metabolised
in an identical form.
2. No re-entry occurs of labelled amino acid.
3. The tracer amino acid appears either in the free amino acid pool or bound
in protein.
4. Enrichment in the plasma pool reflects the average intracellular
enrichment.
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2.3.2 Limitations of the Assumptions and Sources of Error
Some limitations of the assumptions and possible sources of error are:
1. Non-homogeneity of the Free Amino Acid Pool
The model is based on the assumption of a single uniformly mixed free
amino acid pool. This is in fact only partly true because of internal
recycling due to dilution of the label in the intracellular pool with unlabelled
amino acid derived from protein breakdown. This may lead to an error of
up to 20% (Golden and Waterlow, 1977).
2. Non-homogeneity of the protein bound pool
Although measurements and calculations are more straightforward, the
basic two-pool model (Olesen, 1954) is probably over-simplistic and greater
accuracy might be achieved by using more complex multiple-pool models
(Cobelli, 1987).
3. Re-entry of label
The calculation of flux assumes that there is no re-entry of tracer from
labelled protein and this is not entirely correct.
4. Routes of amino acid disposal
In calculating rates of protein synthesis from flux it is assumed that routes
of disposal for amino acids are either by excretion or by incorporation into
protein. However other routes of disposal are present such as the synthesis
of nucleotides and amino acid sugars from amino acids; the formation of
niacin from tryptophan and that of melanin from tyrosine and
phenylalanine.
5. Steady and non-steady states
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All calculations also assume a 'steady' state in which the amino acid pool
sizes are constant throughout the period of investigation. In non-steady
states with changes in pool size during the study period and where plateau
is not attained equations originally developed by Steele (Steele, 1959) for
use in studies of glucose metabolism with radio-active tracers and
subsequently modified for use in stable isotope studies by Miles and
colleagues (Miles et al., 1983) should be used.
2.4 Determination of Whole-body Protein Turnover with
[ir'N]Phenylalanine: Equations for Steady State Conditions
The 15N enrichment of plasma phenylalanine, during a primed continuous
infusion of L-[15N [phenylalanine under plateau conditions, is used to calculate the
components of whole-body phenylalanine kinetics. A two pool model is employed
with a) the free pool of phenylalanine in plasma and in cells and b) the protein-
bound pool of phenylalanine (Figure 2.3). The equations are (Clarke and
Bier, 1982):
Q = B + D
where:
Q = the rate of phenylalanine turnover or flux
B = endogenous phenylalanine appearance or protein breakdown, and
D = dietary intake of phenylalanine.
The units of whole-body phenylalanine kinetics are micromoles of phenylalanine










Figure 2.3 A two pool model of protein turnover with
phenylalanine D = Diet; S = Synthesis; B =
Breakdown; C = Catabolism to tyrosine.
The plasma phenylalanine flux is calculated with the equation:
E
Q - i [ -i -1]
ep
where:
i = infusion rate of L-[15N]phenylalanine (ju.mol/kg/h),
Ei = 15N enrichment of the infused L-[15N]phenylalanine (APE), and
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Ep = 15N enrichment ofplasma L-[15N]phenylalanine (APE) after tracer equilibrium.
In the studies reported here a deep forearm antecubital vein was used as the
sampling site. Ideally with phenylalanine the tracer would have been infused into
the left heart and well mixed samples obtained from the right heart (Layman and
Wolfe, 1987), a clearly impractical approach for studies in man. Infusion into a
peripheral vein approximates a direct infusion into the left heart and sampling
from a vein draining a large vascular bed may have enabled samples to be obtained
which have been little different from right heart samples.
The first steps in the catabolism of phenylalanine involve hydroxylation of
the aromatic ring, producing tyrosine. To calculate phenylalanine entry into
protein an estimate of the rate of conversion of phenylalanine to tyrosine is
required: this is calculated from simultaneous measurements ofphenylalanine flux,
tyrosine flux (with an additional tyrosine tracer), and appearance of the infused
phenylalanine tracer in plasma tyrosine. In the studies reported here tyrosine flux
and phenylalanine catabolism to tyrosine were not measured and, therefore, no
estimate of non-catabolised phenylalanine disappearance (i.e. protein synthesis) can
be made. Only whole-body total phenylalanine appearance and protein breakdown
can be measured with the technique used. The equations for whole-body
phenylalanine turnover are only valid where plateaux exist for both the 15N
enrichment and the concentration of plasma phenylalanine.
There are a number of assumptions underlying the use of these equations;
these are:
a) The metabolism of ir'N-labelled phenylalanine is the same as that of
unlabelled endogenous phenylalanine.
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b) There is negligible recycling of tracer after it is incorporated into protein.
c) There are two pools of phenylalanine: a) free, both in the intravascular and
intracellular compartments, and b) bound into proteins.
d) The degree of dilution of the label (the enrichment of phenylalanine in
plasma) is representative of that of intracellular phenylalanine in the precursor
pool for protein synthesis. Although this has not been confirmed in man it is
shown in animal tissue in vitro and in vivo, for leucine at least, that leucyl-^RNA
is charged with leucine coming predominantly from extracellular fluid or plasma
(Davey and Manchester, 1969; Clark and Zak, 1981; Everett et al, 1981; Airhart et
al, 1982). It is also known that phenylalanine readily enters into cells by the L-
system transporter (used by leucine) and in addition, in liver by the T-system
transporter. Neither of these transporters are modulated by hormones (Yudilevich
and Boyd, 1987). It, therefore appears likely that tracer studies in man in which
plasma phenylalanine enrichment is measured provide some measure of
metabolism at an intracellular level. This approach awaits validation.
e) In subjects where phenylalanine was infused parenterally it entered into
cells and mixed fully throughout the free phenylalanine pool.
2.5 Methods for Investigating Amino Acid and Protein Metabolism in
Human Limb Tissues
Several techniques have been developed in the past two decades to measure
limb muscle protein turnover. These include:
1. A semi-quantitative approach based upon comparison of the net amino acid
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balance (or imbalance) and the extent of loss from muscle of the amino acid
3-methylhistidine, a specific index of myofibrillar protein breakdown
(Lundholm et al., 1982).
2. The use of stable isotopes to determine limb protein synthesis and
breakdown by measuring the arteriovenous exchange of a labelled tracer
amino acid (e.g. [15N]phenylalanine) (Bennet et al., 1990).
3. The measurement of protein synthesis directly by estimating the
incorporation ofstable isotope-labelled amino acids into muscle using muscle
biopsy techniques (Bennet et al., 1989).
2.5.1 Semi-Quantitative Approach using Amino Acid Efflux
The flux of an amino acid (either influx, i.e. uptake of amino acid or efflux,
i.e., release of amino acid from muscle tissue) may be calculated from Fick's
principle by multiplying the arteriovenous difference in concentration of an amino
acid by the blood flow. Assumptions implicit in Fick's principle are that a steady
state exists, that blood flow and metabolic rate are constant, that the blood flow in
is equal to the blood flow out and that there is no interference from recirculation.
The amino acid tyrosine for example is not metabolised to any significant
extent in skeletal muscle (Li et al., 1973). Measurement of tyrosine arteriovenous
difference correlates closely with net amino acid balance (Clowes et al., 1980;
Lundholm et al., 1982; Bennegarde£ al., 1984). The net amino acid balance (which
is the difference between synthesis and breakdown of protein) can then be
compared with efflux of a specific index of protein breakdown such as 3-
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methylhistidine. 3-methylhistidine (i.e. lY-methylhistidine) is an amino acid
produced by post-translational methylation at the AT position of histidine-73 of the
actin chain (Vanderkerckhove and Webster, 1984). When released by the
breakdown of myofibrillar proteins, 3-methylhistidine is not reincorporated into
protein by protein synthesis and does not undergo intermediary metabolism (Young
et al., 1971). 3-methylhistidine is a constituent of actin (Asatoor and Armstrong,
1967) and the heavy chain of myosin in white muscle (Johnson et al., 1967),
proteins which together constitute 50% of muscle protein. Release of 3-
methylhistidine, therefore, provides a specific index of breakdown of these
myofibrillar proteins. It follows that factors modulating changes in the rate of
breakdown of actin and myosin will induce changes in 3-methylhistidine release.
In contrast, factors modulating changes in the rate of breakdown of mixed non-
myofibrillar proteins may not cause any change in 3-methylhistidine release.
Therefore, apparently conflicting results may be obtained from studies comparing
changes in protein breakdown measured using 3-methylhistidine and for example
tyrosine or phenylalanine release (Smith and Sugden, 1986). The release of 3-
methylhistidine in urine has been widely advocated and used as an index of
skeletal muscle protein breakdown in vivo (Ballard and Tomas, 1983). Objections
to such use (Rennie and Millward, 1983) are based on the existence of 3-
methylhisticline in non-muscle protein pools which turn over rapidly and contribute
substantially to the total urine release of 3-methylhistidine (Clark and Spudich,
1977; Young and Munro, 1978; Emery et al., 1986). For the rat, estimates of the
source of total 3-methylhistidine from skeletal muscle, skin and gastrointestinal
smooth muscle are 25%, 7% and 10% respectively; the source of more than half of
the total urine excretion of 3-methylhistidine was not identified (Millward et al.,
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1980c). For healthy man such information is not available. In sepsis however, in
man, approximately 80% ofexcreted 3-methylhistidine derives from skeletal muscle
with approximately 20% from non-muscle sources (Sjolin et al., 1989). In studies
of human protein metabolism seemingly directly conflicting results are reported
with regard to the changes which may occur in urinaiy excretion of 3-
methylhistidine (Rennie et al., 1983). It is, therefore, likely that urinary excretion
of 3-methylhistidine is not adequately specific for monitoring human skeletal
muscle protein breakdown in vivo and only 3-methylhistidine efflux from the
forearm has been employed as an index of skeletal muscle breakdown in the studies
reported here. The major difficulty with the limb arteriovenous exchange technique
is that the plasma concentration of 3-methylhistidine is veiy low (2-6 p,mol/l) and
can only be measured with sophisticated techniques such as automated ion
exchange chromatography with fluorometric detection, used in the present studies.
The 3-methylhistidine efflux was calculated with the following equation:
Bal = (CA-3-mehis - CV-3-mehis) • BF
Where:
CA-3-mehis and Cv-3-mehis = plasma concentrations of 3-methylhistidine (p.mol/1), and
BF = blood flow (ml/lOOg/min).
Units are nmol of 3-methylhistidine per lOOg per min (nmol/lOOg/min).
Thus, in summary, a semiquantitative estimate of protein synthesis can be
made from a comparison of the size and direction of change of tyrosine or
phenylalanine balance and 3-methylhistidine output. No absolute rates of protein
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synthesis can be arrived at however, although it is possible to make judgements
about the direction and relative sizes of changes from normal in protein synthesis
and protein breakdown.
2.5.2 Arteriovenous Phenylalanine Exchange by Limb Tissue Determined
with L-[1BN]phenylalanine
This technique may be used to measure arteriovenous uptake and release
of phenylalanine across a limb (Cheng et al., 1985; Gelfand and Barrett, 1987;
Thompson et al., 1989), which predominantly contains skeletal muscle (Haggmark
et al., 1978). In skeletal muscle the only metabolic fates of phenylalanine are
incorporation into protein and release from protein; catabolism of phenylalanine to
tyrosine occurs predominantly in liver and does not occur in muscle. Uptake and
release of phenylalanine by the limb are therefore, indices of protein synthesis and
breakdown respectively.
The 15N enrichment of arterial and venous plasma phenylalanine, during a
primed continuous infusion of [15N]phenylalanine, and plasma concentrations may
be used to calculate phenylalanine exchange by limb tissue from the degree of
dilution of the tracer in the venous outflow in comparison with the arterial inflow.
The following equations (simplified from those of Cheng et al., 1985) may be used
(Gelfand and Barrett, 1987; Thompson et al., 1989):




Bkdn = release of phenylalanine (protein breakdown) across the leg in nmol of
phenylalanine per 100 g of leg tissue per minute (nmol/lOOg/min),
EA-phe = 15N enrichment of arterial plasma phenylalanine (APE),
Ev-phe = 15N enrichment of venous plasma phenylalanine (APE),
CA-phe = arterial plasma concentration of phenylalanine in nmol/ml or p.mo 1/1, and
BF = Blood flow of the limb in ml per 100 g limb per minute (ml/lOOg/min).
The net arteriovenous balance or the efflux of phenylalanine, a measure of
protein balance, may be calculated with the following equation:
Bal = (CA_phe - Cv_phe) ■ BF
where:
Bal = arteriovenous balance of phenylalanine across the limb (nmol/100 g/min), and
CA-phe and Cv-phe = arterial and venous plasma phenylalanine concentrations
(/xmol/1).
In general the use of the term balance is preferred to the term flux. The
former term was coined before the application of tracer techniques to the
investigation of limb amino acid metabolism. The results with tracer techniques
show that the flux of "flow" of amino acids is much greater than their respective
net balances.
The arteriovenous uptake ofphenylalanine or protein synthesis is calculated
with the equation
Syn = Bal - Bkdn
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where:
Syn = arteriovenous uptake of phenylalanine (nmol/100 g/min).
These equations are only applicable for a steady-state of concentration and
15N enrichment of plasma phenylalanine.
There are a number of assumptions which are integral to the use of these
equations. These are:
a) There are no differences between the metabolism of 15N-labelled and
endogenous phenylalanine.
b) There is negligible recycling of tracer after incorporation into protein.
c) Rapid exchange of phenylalanine occurs between plasma and muscle and,
therefore, the ir>N enrichment of venous phenylalanine represents that entering
protein synthesis within muscle, i.e. that of muscle phenylalanyl-tRNA.
d) The concentration of phenylalanine in plasma is the same as that of free
phenylalanine within muscle.
e) When steady-state conditions are changed by a therapeutic action, complete
exchange of phenylalanine occurs in the intramuscular free pool before further
measurements are made.
f) The blood cells exchange amino acids rapidly and are involved in the across
limb amino acid exchange. Pilot studies in our laboratory suggest that this is the
case but exchange of tracer by the blood elements may be slower than that of
plasma (K. Smith, personal communication).
g) The arterial blood flow is the same as the venous blood flow.
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2.5.3 Calculation of muscle protein synthetic rate by determination of
labelled amino acid incorporation into muscle protein
The method for the measurement of muscle protein synthesis using
incorporation of a labelled amino acid is conceptually simple. A primed constant
infusion of a stable isotope-labelled tracer amino acid is set up and muscle sampled
by either a needle biopsy or conchotome forceps biopsy technique over a period of
time when the plasma amino acid pool is labelled to a constant extent. The use of
a priming bolus of tracer shortens the time required for the constant infusion
(Matthews et al., 1980). Ideally the rate of incorporation of label into protein
should be measured by the comparison of two or more tissue biopsy samples taken
at intervals after attainment of plateau labelling in plasma. However, in both
patients and healthy volunteers, it is often not possible to obtain more than a
single biopsy at the end of the period of infusion (i.e. at time t2). Calculation then
of incorporation (and synthetic rate) must be made from an assumed starting
isotopic enrichment of mixed tissue protein (i.e. at time t0), which can be obtained
by measuring the mean L-[l-13C]leucine enrichment in muscle from patients who
have not been infused with L-[l-1;!C]leucine (Gibson et al., 1988). A further
alternative exists for obtaining base-line values for [l-13C]leucine enrichment of
body protein against which to compare the incorporation of tracer I l-l3C]leucine
into muscle protein. Since basal 13C enrichment of leucine in whole blood proteins
closely reflects the basal 13C enrichment in protein-bound leucine in muscle (Heys
et al., 1990) a blood sample may be collected prior to the tracer infusion and mixed
immediately with 2M perchloric acid for precipitation and later isolation and
analysis, of whole-blood protein 13C leucine enrichment (Heys et al., 1990). This
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was the method used in the present healthy volunteer studies where the local
Ethical Committee approved one muscle biopsy only per study.
Muscle protein synthetic rates (ka) can be calculated from the measured
increase in incorporation of [13C]tracer amino acid into the protein bound pool (AEm)
over a period of time (tv t2) and the average enrichment of the pool chosen to
represent the precursor pool for protein synthesis (Ep). For the primed constant
infusion method the equation used was as follows (Rennie et al., 1982a; Rennie et
al., 1982b):
A E 1
K (%M) * —-— x 1005
E,
where AEm is the difference in enrichment between muscle biopsies or
between a muscle biopsy and (basal) mixed whole blood protein
E is the average enrichment in the pool taken to represent the precursor
and
and t2 represent the time of biopsy (or, for tv sampling of whole blood).
2.6 Methods of measuring albumin turnover
In addition to studies of skeletal muscle and whole-body protein turnover,
towards the end of these studies, as some plasma samples remained, the effect of
Ala-Gin supplementation of conventional non-glutamine containing TPN was also
investigated. A variety of methods have been employed to measure albumin
turnover, including assay of the disappearance of 1:ilI-labelled albumin (Jensen et
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al., 1967; Rossing, 1967) or incorporation of 14C02 (Tavill et al., 1968). These
methods have obvious limitations; they involve radioisotopes and require relatively
long study periods (typically > 12h). Stable isotope tracer methods have also been
applied to the measurement of albumin turnover, initially using [15N]glycine
(Gersovitz et al., 1980; Olefumi et al., 1990; Yudkoff et al., 1987). [13C]leucine
administered as a constant infusion (Carraro et al., 1990; Olefumi et al., 1990;
Carraro et al., 1990) or as a flooding dose (Ballmer et al., 1990) has been used to
investigate the effects on albumin synthesis of varying dietary protein (Carraro et
al., 1990), exercise (Carraro et al., 1990), pregnancy (Olefumi etal., 1991), diabetes
and insulin administration (DeFeo et al., 1991; Pacy et al., 1990) and cirrhosis
(Ballmer et al., 1992).
Albumin synthesis rates obtained by the flooding dose (0.30%/h) and
constant infusion (0.25%/h) are reportedly not very different when measured in
separate studies by different investigators, when comparison has been made, and
the size of any true difference could have been obscured (Ballmer et al., 1990;
Olefumi et al., 1990). A recent study undertaken in our laboratory to directly
compare the two methods suggests that the flooding dose method per se stimulates
albumin synthesis (Smith et al., 1993) and therefore should be considered carefully
with regard to results obtained by its use in studies of e.g. nutritional intervention
on albumin synthesis.
2.6.1 Calculation of albumin protein synthetic rate
In calculating albumin synthetic rate for greater accuracy it is advisable to
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take into account the lag period between the synthesis and processing of albumin
by the liver and its eventual secretion into plasma, i.e. the secretion time (tj. The
relationship between precursor and product is displaced by this secretion time,
which can be calculated by plotting the regression line of the linear portion of the
f13C lleucine incorporation into albumin and extrapolating to the basal enrichment.
The rates of albumin synthesis were calculated by standard equations for
the constant infusion method (Ballmer et al., 1990; Garlick et al., 1989; Rennie et
al., 1982). Albumin synthetic rate was calculated from the change in the measured
13C enrichment of leucine in albumin divided by the area under the curve of
precursor enrichment and was calculated after correcting for the lag period between
infusion of label, its incorporation into albumin and its subsequent secretion from
the liver. The secretion time (ts) was calculated by extrapolation of the linear part
of the curve of leucine incorporation into albumin to the base-line enrichment. The
area under the curve of venous plasma a-ketoisocaproate (a-KIC) during each of
the four hour periods of the split-period study was used as a measure of precursor
enrichment during that period, i.e. in each case between 4 h of ts and the time at
which the end-of-period plasma sample was taken minus ts. One criticism of using
this approach is that the ketoacids are formed primarily in muscle, whereas
albumin is synthesized mainly in the liver. However, this approach has recently
been supported both by the closeness of the labelling of another branched-chain
keto-acid, a-ketoisocaproate (aKIC), to that of the liver-derived very-low-density
lipoprotein apolipoprotein B-100 (Pacy etal., 1991) and by the similarity of albumin
synthesis rate observed when the rate is calculated on the basis of aKIC and urea




Healthy volunteers were recruited from the staff of the Department of
Anatomy and Physiology of the University of Dundee and the Department of
Surgery of Ninewells Hospital and Medical School, Dundee. All healthy volunteers
were screened by way of medical history-taking and none suffered from any acute
or chronic illnesses and none were taking any medication. Pre-study screening
blood tests for urea, creatinine, electrolytes, glucose and full blood count were
normal. All subjects had stable body weights prior to study. There were no recent
significant dietary changes and the diets were weight-maintaining.
Completed studies were performed in 16 patients who had undergone major
elective abdominal surgery i.e. potentially curative oesophagectomy or
oesophagogastrectomy for localised (as established by clinical examination,
abdominal ultrasound and computerised axial tomography abdominal and thoracic
scans) squamous or adeno-carcinoma of the lower third region of the oesophagus
or of the gastro-oesophageal junction. They were provided with routine post¬
operative intensive care and parenteral nutritional support and were studied on the
3rd post-operative day. The expected age range of patients at the study outset,
based on a review of hospital theatre records over the previous three years was 40-
70 years. In order to minimise the effect of factors or variables known to affect
muscle protein turnover, patients were excluded from the study if i) they had
hormonal disorders (e.g. diabetes, thyroid disease), with the aim of avoiding the
influence of these hormonal conditions on the protein turnover of patients studied
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ii) metastatic neoplastic disease, to exclude the influence of cancer cachexia (Rennie
et al., 1983b) as a variable. All patients were allocated an APACHE II score
(Knaus et al., 1985) after an assessment carried out on routine post-operative
admission to the intensive care unit, to provide an indication of the degree of
pathophysiological disturbance resulting from the injury of surgery.
2.7.2 Ethical Approval
The studies reported in this work have been submitted for consideration by the
Ethical Committee on Clinical Studies of the Dundee General Hospitals Group and
formal approval has been obtained.
2.8 Adenocarcinoma of the Oesophagus
2.8.1 Pathology
The oesophagus is lined by stratified squamous epithelium down to the
lower 2-3 cm. Ninety-nine percent of malignancies are squamous cell carcinomata.
These are commonest in the mid-oesophagus just below the arch of the aorta. One
percent of malignancies are adenocarcinomata. These arise in the lowest
oesophagus either from an ectopic island of mucous epithelium which may occur
just above the oesophago-gastric junction, or as a spread upwards of carcinoma of
the cardia. Predisposing factors include oesophageal achalasia, a long-standing
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structure, and the Plummer-Vinson syndrome (Watt and Spence, 1986). It is more
common in smokers. It is likely that environmental factors are involved and the
condition occurs more commonly in certain geographical areas (e.g. Brittany,
Normandy and Transkei). The tumour typically spreads by submucosal invasion
along the oesophagus. Lymphatic spread is either to the supraclavicular,
subdiaphragmatic or mediastinal nodes. The oesophagus lies near vital
neurovascular structures in the mediastinum which may be involved by local
invasion. For these reasons effective surgical removal is difficult to achieve in
other than early lesions, and the prognosis is usually poor.
2.8.2 Clinical presentation
The patient is usually over the age of 60. Lower third carcinoma are more
common in males than females although the sex incidence for carcinomas of the
middle and upper thirds is equal. The patient typically presents with a short
history of progressive dysphagia. This initially affects solids only, but gradually
increases until even swallowing liquids becomes a problem. Retrosternal pain may
occur but is usually a late symptom. There may be regurgitation of food or fluids,
or bloodstained vomiting. There is frequently a history of significant weight loss
and the patient is usually cachectic. They may have palpable nodes and an
enlarged liver but often, there are no abnormal signs.
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2.8.3 Investigations
Barium swallow. Carcinoma of the oesophagus has a characteristic
appearance of narrowing of the lumen which has an irregular, craggy, pitted
surface and raised, rolled edges. The length of the narrowed lumen is used in
staging.
Oesophagoscopy and biopsy. The carcinoma may be seen either as a
malignant ulcer, a papillary growth or an irregular stricture. A biopsy is taken to
confirm the diagnosis.
Oesophageal lavage and cytology. A cytological diagnosis of carcinoma may
be made from cells isolated from oesophageal washings.
Computerized axial tomography. This gives a clear picture of the degree of
mediastinal involvement.
These investigations aid in staging the extent of the disease and
determining whether the tumour is potentially curable by local resection or not,
and whether the patient is fit for major surgeiy. Of every 100 patients seen, about
60 will be considered operable. A final decision also takes into account the
patient's general condition. The TNM (Tumour, Node, Metastasis) system of
clinical staging is given in Table 2.1. In Western series the five-year overall
survival is a disappointingly low 5% regardless of treatment. Prognosis appears
to be related to size, especially length, and degree of spread at the time of
treatment rather than to any histological feature, although adenocarcinomas tend
to have a worse prognosis than squamous carcinomas.
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TABLE 2.1 TNM (Tumour, Node, Metastasis) clinical staging of oesophageal
carcinoma
Tis - Pre-invasive carcinoma (carcinoma-in-situ)
TO - No evidence of primary tumour
T1 - Tumour involving 5 cm or less of the oesophageal length, producing no
obstruction, does not involve the entire circumference of the oesophagus and
which shows no evidence of extra-oesophageal spread
T2 - Tumour involving more than 5 cm of the oesophageal length and with no
evidence of extra-oesophageal spread, or tumour of any size producing
obstruction and /or involvement of the entire circumference of the
oesophagus but with no extra-oesophageal spread
T3 - Tumour with evidence of extra-oesophageal spread, such as recurrent
laryngeal, phrenic or sympathetic nerve involvement, fistula formation,
involvement of trachea or bronchial tree, vena cava or azygos vein
obstruction or malignant effusion
Cervical oesophagus
NO - No evidence of regional lymph node involvement
N1 - Evidence of involvement of moveable unilateral regional nodes
N2 - Evidence of involvement of moveable bilateral regional nodes
N3 - Evidence of fixed regional nodes
Thoracic oesophagus
NO - No evidence of regional node involvement on exploration or mediastinoscopy
N1 - Involved regional nodes
Distant metastases
MO - No evidence
Ml - Presence of distal metastases
2.8.4 Forms of therapy
Oesophageal carcinoma may be treated by surgical resection, radiotherapy
or palliative intubation or bypass. Squamous cell carcinoma can either be treated
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by surgery or radiotherapy. Adenocarcinoma is not sensitive to radiotherapy.
2.8.4.1. Surgical resection
This is only attempted for growths confined to the oesophagus with no
evidence of lymphatic or mediastinal spread. Of the 60 patients considered
operable one third will be found to have more extensive tumours at the time of
operation. Because of the likely presence of submucosal invasion curative resection
requires wide excision of the oesophagus above and below the growth. The type of
operation performed depends on the site of the growth (Table 2.2) (Dunn and
Rawlinson, 1985).









All the patients in the present studies had carcinoma of the lower third
oesophagus or oesophago-gastric junction and oesophago-gastrectomy was the
operative procedure performed. The stomach and lower oesophagus are mobilized
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and the liver palpated. If the tumour is considered resectable, the chest is opened
(left thoraco-abdominal incision) and the lower oesophagus including the tumour,
all or part of the stomach, spleen and omentum are removed. The continuity of the
oesophagus is usually restored either by anastomosis to the stomach remnant or,
if all the stomach is resected, to a loop of jejunum.
2.8.4.2. Radiotherapy
This is used for squamous cell carcinoma in patients unfit for surgery or
patients with a carcinoma involving the oesophagus above the arch of the aorta.
There are few trials of radiotherapy performed for early carcinoma which would
normally be considered resectable. The results appear to compare favourably with
surgery although objective assessment cannot be made as the groups of patients
are not comparable. Radiotherapy is also effective palliative treatment for
dysphagia in some cases. Fifty per cent of patients need follow-up oesophageal
dilatation. Complications include leucopenia, pulmonary fibrosis and spinal cord
compression, all of which are rare with modern techniques.
2.8.4.3. Palliation
Of any 100 patients with oesophageal carcinoma, 60 will be found to have
inoperable tumours and many of these will require some form of symptomatic
relief. The most significant symptom is dysphagia. This may be relieved by i)
intubation of the tumour, ii) a bypass operation iii) radiotherapy.
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2.9 Experimental Environment
All subjects in the healthy volunteer studies attended the Department of
Surgery on the day prior to the study. On arrival their weight, height and body fat
composition - estimated from skin-fold thickness at four sites (Durnin and
Womersley, 1974) - were determined. Informed written consent was obtained for
participation in the study. The subjects re-attended the Department at 0645 h on
the following day for the study. They remained recumbent throughout the study
and the study room was maintained at a thermoneutral temperature between 25-27
°C.
In the patient studies the clinical background, including a review of the case
records, of subjects who met the entry and exclusion criteria for the post-operative
metabolic studies was discussed in detail with the clinician in charge of their care
prior to their admission to hospital. All patients were approached on the day of
their admission to one of the surgical wai'ds in Ninewells Hospital and Medical
School, usually the day prior to their operation. Informed written consent for
participation in the metabolic studies was obtained and as with the healthy
subjects, their weight, height and body fat composition were determined. The
metabolic studies were carried out in the Intensive Care Unit, Ninewells Hospital
and Medical School, on the third post-operative day. The subjects generally
remained in a recumbent position throughout most of the duration of the study,
excepting five to six brief periods of time (15-20 min each) when they received




All stable isotope labelled amino acids i.e., L-[l-13C]leucine (99% 13C), L-
[15N]phenylalanine (99% 15N) and sodium [13C|bicarbonate were purchased from
Tracer Technologies Incorporated, Newton, MA, U.S.A. Immediately prior to
administration the tracers were mixed in sterile pyrogen-free sodium chloride
(NaCl) solution (Baxter Healthcare, Norfolk, U.K.) using an aseptic technique and
the tracers were sterilised by passage through a 0.22 pm filters (Millipore SA,
Molsheim, France). The tracer infusates were subsequently diluted to a total
volume of 500 ml in sterile pyrogen-free NaCl solution (Baxter Healthcare, Norfolk,
U.K.) and were infused via a second 0.22 pm filter.
2.10.2 Alanine, Glycine and Ala-Gin solutions
Solutions of the dipeptide Ala-Gin (Kabi-Pfrimmer, Erlangen, F.D.R.) and
a mixture of the unlabelled amino acids L-alanine and glycine (Sigma Laboratories,
U.K.) were prepared under aseptic conditions in sterile, pyrogen-free 0.9% (150
mmol/1) sodium chloride solution (Baxter Healthcare Ltd, Thetford, Norfolk, U.K.).
The solutions were sterilized by filtration through 0.22pm filters (Millipore SA,
Molsheim, France). At the time of administration they also were infused via a
second 0.22 pm filter.
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2.10.3 TPN
From the first post-operative day, patients received parenteral nutrition
consisting of a 50:50 mixture of two conventional commercial mixed amino acid
solutions (Synthamin 9 and Synthamin 14, from Baxter Healthcare, Thetford, UK)
providing 11.5 g nitrogen, Table 2.3) with 450 g glucose, 70 mmol Na+ and 80 mmol
K+, all in 2.5 1 water per 24 h. Patients received a 2.5 1 bag of the solution over 24
h containing:
500 ml Synthamin 141
500 ml Synthamin 9 I (providing 11.5 g N/ 2.5 1 bag)
1500 ml Glucose 30% (providing 7532 kJ)
70 mmol Na+
80 mmol K+
2.11 Blood sampling and infusion technique
In healthy volunteers, arterialised venous blood samples were taken from
a 1.7 mm outer-diameter cannula (Venflon, Viggo AB, Helsinborg, Sweden), placed
retrogradely in a dorsal hand vein and patency was maintained by a slow infusion
of NaCl solution (250 ml over 8 h, 150 mmol/1). Before sampling, the hand was
warmed for a minimum of 15 min by insertion into a thermostatically controlled
chamber with a circulating air temperature of 75 - 80"C (Abumrad et al., 1981).
In the whole-body kinetics technique, it is essential to obtain mixed blood
representative of that in all tissues, i.e., arterial blood, and the arteriovenous
exchange technique also places a requirement for arterial samples. Arterial
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Table 2.3 Composition of Synthamin Amino Acid Solutions
















Total L-Amino Acids 55.0 85.0
Total Nitrogen 9.1 14.0
cannulation however, used in research, poses unacceptable risks of complications
to healthy subjects (Hall, 1971). The use of a heated superficial vein to obtain
arterialised blood, the technique used on healthy subjects in the present studies,
has been validated for obtaining arterial samples for blood gases and lactate
(Forster et al., 1972), glucose and alanine (Abumrad et al., 1981) and ketone bodies
(Sonnenberg and Keller, 1982).
A second 1.7 mm outer-diameter cannula was placed antegradely in an
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ipsilateral antecubital vein of the forearm for infusion of amino acids, tracers and
the dipeptide L-alanyl-L-glutamine. In the arteriovenous exchange studies, a third
1.7 mm. outer-diameter cannula was placed retrogradely in an antecubital vein of
the contralateral forearm, to allow sampling of deep venous blood from the forearm.
A paediatric sphygmomanometer cuff placed around the wrist was inflated to a
pressure of 200 mmHg for 60 s before sampling to occlude the venous drainage
from the hand. In composition, the hand proportionately has a much higher
percentage of skin and bone and conversely muscle in comparison with the forearm
and by excluding the hand circulation during venous sampling times, a greater
portion of the venous drainage would come from the forearm, composed
predominantly of muscle (about 75%). In man, bone accounts for about 10-12% of
forearm volume: this tissue has a very slow turnover rate and bone blood flow was
not recorded separately by the technique used in these studies. The remaining
proportion of forearm, adipose tissue, has a low unit blood flow and contributes to,
for example, phenylalanine metabolism to a negligible extent. It would appear
therefore that muscle protein turnover predominantly accounts for the protein
turnover of human limbs.
Blood gases (Pco2, Po,, Sa02%) were measured routinely to ensure sufficient
arterialisation i.e. >95% 02 saturation was obtained and that deep venous blood
was obtained from a site draining predominantly muscle, i.e. low 02 saturation,
<50% (Jackson et al, 1987), using a Corning 189 blood gas analyser (Corning
Medical, Mass., USA).
In the studies involving postoperative subjects, arterial blood samples were
obtained rather than arterialised venous samples, as these patients, studied in an
intensive care unit (ICU) setting, had routine radial artery cannulation performed
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by the anaesthetist in charge for the purpose of clinical monitoring of the patient's
arterial blood gases. A cannula for sampling of venous blood was inserted
retrogradely into an antecubital vein, as for the studies in healthy subjects.
Patients also routinely had insertion of a triple-lumen cannula (KeyMed, UK), by
a senior anaesthetist, into an internal jugular vein at the time of surgery, for
subsequent use in monitoring central venous pressure in the 24-48 h postoperative
period and for the infusion of intravenous drugs in this period. From the first post¬
operative day, one channel of the triple lumen cannula was used for the infusion
of intravenous parenteral nutrition. On the third postoperative day, when the
present studies were carried out, the second channel was used for the infusion of
the study solutions (L-alanyl-L-glutamine, glycine and L-alanine). The third
channel was used for infusion of tracer amino acids.
2.12 Blood Sample Handling
Blood samples were collected in tubes which contained additives appropriate
for subsequent biochemical assays (Table 2.4). All blood samples were stored on
ice prior to separation in a refrigerated centrifuge (4°C) at 1700 times gravity for
20 min. Samples were stored at -80°C until analysis. To prepare plasma for free
amino acid concentration analysis, the plasma was deproteinised with
sulphosalicylic acid (100 g/1, 1:4 v:v) containing norvaline internal standard (64
/xmol/T), incubated for 30 min at 4"C to precipitate ^-lipoproteins, passed through
0.45 p,m filters before storage at -80"C. The perchloric acid extracts of blood for D-(-
)-3-hydroxybutyrate analysis were neutralised by the addition of an alkaline
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Abbreviations: Li Hep, lithium heparin; EDTA, ethylenediaminetetra-acetic acid;
KIU, kallikrein inhibitor units.
solution containing 2 mol/1 KOH, 0.4 mol/1 KC1 and 0.4 mol/1 imidazole before
storage at -80"C. Plasma for hormone analysis e.g. insulin and glucagon, was
aliquoted separately into EDTA tubes and stored at -80"C until analysis. To treat
and store blood for subsequent determination of whole blood carbon dioxide
concentration and 13C enrichment, the blood (1 ml) was added to 20 ml glass
evacuated tubes (Vacutainer, Becton Dickinson, NJ, USA) immediately on
sampling. Before use these tubes were prepared by adding 1 ml of a mixture of
orthophosphoric acid (6 mol/1) and silicone antifoam (10% by volume) and the tubes
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were degassed to a pressure of 0.4 mbar and sealed (Read et al., 1984).
2.13 Breath Sampling and Indirect Calorimetry
Before tracer administration and at intervals throughout the healthy
volunteer studies expired breath was collected into 2 1 latex bags and an aliquot
was transferred into 20 ml evacuated glass tubes (Vacutainer) for storage and
subsequent determination of 13C enrichment in carbon dioxide, as detailed below.
Total carbon dioxide production and oxygen consumption was determined over the
8 h period by two separate 10 min collections of expired breath into a 100 litre
Douglas bag, the volume being determined by a Harvard dry gas meter. Samples
of the breath (200 ml) were subsequently analyzed for C02 with an infra-red
absorption C02 gas analyzer (Analytical Development Co., Ltd., U.K.). In patients,
the protocol requirements and the arrangements for expired breath collections and
indirect calorimetry were initially identical, although in a large number of patients,
because of technical and other limitations described in Chapter 5, the protocol
requirements could not be met.
2.14 Muscle Biopsy Technique
Anterior tibial muscle was biopsied using 6.5 mm Tilley Henckel ethmoid
punches (S. Murray and Co., Sheffield, U.K.) via a 10 mm long skin incision made
after 5 ml of 20 g/1 lignocaine local anaesthetic was infiltrated superficially to the
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fascia (Dietrichson et al., 1987). At each time point one to three biopsies were
obtained providing 100 to 300 mg wet weight of muscle. The biopsies were from
the fullest part of the shin and were taken 10 mm deep to the fascia. After each
biopsy firm pressure was applied for 10 to 15 min over the site, and the skin
incision was held closed with surgical tape. In the patient studies a second biopsy
was taken from either the same leg, at a distance of 40 mm to the first biopsy, or
from the contralateral leg. A third biopsy was taken from the leg contralateral to
that first biopsied. The muscle samples were immediately frozen in liquid nitrogen
and stored at -196°C until analysis.
2.15 Limb Blood Flow
Blood flow was measured in the study forearm using venous occlusion strain
gauge plethysmography using a commercially available instrument (Medimatic,
Denmark) regularly maintained and calibrated by the Vascular Laboratory,
Ninewells Hospital and Medical School, Dundee and kindly lent for the present
metabolic studies. Appropriate precautions were taken according to guidelines
outlined by Jackson et al. (1987) with, in particular, a paediatric wrist cuff being
applied, as described above, prior to blood flow measurement in order to stabilise
the measured blood flow by minimising the variable effects of the cutaneous
circulation on flow. The technique of mercury-silastic strain gauge
plethysmography (Whitney, 1953; Needham, 1972; Englund et al., 1972; Sumner,
1985) has been shown to give reproducible results (Roberts et al., 1986) and to show
appropriate blood flow changes resulting from exercise (Hughson, 1988).
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2.15.1 Tracer Infusions
At the start of tracer infusion doses of L-| l-13C|leucine (1.0 mg/kg) and
sodium [13C] bicarbonate (either 0.16 for volunteer or 0.24 mg/kg for patient
studies) were administered to prime their respective body pools (Allsop et al., 1978;
Matthews et al., 1980; Nair et al., 1988a). A continuous infusion of L-| 1-''SC[leucine
at a rate of 1 mg/kg/h was administered throughout the studies. This was diluted
to a volume of 500 ml in sodium chloride (150 mmol/1 NaCI), and was delivered at
a rate of 62.5 ml/h with IMED 928 volumetric infusion pumps (IMED Ltd,
Abington, U.K.). In the arteriovenous exchange studies priming doses of L-
L1SN [phenylalanine (0.5 mg/kg) were administered, followed by a continuous
infusion (0.5 mg/kg/h) throughout the studies.
2.15.2 Ala-Gin and Ala + Gly infusions
In the healthy volunteer studies, control subjects received an 8 h constant
infusion of alanine and glycine (Kabi-Vitrum, Sweden) at 4.8 mg/kg/h and 8.0
mg/kg/h respectively (after priming bolus doses of 4.8 mg/kg and 8.0 mg/kg)
providing a total of 2.25 mg amino-N/kg/h. The study group received a primed
constant 8 h infusion of L-alanyl-L-glutamine (Kabi-Vitrum, Sweden) at 11.7
mg/kg/h, also providing 2.25 mg amino-N/kg/h, after a priming dose of 11.7 mg/kg.
The solutions were delivered by an IMED 928 volumetric mixed infusion pump
(IMED Ltd, Abington, U.K.). In the longitudinal patient study (see below for
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description of protocol), a mixed solution of alanine (4.8 mg/g/h) and glycine (8
mg/kg/h) were infused in the first 4 h period in amounts isonitrogenous with the
alanyl-glutamine (11.7 mg/kg/h) given in the second 4 h period, when the alanine
and glycine were discontinued. Priming doses were given of the alanine and
glycine mixture and the alanyl-glutamine solution in the first 10 min of each 4 h
period respectively, the priming doses providing the same dose of alanine and
glycine or alanyl-glutamine as the amount infused during each hour of the
subsequent continuous infusion.
2.16 PROTOCOLS
2.16.1 Protocol 1: Healthy Volunteer Studies
This protocol (Figure 2.4) was designed to investigate the acute effects on
skeletal muscle protein synthesis and breakdown of the dipeptide L-alanyl-L-
glutamine administered parenterally as a continuous infusion to healthy
volunteers. Standard stable isotope methodology was used with administration of
a primed constant infusion of tracer ([l-13C]leucine and 115N]-phenylalanine) and
measurements of tracer ([l-13C]leucine) incorporation into muscle protein, to
determine protein synthesis, and measurements of arteriovenous dilution of tracer
([15N]-phenylalanine) to determine protein breakdown and synthesis over an 8 h
period. In an analogous manner to a previous clinical study in post-operative
patients (Stehle et al., 1989), an isonitrogenous solution of glycine and alanine was
used as the control solution. All the subjects consumed a weight-maintaining diet
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Protocol to Study Effect of Ala-Gin Infusion on
Protein Turnover in Healthy Man
Primed constant infusion of [1- 13 C]Leu and 15 N-Phe
Constant infusion of Ala + Gly or Ala-Gin
^ ^ ^ ^ ^ ^ ^
Breaths + Arterial & Venous blood samples + BLOOD FLOW




Figure 2.4 Protocol 1: for the study of healthy subjects.
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during the week before the study. They took their evening meal between 5-30 and
7 pm, on the evening prior to the study. Thereafter they consumed no food by
mouth until completion of the study on the following day; only water was given.
The study was carried out between 7 am and 4 pm.
2.16.2 Protocols 2 and 3: Patient Studies
These studies were designed to investigate the effect of conventional total
parenteral nutrition (TPN) on muscle protein synthesis and breakdown in post¬
operative subjects (i.e. receiving TPN alone) and subsequently to investigate the
acute effects on protein synthesis and breakdown of alanyl-glutamine
supplementation of the conventional TPN. All patients were provided with routine
post-operative intensive care and nutritional support. The patients were studied
on their 3rd post-operative day. From the first post-operative day, all patients
received TPN and this was continued at least up to and including the third post¬
operative day when the tracer study was carried out. On the third post-operative
day, during the course of an 8 h [l-13C]leucine and [ir>N ^phenylalanine infusion,
the incorporation of tracer into skeletal muscle protein and the arteriovenous
dilution of tracer across the forearm was measured using two different protocols.
The first patient study protocol, a 'cross-sectional' control study of Ala-Gin
supplementation, Protocol 2 (Figure 2.5) was used on a 'pilot' basis to obtain
information on the effect of conventional TPN on skeletal muscle protein synthesis
and breakdown in these patients, who had undergone major surgery, by direct
(tracer incorporation into muscle protein, to determine protein synthesis) and
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Protocol to Study Effect of Conventional TPN alone on
Protein Turnover in Post-Surgical Patients
13 15
Primed constant infusion of [1- CJLeu and N-Phe
Conventional TPN (Synthamin: 9 + 14, 50:50 mixture)
^ ^ ^ ^ ^ ^








Figure 2.5 Protocol 2: for the study of post-operative patients receiving
TPN alone.
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Protocol to Study Effect of Ala-Gin Infusion on
Protein Turnover in Post-Surgical Patients








TPN + Ala + Gly TPN + Ala-Gin
^ ^ ^ ^ ^ ^ ^ ^
Breaths + Arterial & Venous blood samples + BLOOD FLOW




Figure 2.6 Protocol 3: for the study of post-operative patients receiving
TPN supplemented by either Ala+Gly or Ala-Gin.
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indirect (arteriovenous dilution of tracer to determine protein breakdown and
synthesis) measurements over an 8 h period.
The second patient study protocol, a 'longitudinal' study of Ala-Gin
supplementation, Protocol 3 (Figure 2.6), required measurement of the
incorporation of[l- 1;iC (leucine into muscle protein and arteriovenous dilution of
I ir'NJ-phenylalanine during two 4 h periods: firstly the conventional TPN solution
was supplemented with alanine (4.8 mg/kg/h) and glycine (8 mg/kg/h) in amounts
isonitrogenous with the alanyl-glutamine (11.7 mg/kg/h) given in the second 4 h
period, when the alanine and glycine were discontinued. Priming doses of the
alanine and glycine mixture and the alanyl-glutamine solution were infused over
the first 10 min of each 4 h period respectively: these priming doses provided the
same dose of alanine and glycine or alanyl-glutamine as the amount infused during
each hour of the subsequent continuous infusion. This protocol produced steady-
states for both the plasma leucine and phenylalanine concentration and the 13C
enrichments of leucine, a-ketoisocaproate and 15N enrichment of phenylalanine
about 30-60 min after commencement of the respective study solutions. The TPN
solution, the tracer solution and the study solutions were infused at a constant rate
by separate IMED 928 volumetric infusion pumps.
2.17 LABORATORY ANALYSIS
2.17.1 Gas Chromatography-Mass Spectrometry methods for the
determination of enrichment and concentration
The concentration and enrichment of the tracer amino acids and keto-acids
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were determined by gas chromatography-mass-spectrometry (GC-MS). The 13C
enrichment of the amino- and keto-acids was determined by monitoring a specific
fragment (or m/z), containing the labelled moiety in the mass spectrum of each
amino- or keto-acid (see Table 2.5). In each case the [13C] label is revealed as 1
atomic unit (amu) higher than the unlabelled compound. This distinction permits
the determination of the amount of labelled material present via changes in the
(M+l)+ to (M)+ ratio i.e. 13C:12C. The isotope ratio of 13C to 12C is calculated from
the integrated area under the peak from both masses. Comparison of this ratio
before and during infusion of tracer allows determination of the enrichment of the
compound of interest and may be calculated from the equation:
R - R
Enrichment (APE) = -—- x 100
1 + (RS- Rb)
where, APE = atoms percent excess
Rs = isotope ratio of enriched sample, and
Rb = isotope ratio of unenriched or basal sample
The concentration was determined by the addition to plasma, before the
addition of urease, of the internal standards L-[methyl-2,4,5-13C]leucine, L-[ring-
2H,]phenylalanine and a-[5,5,5-2H5]ketoisocaproic acid, at approximately 5-10% of
the concentration of tracee (endogenous amino- of keto-acid) expected in plasma.
The ratio of the peak area of amino acid or ketoacid to the internal standard i.e.
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Table 2.5 Ratios of mass to charge (m/z) monitored for the
determination of tracer enrichment and concentration.
(M)+ (M+l)+ Internal Standard*
(M+xr
Amino acids
Valine 288 289 291
Leucine 302 303 305
Phenylalanine 336 337 341
cx-KIC 259 260 262
*
where X equals the number of mass units each internal standard is above the
naturally occurring compound e.g. rmg-d5phenylalanine = (M+5)+ or 234+5 = 239.
(M)+ + (M+1)7(M+X)+ was then compared with a standard curve containing known
amounts of standard relative to the internal standard prepared and treated
identically to the plasma samples.
Gas chromatography-mass spectrometry was performed on one of two
instruments: a Finnigan 1020 GC-MS (Finnigan MAT, Hemel Hempstead, UK) or
an HP 5971A MSD (Hewlett Packard, Cheadle Heath, UK) operated in the
selected-ion-monitoring (SIM) mode, using electron-impact (EI) ionization (70 eV).
The column (OV-l type, 15 m x 0.32 mm i.d.) and operating conditions employed
were similar for both instruments and for both amino and ketoacid derivatives.
The initial column temperature, for amino acid separation, was 140"C which
was held for 1 min before being increased to 280"C at 20"C min"' where it was held
for 3 min prior to cooling. The injector temperature was 250"C; injection was
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performed in the splitless mode and the transfer line was maintained at 280UC.
The carrier gas was helium (BOC, UK) and the column head pressure was set at
5-7 kPa. Conditions for keto-acid separation differed slightly in that the column
temperature programme was increased by 15°C min"1 to 260"C and the injector
temperature was 240"C. This allowed better separation and peak symmetry of the
keto-acid quinoxalinol-^-BDMS derivatives.
Table 2.6 Determination of Isotope Ratio of Plasma Leucine and
Phenylalanine
This analysis was based on the method of Mawhinney et al., (1986) and employed
a t-butyldimethylsilyl derivative, separation by gas chromatography and isotope
quantification by mass spectrometry in the electron impact mode.
Method
1) To a microcentrifuge tube add 600 pi of plasma and 20 p\ of urease solution
(Urease from jack bean, Type IX, 500 units/ml in 0.01 mol/l phosphate
buffer, pH 6.7 with sodium azide 1 p.mol/1), vortex to mix and incubate at
37°C for 15 min. For samples where high leucine and phenylalanine
concentrations are anticipated the initial volume should be appropriately
reduced.
2) To precipitate the proteins, add 700 pi methanol/HCL (4:1 v/v), vortex to
mix and centrifuge at high speed for 5 min.
3) Decant supernatant to a screw top microcentrifuge tube and remove the
solvent by overnight rotary-evaporation.
4) Add 200 pi pyridine and 50 pi N-methyl-N-(t-butyldimethylsilyl)-
trifluoroacetamide, cap tightly and vortex.
5) Incubate at 80°C for 60 min total; remove from the oven after 30 min, vortex
to mix and return to the oven.
6) Add 400 pi decane, vortex and centrifuge for 3 min at high speed. Transfer
to autosampler vials
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2.17.2 13C Analysis of Plasma Leucine
1-13C Enrichment of leucine in plasma was determined after extraction of
amino acids and preparation of tert-butyldimethylsilyl derivatives by reaction with
N-methyl-N-(/enbbutyldimethylsilyl)trifluoroacetamide (Regis Chemical Company,
Morton Grove, IL, U.S.A.) (Mawhinney et al., 1986). (Table 2.6). The [1-13C]
enrichment in leucine was determined by monitoring ion currents m/z 302 and 303.
The retention time for this derivative of leucine was 3.7 to 3.8 min.
2.17.3 ir'N Analysis of Phenylalanine
The preparation of plasma phenylalanine samples for 15N enrichment
analysis by gas chromatography-mass spectrometry was identical to that used for
leucine (Table 2.6). The ion currents m/z 336 and 337 were monitored. The
retention times for the phenylalanine derivative were in the range of 5.6 to 5.8 min
(i.e. longer than those for leucine). The analysis of leucine and phenylalanine was
normally carried out on the same sample.
2.17.4 13C Analysis of Intramuscular Free Leucine
The 1:3C enrichment of intramuscular free leucine was determined in
neutralized perchloric acid (0.5 mol/1) extracts of muscle, ground to a fine powder
in liquid nitrogen (-196°C), using a pre-cooled mortar and pestle. The samples were
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purified using cationic ion exchange-chromatography (Table 2.7). t-
Butyldimethylsilyl derivatives were prepared and gas chromatography-mass
spectrometry was carried out a minimum of two times on each sample.
Table 2.7 Determination of Isotope Ratio of Intramuscular Free Amino
Acids
This analysis was also based on the method of Mawhinney et al. (1986), and
employed a t-butyldimethylsilyl derivative, separation by gas chromatography and
isotope quantification by mass spectrometry in the electron impact mode.
Method
1) A sample of muscle (about 100-300 mg) is ground to a fine powder in liquid
nitrogen with a pre-cooled mortar and pestle with removal of any obvious
pieces of connective tissue. An aliquot (approximately 20 mg in weight) of
the finely ground powder was taken for estimation of free amino acid
concentrations, extracted with ice-cold perchloric acid (PCA).
2) Extract free amino acids by adding 3 ml perchloric acid (0.5 mol/1, with
norvaline 4 pmol/1 to quantify amino acids using the amino acid analyser),
vortex and stand in ice for 30 min.
3) Centrifuge for 20 min (3000 RPM, 4°C) and decant supernatant. The isotope
ratio of protein-bound leucine is determined in the residue (Table 2.8).
4) To 500 pi of the supernatant add one drop of universal pH indicator and
neutralise with potassium bicarbonate (2 mol/1). Vortex, let stand in ice for
20 min and vortex again.
5) Centrifuge (3000 RPM, 20 min, 4°C) and pipette off supernatant. Mix with
an equal volume of glacial acetic acid. Apply to a 2.5 ml bed of ion-exchange
resin (Dowex 50W-X8(H+), 100-200 mesh), prewashed in HCL (1 mol/1).
6) The column is washed with HCL (2x1 ml) and then distilled deionized water
(2x1 ml).
7) The amino acids are eluted with 3 ml of ammonia solution (4 mol/1) and are
collected in a screw-top microcentrifuge test tube.
8) Remove the ammonia by overnight rotary-evaporation.
9) Add 50 pi pyridine and 50 ul N-methyl-N-(t-butyldimethylsilyl)-
trifluoroacetamide, cap tightly and vortex.
10) Incubate at 80"C for 60 min total; remove from the oven after 30 min, vortex
to mix and return to the oven.
11) Add 50 pi decane, vortex and centrifuge for 3 min at high speed. Transfer
to autosampler vials.
Ketovalerate was included as internal standard to quantify the a-ketoisocaproate.
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2.17.5 l3C Analysis of Plasma cx-Ketoisocaproate
To determine the 13C enrichment of plasma a-ketoisocaproate, o-
trimethylsilyl quinoxalinol derivatives were prepared using bis-
(trimethylsilyl)trifluoroacetamide (Regis Chemical Company or Sigma Chemical
Company Ltd, Poole. U.K.) (Table 2.8) (Rocchiccioli et al., 1981). Gas
chromatography-mass spectrometry was by analogous methods to those used for
plasma amino acid analysis with monitoring of ion-currents m/z 259 and 260.
2.17.6.1 Isotope Ratio Mass Spectrometry
The enrichment of 13C in carbon dioxide was measured with an automated
Finnigan MAT breath gas analysis system attached to a Finnigan Delta D isotope
ratio-mass spectrometer.
2.17.6.2 l,!C Analysis of Carbon Dioxide in Breath and Blood
Carbon dioxide in breath was cryogenically purified on-line before
measurement of enrichment (Scrimgeour and Rennie, 1988). Analysis of 13C
enrichment of carbon dioxide in whole blood was performed with the same
equipment after liberation of the carbon dioxide with ox-thophosphoric acid. The
total blood concentration of cai'bon dioxide was measured at the same time by
comparing the pressure of the carbon dioxide released from the blood into the
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Table 2.8 Determination of Isotope Ratio of Plasma a-Ketoisocaproate
This analysis used the method of Rocchiccioli et al., (1981), further modified
by Ford et al., (1985), employing a quinoxalinol derivative, separation by gas
chromatography and isotope quantification by mass spectrometry in the
electron impact mode.
Method
1) To a microcentrifuge tube add 600 pi plasma, 30 pi ketovaleric acid solution
(0.1 mg/ml) and 800 pi ethanol to precipitate the protein. Vortex to mix.
2) Centrifuge at high speed for 3 min, decant the supernatant to a test tube
and dry under a stream of nitrogen at 50"C.
3) To the residue add 200 pi distilled water and 100 pi o-phenylenediamine
solution (2% w/v in HCL 4 mol/1).
4) Heat in the oven for 60 min at 90"C, then cool.
5) Extract with 2 by 1 ml aliquots of ethylacetate and dry the combined
extracts over anhydrous sodium sulphate.
6) Decant the dried ethylacetate to a reaction vial, taking care not to transfer
any sodium sulphate. Dry under nitrogen at room temperature.
7) Dissolve the residue in 100 pi pyridine. Add 100 pi 6is-(trimethylsilyl)-
trifluoroacetamide, cap tightly and heat at 120°C for 30 min.
8) Cool vials and evaporate to dryness under nitrogen at room temperature.
9) Dissolve the residue in 500 pi decane containing 5% 6i's-(trimethylsilyl)-
trifluoroacetamide and transfer to an autosampler vial.
evacuated sample tubes with that from a range of carbonated standards prepared
in the same way (Scrimgeour and Rennie, 1988).
2.17.7.1 1,!C Analysis of Protein-Bound Leucine
To prepare the muscle samples for determination of I l-1:jC|leucine
enrichment, the samples were retrieved from their storage in liquid nitrogen and
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weighed (typically 75-350 mg wet weight). They were then pulverised in liquid
nitrogen with a pre-cooled mortar and pestle with removal of any obvious pieces of
connective tissue. An aliquot (approximately 20 mg in weight) of the finely ground
powder was taken for estimation of free amino acid concentrations, extracted with
ice-cold perchloric acid (PCA) (see 2.17.4) and the residue hydrolysed in 6 mol/1
hydrochloric acid (Table 2.9 and Table 2.10). Leucine was separated by preparative
gas chromatography (Smith et al., 1988). The carboxyl carbon of the isolated
leucine was liberated as carbon dioxide by ninhydrin and its 13C enrichment was
determined with the breath gas system, optimised for small quantities of carbon
dioxide (Scrimgeour et al., 1988).
2.17.7.2 Derivatization
Initially the trifluoroacetate isobutyl ester derivative of the amino acids was
the adduct chosen (Roach and Gehrke, 1969; Smith et al., 1988) for the preparative
GC separation of protein amino acids. However later, the method was improved
by the use of MTBSTFA as the derivatizing reagent (Biermann et al., 1986;
Schwenk et al., 1984). This has two major advantages in that the derivatization
is a simple, rapid one step procedure and the recovery of amino acid from the
preparative gas chromatography is much greater (=98% cf 40%). Briefly, 50-75 /xl
of MTBSTFA (Phase Separation Ltd, Clwyd, UK) together with an equal volume
of pyridine were added to each sample then heated in an oven at 80-90"C for 90
min, or until the sample was completely dissolved. The derivatization was carried
out immediately prior to the preparative chromatography as the sample is readily
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Table 2.9 Determination of Isotope Ratio of Muscular Bound Leucine
This analysis was based on the method of Smith et al. (1988), where ground
muscle protein is washed and acid-hydrolysed, leucine is separated by
preparative gas chromatography of trifluoroacetyl isobutyl esters, and
isotope quantification is by isotope ratio mass spectrometry of the carboxyl
carbon after liberation as C02 with ninhydrin.
Method
Protein Extraction
1) A weighed sample of muscle (about 100-300 mg) is ground to a fine powder
in liquid nitrogen with a pre-cooled mortar and pestle.
2) Extract free amino acids by adding 3 ml perchloric acid (0.5 mol/1), vortex
and stand in ice for 30 min. Centrifuge for 20 min (3000 RPM, 4"C) and
decant supernatant
3) To the residue add a further 3 ml perchloric acid (0.2 mol/1) vortex to mix
and decant the supernatant. Repeat two times.
4) Add 3 ml NaOH (0.5 ml), mix and incubate at 37"C for 60 min in a water
bath. Remove 100 pi, which can be used for a protein assay. Add 2
perchloric acid (1 mol/1) and centrifuge (3000 RPM, 20 min).
5) Suspend in 2 ml of perchloric acid (0.2 mol/1), vortex, centrifuge and decant
supernatant.
6) Add 5 ml perchloric acid (1 mol/1) resuspend the pellet and heat at 70°C for
30 min in a water bath. Centrifuge (3000 RPM, 20 min) and decant
supernatant.
7) Suspend the protein pellet in 3 ml HCL ( mol/1) and transfer to a hydrolysis
tube. Heat at 120"C overnight.
Ion-Exchange Chromatography
8) Transfer to a centrifuge tube and remove the solvent by rotary evaporation.
Dissolve the residue in 50% glacial acetic acid.
9) Apply to a 2.5 ml column of ion-exchange resin (Dowex 50W-X8(H+), 100-200
mesh, prewashed with 1 mol/1 HCL). Rinse out the hydrolysis tube with 2x1
ml HCL (1 mol/1). Rinse the column with deionized distilled water (2x1 ml).
10) Elute the amino acids with 3 ml ammonia solution (4 mol/1). Collect the
eluent into reaction vials, and blow-off the ammonia under nitrogen for
about 30 min at room temperature (until pH is 7-9). Freeze with liquid
nitrogen and lyophilize overnight.
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Table 2.10 Determination of Isotope Ratio of Muscular Bound Leucine
Derivatization Procedure
11) Add an aliquot of dichloromethane (500 pi) and dry by evaporation under
nitrogen at room temperature. Dissolve the residue in 400 p1 3 mol/1 HCL-
isobutanol and heat at 110°C for 30 min. Allow to cool and evaporate under
nitrogen at room temperature.
12) Dissolve the residue in ethyl acetate (250 pi) and trifluoroacetic anhydride
(100 pi) and react at 120-130 min for 30 min, releasing the pressure after
15 min. Allow to cool and evaporate off solvent under nitrogen at room
temperature.
13) Dissolve in 100 pi of n-heptane and transfer to an autosampler vial. Reduce
the volume to 100 pi under nitrogen at room temperature.
Preparative Gas Chromatography
14) An aliquot (50-100/xl) of sample is injected into the injection port of a Pye
304 chromatography fitted with a wide-bore glass column (6 mm inside
diameter x 4.6 m) packed with 2% EGA on 60-80 mesh Chromosorb W AW
(Phase Sep, Queensferry, Clwyd, U.K.) and with a post column splitter (split
ratio 99:1)
15) Argon was the carrier gas at a flow of 30 ml/min. The temperature of the
injector was 200°C and the oven was programmed from 150 to 165"C at
2°C/min, then held at 165°C for 6 min before being increased to 220"C to
drive off later eluting amino acid derivatives.
16) The leucine derivative is condensed in a demountable U-trap, cooled with
liquid nitrogen. The leucine fraction is identified by comparison of retention
times with these of leucine standards (about 11.5 min).
17) The leucine derivative is hydrolysed by adding 100 ql KOH (1 mol/1) and
heating at 90"C for 45 min or leaving at room temperature overnight. The
sample is transferred with 2 ml of buffer (pH 2) to a Vacutainer and is
stored at 4"C overnight.
18) The vacutainer is cooled in ice before adding ninhydrin (25 mg) and a drop
of antifoaming agent. After degassing and sealing, the sample is heated in
a water bath at 90"C for 30 min to liberate the carboxyl-C as C02 for isotope
ratio mass spectral analysis (Scrimgeour et al., 1988).
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hydrolysed by moisture.
2.17.8 Alkali-soluble protein, DNA and RNA estimation.
Alkali-soluble protein concentration of biopsy samples was determined by
using the Lowry (Lowry et al., 1951) method. Nucleic acids were extracted from
the muscle samples (Schneider and Greco, 1971) and assayed by double-wavelength
spectrophotometry (Tsanev and Markov, 1960).
2.17.9.1 Isolation and purification of plasma albumin
Plasma was stored at -80°C prior to the isolation of albumin. Total plasma
protein was precipitated by the addition of ice cold 10% trichloroacetic acid (TCA,
4 ml) to plasma (1 ml) and centrifugation at 4"C for 20 min (1500 g), the
supernatant was discarded. Albumin was first extracted into ethanol (5 ml), by
vortex mixing then separated from the non-alcohol soluble protein by centrifugation
at 4"C for 20 min (1500 g). The alcohol layer was decanted and evaporated under
nitrogen at 70°C using the TurboVap" LV evaporator. This albumin containing and
fraction was added to 10% SDS for subsequent polyacrylamide gel electrophoresis
(PAGE) analysis (Laemmli et al., 1970).
Contamination by free amino acids was minimized by redissolving the
albumin in 0.3 N NaOH at 37°C for 30 min, then reprecipitating with ice cold 2M
HC104 and discarding the supernatant. The protein pellet was then subjected to
acid hydrolysis, purification of the acid hydrolysate by ion-exchange
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chromatography, preparative gas chromatography and isotope ratio mass
spectrometry of carboxyl-C02 as described for muscle.
2.17.9.2 Purity and Identification of Plasma Albumin
Plasma albumin was identified by polyacrylamide gel electrophoresis (PAGE)
using the method of Laemmli et al. (Laemmli et al., 1970). Albumin was extracted
from plasma into ethanol using the method described above. An aliquot of the
ethanolic extract was removed and dried, then the protein solubilised in 10%
sodium dodecyl sulphate (SDS) and an aliquot was removed and diluted with an
equal volume of sample buffer. Separation was performed on a 10% acrylamide gel,
using a 4% stacking gel run at 30 milliamps (mA, constant current) for
approximately 1 h (Mini-Protean* II, Bio Rad, Hemel Hempstead, UK). The
proteins were stained with 0.1% Coomassie Brilliant Blue R250 in 50% methanol,
10% glacial acetic acid overnight, then visualized by destaining with a 10%
methanol, 70% acetic acid solution. A low molecular weight standard protein mix
(Sigma, UK) and authentic human albumin (Immuno, Italy) were run in parallel
in order to assess the molecular weight and verify the identity of protein in the
alcohol soluble fraction. Purity was determined by the presence or absence of other
protein bands; in several gels a low molecular weight protein band was observed.
Semi-quantitation of the relative abundances of the albumin band and this
unidentified low molecular weight protein was performed using a laser
densitometer (2202 Ultroscan, LKB, Sweden) linked to a chart recorder.
Measurement of the relative peak heights suggested that this band represented less
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than 2% of the total purified. It was also possible that this protein fragment was
a cleavage product from albumin generated during the isolation procedure.
2.17.10 Free Amino Acid Concentrations in Plasma and Muscle
Amino acid concentrations were determined in sulphosalicyclic acid extracts
of plasma and perchloric acid (0.5 mol/1) extracts of muscle. Automated amino acid
analyzers were used employing either a) ion-exchange chromatography with elution
and separation of amino acids with strongly acidic lithium citrate buffers, norvaline
as internal standard, post-column derivatisation with o-pthalaldehyde/-2-
mercaptoethanol and fluorometric detection (LC5000, Biotronic GmbH, Munchen,
F.D.R.); b) ion-exchange chromatography, lithium citrate buffers, no internal
standard, post-column derivatization with ninhydrin and photometric detection
(LC5000).
2.17.11 Plasma Hormone Concentrations
Plasma hormones were measured by radioimmunoassay. Insulin was
determined with an enzyme-linked immunoabsorbent assay (Enzymun-Test®,
Boehringer Mannheim, UK). The co-efficient of variation was 7%-9%. Glucagon
was determined by a commercially available kit (Novo Nordisk, Denmark) and the
co-efficient of between assay variation was 7%-12% over the assay range. Insulin¬
like growth factor 1 was determined with a double-antibody kit (Nicols Institute
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Diagnostics, Essex, UK). The inter-assay co-efficient of variation was 8%-12%. C-
peptide was measured with a commercially available kit (Novo Nordisk, Denmark);
the co-efficient of between assay variation was 5%-8% over the assay range.
2.17.12 D-(-)-3-Hydroxybutyrate Concentration
The blood concentration of D-(-)-3-hydroxybutyrate was measured by an
enzymic fluorometric continuous flow assay (Roche Diagnostics, Herts., UK) and
the inter-assay co-efficient of variation was 2%-9%.
2.17.13 Blood Gas Analysis
The P02, oxygen saturation, pH and total bicarbonate concentration of
arterial and venous blood was measured using a Corning 189 blood gas analyzer
(Corning Medical, Medfield, Massachussetts, U.S.A.).
2.18 Statistical Analysis
In the text as well as in the tables and figures, mean values and standard
errors are presented. Results from the two phases within studies were compared
with the two-tailed Student's t-test for paired data, except where otherwise stated.
In general, 95% confidence intervals have also been given throughout. The
Student's t-test for unpaired data was used to compare different study groups, with
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significance assigned at the 5% level i.e. p < 0.05. A stepwise regression analysis
was performed to compare rates of protein synthesis with intramuscular free
glutamine concentration. A microcomputer-based statistical package was used for
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In this study the acute effects of L-alanyl-L-glutamine (Ala-Gin) dipeptide
infusion on protein synthesis in human anterior tibial muscle have been
investigated. Fifteen healthy male post-absorptive subjects were studied: seven
subjects received an infusion ofAla-Gin (11.67 mg/kg/h) and eight subjects received
an isonitrogenous infusion of L-alanine (4.78 mg/kg/h) plus glycine (8.03 mg/kg/h)
(Ala+Gly). Whole body and skeletal muscle protein synthesis were measured using
a primed, constant infusion of [l-13C]leucine with determination of plasma leucine-C
flux and UC02 production, and assay of [l-13C|leucine incorporation into mixed
anterior tibial muscle protein sampled by biopsy.
Arterialized venous blood glutamine concentration was higher during Ala-
Gin than Ala+Gly infusion (640+40 (448, 948) versus 563+22 (506, 620) /xmol/1,
respectively, mean+SEM (95% confidence intervals), p=0.03). Intramuscular free
glutamine concentration was also elevated after Ala-Gin infusion (78+9 (56, 100)
versus 58^5 (46, 71)) pmol/g protein, p<0.02). Intramuscular free branched-chain
amino acid concentrations were not significantly different (4.2+0.4 (3.0, 5.4) versus
3.3+0.3 (2.5, 4.1) /xmol/g protein).
Muscle protein synthesis, calculated assuming plasma a-ketoisocaproate as
precursor, was greater with Ala-Gin than with Ala+Gly infusion (0.051+0.003
(0.044, 0.058) versus 0.042+0.001 (0.039, 0.045) %/h, p<0.03). Whole body leucine
flux and oxidation values, although similar in the two groups (104+4 (94, 115)
versus 115+4 (105, 125), and 15+1.5 (11, 20) versus 17 + 1.4 (13, 21) /xmol/kg/h,
respectively), tended to be lower with Ala-Gin infusion. Non-oxidative leucine
disposal, i.e. whole body protein synthesis, also did not differ significantly (90+3
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(81, 98) versus 98+4 (87, 109) /xmol/kg/h), between the two groups.
These results suggest that in healthy man increased availability of
glutamine alone, provided as the dipeptide Ala-Gin, may acutely stimulate muscle
protein synthesis in the post-absorptive state.
3.2 Introduction
It is well recognised that skeletal muscle plays a key role in the metabolic
response to injury and sepsis and in the negative nitrogen balance often associated
with these conditions. Characteristically, skeletal muscle wasting occurs resulting
in efflux of amino acids which are used as substrates for gluconeogenesis, wound
healing and visceral protein synthesis (Rennie, 1985). In particular, loss of muscle-
derived amino acids to the viscera includes the 'non-essential' amino acid
glutamine, the most abundant free amino acid in human skeletal muscle (Furst,
1983) and a significant diminution occurs (up to 60%) in the intramuscular free
glutamine pool (Vinnars et al., 1975; Askanazi et al., 1980a; Askanazi et al., 1980b;
Roth et al., 1982; Furst, 1984). In several recent studies the effects of glutamine
on the rates of protein synthesis and breakdown in skeletal muscle have been
investigated, both in vitro and in vivo. Thus glutamine has been shown to inhibit
protein breakdown in cultured rat and chick skeletal muscle (Smith, 1985; Wu and
Thompson, 1990). Also, Wu and Thompson demonstrated an increase in protein
synthesis in chick skeletal muscle incubated with 2-15 mM glutamine in vitro (Wu
and Thompson, 1990) and in perfused rat hindlimb there is an anabolic relationship
between glutamine availability and muscle protein turnover (MacLennan et al.,
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1987. Fasted, injured and endotoxin-treated rats show a positive relationship
between intramuscular glutamine concentration and the rates of muscle protein
synthesis in vivo (Jepson et al., 1988). The evidence that maintenance of the
intracellular glutamine pool may help conserve muscle protein is strengthened by
the findings of Kapadia and co-workers who achieved a reduction in efflux of amino
acids in dog hindlimb and sustained intramuscular glutamine levels following
surgical trauma by infusing an amino acid solution containing glutamine (Kapadia
et al., 1985). Thus it would seem desirable, in the clinical context, to include
glutamine in parenteral nutrition formulations. Hammarqvist and colleagues have
demonstrated that such a solution administered to patients undergoing elective
abdominal surgery reduces the fall in intramuscular free glutamine, counteracts
the fall in muscle polyribosome concentration (used as an index of muscle protein
synthesis) and improves nitrogen balance (Hammarqvist et al., 1989).
Practical difficulties may arise however in administering glutamine-
containing parenteral nutrition regimes as glutamine is unstable when stored in
solution (Stehle et al., 1984), forming the possibly toxic substance pyroglutamic acid
(Furst et al., 1987). Provision of glutamine in an alternative, stable form as the
dipeptide L-alanyl-L-glutamine (Ala-Gin) (Stehle et al., 1984; Furst et al., 1987;
Albers et al., 1988; Albers et al., 1989) increases glutamine availability, reduces
post-operative muscle loss of alanine and glutamine (Roth et al., 1988) and whole-
body N-excretion (Stehle et al., 1989), although no data are currently available to
explain the mechanisms of this action in human subjects. We have therefore begun
by investigating the possible acute effects of Ala-Gin infusion on muscle protein
synthesis and whole-body protein turnover in healthy male postabsorptive subjects




Fifteen healthy male subjects (age 24-52 y, weight 63.8-84.5 kg) were studied
in the Department of Surgery, Ninewells Hospital and Medical School, Dundee
University. Each subject gave written consent after a full explanation of the study.
The protocol for the study was approved according to the Declaration of Helsinki
guidelines by the Dundee General Hospitals Committee on Medical Ethics of the
Tayside Health Board.
3.3.2 Study Design
Subjects (Table 3.1) were randomised to receive either Ala-Gin infusion (n=7,
age 33.1^8 y, 95% confidence intervals (25, 42); weight 72.6+7 (66, 79) kg; body-
mass index 25.1+2.3 (23, 27) kg.m"2; fat-free mass 54.8+6 (48, 62) kg, as estimated
from calliper-measured skin-fold thicknesses (Durnin and Womersley, 1973) or
isonitrogenous Ala plus Gly (n=8, age 33.3+8 (26, 41) y ; weight 72.5+8 (66, 80) kg
; body-mass index 23.5jfl.2 (22, 25) kg.m'2 ; fat-free mass 57.2+5 (53, 62) kg)
(Protocol 1, Chapter 2). After an overnight 15 h fast, subjects were studied in the
supine position in a thermoneutral environment (25-27°C). No food or water was
given to the subjects until the study was complete. Whole-body tracer leucine-C
kinetics and the incorporation of I l-13C]leucine into M. tibialis anterior were
investigated over an 8 h period in each group.
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3.3.3 Materials
Solutions of L-l l-1:iC]leucine and sodium MC-bicarbonate (both 99 Atoms
%, Tracer Technologies Inc., Newton, MA, U.S.A.) were prepared under aseptic
conditions in sterile, pyrogen-free 0.9% (150 mmol/1) sodium chloride solution
(Baxter Healthcare Ltd, Thetford, Norfolk, U.K.). The solutions were sterilized
by filtration through 0.22/xm filters (Millipore SA, Molsheim, France). Solutions
were similarly prepared of the dipeptide Ala-Gin (Kabi-Pfrimmer, Erlangen,
F.D.R.) and a mixture of the unlabelled amino acids L-alanine and glycine
(Sigma Laboratories, LT.K.).
3.3.4 Study Details
Arterialized venous blood ('arterial' blood) sampling was carried out via
a 1.7 mm outer diameter cannula (Venflon, Viggo AB, Helsingborg, Sweden),
placed retrogradely in a dorsal hand vein and maintained patent by slow
infusion of 150 mmol/1 NaCl solution. Before each sampling the hand was
warmed for 10 min by insertion in a thermostatic chamber heated to 65"C
(Abumrad et al., 1981). A second cannula was placed antegradely in an
antecubital vein of the ipsilateral arm for tracer amino acid and dipeptide
infusions. The third cannula was inserted retrogradely in an antecubital vein
of the contralateral forearm for venous blood sampling. A paediatric
sphygmomanometer wrist cuff was applied at the wrist on this side, with the
cuff being inflated to 300 mmHg 2 minutes prior to blood sampling in order to
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avoid admixture of the predominantly cutaneous venous drainage of the hand
with the venous drainage from the muscle bed of the forearm (Jackson et al.,
1987). Priming doses of L-| l-13C]leucine (1 mg/kg) and NaH13C03 (0.20 mg/kg)
were administered (Matthews et al., 1980; Nair et al., 1988b) followed by a
constant infusion of tracer L-[l-13C]leucine (1 mg/kg/h) with Ala and Gly (4.78
and 8.03 mg/kg/h respectively, control group) or L-[l-'3C]leucine with Ala-Gin
(11.67 mg/kg/h, study group) maintained and delivered over 8 h with an IMED
928 volumetric infusion pump (IMED Ltd, Abington, U.K.). Blood samples were
taken before the start of the tracer infusion and at intervals throughout the
study (30, 90, 150, 240, 330, 420, 480 min) for blood gas analysis (Pco2, Po2,
Sa02% - Corning 178 Blood Gas Analyzer, CIBA Corning Diagnostics, Essex,
U.K.), amino acid concentrations and for determination of 13C enrichment of
(plasma) a-ketoisocaproate (a-KIC). In order to obtain base-line values for [1-
13C]leucine enrichment of body protein, against which to compare the
incorporation of tracer [l-l3C]leucine into muscle protein, a 5 ml blood sample
was collected prior to the tracer infusion and mixed immediately with 5 ml 2M
perchloric acid for precipitation, and later isolation and analysis, of whole-blood
protein (Heys et al., 1990). Expired air was collected into evacuated glass tubes
(Vacutainer, Becton Dickinson, Rutherford, U.S.A.) for short-term storage prior
to 13C analysis of C02. C02 production rate was determined over the 8 h period
by two separate 10 min collections of expired breath into a 100 litre Douglas
bag, the volume being determined by a Harvard dry gas meter. Samples of the
breath (200 ml) were subsequently analyzed for C02 with an infra-red
absorption C02 gas analyzer (Analytical Development Co., Ltd., U.K.). Muscle
biopsy was carried out after 8 h of infusion. After infiltration of the skin and
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subcutaneous tissues down to the deep fascia with 5 ml 1% lignocaine, a 10 mm
skin incision was made over the tibialis anterior at mid-leg level and using 6.5
mm Tilley-Henckel ethmoid punches (S. Murray and Co., Sheffield, U.K.) a 150-
200 mg sample of muscle tissue was obtained (Dietrichson et al., 1987) and
stored in liquid nitrogen until analysis.
3.3.5 Analysis of Samples
The laboratory methods of analysis of samples used here have been
detailed previously in Chapter 2, section 2.17.
3.3.6 Calculations
Muscle protein synthetic rate was calculated from L-[l-13C]leucine
incorporation into the protein-bound leucine pool. Calculations were made
assuming that labelling of the precursor pool of leucyl-^RNA was approximated
by venous plasma oc-KIC (Rennie et al., 1982b) and assuming that basal 13C
enrichment of leucine in whole blood proteins reflected the basal 13C enrichment
in protein-bound leucine in muscle (Heys et al., 1990). The components of
plasma leucine turnover were calculated from the mean arterial oc-KIC
enrichment from 330 to 480 min. Leucine oxidation was calculated from whole-
body 13C02 excretion and the arterial plasma cx-KIC enrichment. Intramuscular
free amino acid concentrations were expressed per g of alkali-soluble muscle protein.
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3.3.7 Statistical Analysis
Intergroup differences in results were analyzed with the Student's i-test
for non-paired data (two-tailed). When comparing intra-group differences as for
example in results of basal and plateau plasma amino acid concentrations,
Student's £-test for paired data was used (two-tailed, except where otherwise
stated). Both in the tables and in the text, 95% confidence intervals around the
mean are presented.
3.4 Results
3.4.1 Plasma Free Amino Acid Concentrations
The basal arterial plasma Gin concentration in the control group was
555+22 (498, 611) /xmol/1 (mean+SEM (95% CI)) and 563+22 (506, 620) /xmol/1
during the period 90 to 480 min, thus showing little change during the study
period (Table 3.2 and Figure 3.1 ). In the Ala-Gin group the basal glutamine
concentration was 566+36 (476, 651) /xmol/1, rising (p=0.03) to a plateau
concentration of 640+43 (534, 746) /xmol/1, between 90 to 480 min. There were
no significant differences in either the basal or the peri-infusion concentrations
of alanine between the groups (258+17 (216,300) and 291+34 (206, 376) /xmol/1,
control, versus 243+29 (166, 320) and 274+24 (210, 337) /xmol/1, Ala-Gin). The
plasma glycine concentration rose sharply (249+10 (224, 274) versus 443^14









Figure 3.1 Basal and plateau (90-480 min) free glutamine concentrations in
arterial plasma, in the control group receiving Ala+Gly (solid bar)
and study group receiving Ala-Gin (hatched bar).
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Table 3.3 Intramuscular free glutamine concentrations. CI = 95% confidence
intervals.
Ala+Gly Ala-Gin
Subject Gin conc. Subject Gin conc.




















plasma glycine concentration fell (203+7 (185, 220) versus 179+6 (162, 196) /xmol/1,
p<0.02) in the Ala-Gin group. Other amino acid concentrations (L-leucine, L-
phenylalanine, L-tyrosine and L-glutamic acid) also changed from their basal
values in both groups, although there was no significant difference in the values
between the groups.
3.4.2 Intramuscular Free Amino Acid Concentrations.
The intramuscular free Gin concentration (Tables 3.3, 3.4 and Figure 3.2)
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Table 3.4 Intramuscular free amino acid concentrations. BCAA, total branched
chain amino acids. The results are means+SEM. CI = 95% confidence
intervals.
Amino acid concn. (/xmol/g protein)
Ala+Gly CI Ala-Gin CI
ALA 9.3+0.5 (8.1, 10.5) 12.4+3.1 (3.8, 21)
ARG 1.6+0.1 (1.4, 1.8) 2.5+0.6 (0.7, 4.3)
ASP 4.7+0.7 (2.9, 6.5) 3.6+1.1 (0.5, 6.7)
GLU 21.9+2.4 (15.8, 28.1) 24+2.7 (16.3, 31.7)
GLN 58.1+5 (45.7, 70.5) 78+9 (55.6, 100.2)
GLY 10.0+1.0 (7.5, 12.6) 6.5+0.7 (4.4, 8.6)
HIS 2.0+0.1 (1.6, 2.3) 2.3+0.5 (1.0, 3.6)
ISO 0.3+0.03 (0.2, 0.4) 0.5+0.04 (0.4, 0.6)
LEU 1.3+0.1 (1.0, 1.6) 1.7+0.2 (1.3, 2.2)
LYS 12.4+6.6 (-4,4, 29.2) 40.2+26.4 (-34.1, 114.5)
PHE 0.5+0.1 (0.4, 0.7) 0.7+0.1 (0.3, 1.1)
SER 3.2+0.2 (2.7, 3.7) 3.4+0.6 (1.8, 4.9)
TAU 95.2+12 (65.7, 124.7) 119.7+14 (80.4, 158.9)
THR 2.6+0.1 (2.3, 3.0) 2.2 +0.6 (0.5, 3.8)
TRY 36.5 + 14 (-2.7, 75.7) 27.5+12 (-6.4, 61.4)
TYR 0.30+0.04 (0.2, 0.5) 0.4+0.1 (0.2, 0.7)
VAL 1.7+0.2 (1.2, 2.1) 2.0+0.2 (1.3, 2.7)
BCAA 3.3+0.3 (2.5, 4.1) 4.2+0.4 (3.0, 5.4)
was greater in the Ala-Gin group (78+9 (56, 100) versus 58+5 (49, 71) /xmol/g
protein, p<0.02). Isoleucine and leucine concentrations (Figure 3.3) were also
higher in this group (0.5+0.04 (0.4, 0.6) versus 0.3+0.03 (0.2, 0.4) pmol/g protein,





Figure 3.2 Intramuscular free glutamine concentrations, in the group





■ Ala + Gly 0 Ala-Gin
Figure 3.3 Intramuscular concentrations of the free branched chain amino acids
leucine, isoleucine and valine in the Ala+Gly group (solid bar) and
Ala-Gin group (hatched bar).
158
3.4.3 Plasma Concentrations and l8C Enrichment of Leucine and a-KIC
Plateau values were attained for the enrichment of'arterial' plasma leucine
and a-ketoisocaproate during the periods 90-480 min of each study (Figures 3.4 and
3.5). There were no significant differences in enrichment of leucine and a-
ketoisocaproate between the two groups in either arterial (plasma leucine APE:
6.9+0.4 (6.05, 7.82), Ala+Gly versus 7.5+0.1 (7.13, 7.81), Ala-Gin; a-KIC APE:
5.5+0.3 (4.8, 6.2), Ala+Gly versus 6.0+0.3, (5.2, 6.7) Ala-Gin) or venous (leucine
APE: 5.8+0.4 (4.9, 6.7), Ala+Gly versus 6.0+0.2 (5.5, 6.5), Ala-Gin; a-KIC APE:
4.8+0.3 (4.0, 5.6), Ala+Gly versus 5.2^0.3 (4.4, 6.0), Ala-Gin) plasma. The
concentrations of'arterial' plasma leucine and a-ketoisocaproate were stable during
the periods 90-480 min of each study (Figures 3.6 and 3.7) and there were no
significant differences in the concentrations of either, during this period, between
the two groups.
3.4.4 Fractional Muscle Protein Synthetic Rate
The muscle fractional mixed protein synthetic rate, calculated assuming
plasma a-ketoisocaproate (Table 3.5 and Figure 3.8) as precursor, was greater with
Ala-Gin infusion than with Ala+Gly infusion (0.051+0.003 (0.044, 0.058) versus
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Figure 3.4 Plasma arterial (□) and venous (■) enrichment of free leucine in the
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Figure 3.5 Plasma arterial (A) and venous (▼) enrichment of a-ketoisocaproate
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Figure 3.6 Plasma arterial (□) and venous (■) concentrations of free leucine in
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Figure 3.7 Plasma arterial (A) and venous (T) concentrations of a-




















Figure 3.8 Skeletal muscle fractional mixed protein synthesis, calculated using
the (surrogate) precursor pool of plasma a-ketoisocaproate, in the
group receiving Ala+Gly (filled bar) and the group receiving Ala-Gin
(hatched bar).
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Table 3.5 Fractional protein synthetic rate (ks) in M. tibialis anterior.
Calculated on the basis of cx-KIC as precursor. CI = 95% confidence
intervals.
Ala+Gly Ala-Gin
Subject Ks (%h) Subject Ks (%h)
1 0.040 9 0.059
2 0.038 10 0.062
3 0.044 11 0.044
4 0.046 12 0.044
5 0.038 13 0.043
6 0.043 14 0.055
7 0.046 15 0.051
8 0.042
Mean+SEM 0.042+0.001 0.051+0.003
CI (0.039, 0.045) (0.044,0.058)
3.4.5 Protein/DNA, RNA/protein and RNA/DNA
There were no overall significant differences in the muscle samples from the
Ala-Gin and Ala+Gly groups in protein/DNA (525+30 (450, 599) versus 544+21
(493,595) fJLg/ng) (Table 3.6), RNA/protein (2.9+0.17 (2.5, 3.3) versus 2.6+0.15
(2.3,3.0) yxg/mg) or RNA/DNA (1.50+0.11 (1.2,1.8) versus 1.43+0.09 (1.2,1.6) /rg/gg).
3.4.6 Whole-body Leucine Kinetics
Whole-body leucine kinetics (Table 3.7) showed no significant difference at
165
Table 3.6 Intramuscular protein/DNA, RNA/protein and RNA/DNA ratios.















the 95% level between the Ala-Gin and Ala+Gly groups. However whole-body
leucine flux and whole-body protein breakdown tended to be lower with Ala-Gin
(both 104+4 (94, 115) /imol/kg/h) than with Ala+Gly (115 + 11 (105, 125) p,mol/kg/h).
Similarly, leucine oxidation (15+1.5 (11, 20) versus 17 + 1.4 (13, 21) gmol/kg/h) and
whole-body protein synthesis (90+3 (81, 98) versus 98+4 (87, 109) p,mol/kg/h) were
a little lower, at 12 % and 8 % respectively, with Ala-Gin infusion.
3.5 Discussion
This study provides, for the first time, direct evidence for a small but
significant acute stimulatory effect on skeletal muscle protein synthesis in man by
glutamine administered parenterally as the dipeptide Ala-Gin. The infusion rate
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Table 3.7 Whole-body leucine kinetics. Results are means+SEM. CI = 95%
confidence intervals.
Rate (/xmol/kg/h)
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of Ala-Gin chosen for this study (11.67 mg/kg/h) was the highest that had
previously been shown to be safe and effective in raising plasma glutamine
concentrations in man (Stehle et al., 1989). In this study we achieved greater
plasma and intramuscular concentrations of free glutamine in the dipeptide treated
group (Tables 3.2 and 3.3). With infusion of equivalent amounts of alanine in the
free and dipeptide form (as Ala-Gin), there were no differences in its mean (free)
intramuscular concentration between the respective groups. Infusion of glycine
resulted in a significantly greater intramuscular concentration in the control group.
We have no evidence that muscle protein synthesis was adversely affected by the
greater intramuscular glycine as the synthesis rates are similar to previously
published basal values for M. tibialis anterior in postabsorptive subjects from our
laboratory (Bennet et al., 1989). This finding is consonant with that of Jepson et
al 1988) who found no relationship existed between the intramuscular glycine
concentration and muscle protein synthesis in rats. Intramuscular concentrations
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of the branched-chain amino acids leucine and isoleucine were significantly raised
(by 32%, p<0.05 and by 50%, p<0.01, respectively) in the Ala-Gin group although
there was no change in the concentration of valine. These changes differ
qualitatively from those reported by Wu (Wu and Thompson, 1990) in chick
extensor digitorum communis muscle in vitro in which concentrations of all three
amino acids decreased with increased glutamine concentration. The discrepancy
may in part be species related, or may be explained by the veiy different study
conditions involved.
In investigating the effect of intervention on a biological variable (e.g.
protein synthesis) in man it would seem probable that, unlike equivalent studies
in laboratory animals of similar genetic types, the results may demonstrate a
greater heterogeneity of response. This is evident in the present study (although
the subjects were well-matched) in which there was a considerable variation in
response to Ala-Gin and Ala+Gly infusions in the plasma and intramuscular free
amino acid concentrations (see Tables 3.2 and 3.4) and in the muscle protein
synthetic rates (Table 3.5). It is also possible that analytical factors contributed a
little to the variability. Nevertheless, in this relatively small randomized study the
differences in the mean values of intramuscular free glutamine concentration and
muscle protein synthesis rates between the groups are significant. Additionally,
there appears to be a trend towards a positive association between increased
muscle glutamine concentration and increased muscle protein synthesis, although
in view of the small numbers of subjects in each group the power of the study was
insufficient to demonstrate any statistically significant correlation. A positive
anabolic effect of glutamine does not appear to be species-specific as it has already
been demonstrated in rat skeletal muscle (MacLennan et al., 1987). Since
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glutamine also stimulates chick skeletal muscle protein synthesis (Wu and
Thompson, 1990), the phenomenon is clearly a more general one and not confined
to mammalian muscle tissue alone.
Previous studies showing a positive relationship between skeletal muscle
glutamine concentration and protein synthesis in vivo have done so in disease or
post-traumatic states (Jepson et al., 1988; Hammarqvist et al., 1989), with the
intramuscular glutamine concentration ranging from low to physiological. To our
knowledge this study shows for the first time that increasing plasma glutamine
concentration can cause an increase in its intramuscular concentration in healthy
subjects. Furthermore, the positive association between raised intramuscular
glutamine concentration and muscle protein synthesis previously demonstrated in
studies on animal muscle in vitro (MacLennan et al., 1987; Wu and Thompson,
1990) and in vivo (Jepson et al., 1988) is demonstrated in vivo in healthy man.
The mechanism by which glutamine stimulates skeletal muscle protein
synthesis is not explained by this study. An indirect effect, possibly hormonally
mediated, cannot be excluded as investigation of possible changes in plasma
hormones accompanying Ala-Gin infusion was not undertaken. None of the amino
acids alanine, glycine and glutamine are insulinogenic (Goodner and Porte, 1972)
but no such information is currently available for the dipeptide Ala-glutamine. It
has been suggested by Millward et al that hormones such as insulin may influence
the relationship between intramuscular glutamine concentration and muscle
protein synthesis in disease states (Jepson et al., 1988; Millward et al., 1989).
Whether such influence is exerted in health, by hormones such as insulin, growth
hormone and IGF-1, merits further study.
A further possibility of an indirect mechanism arises from the unexpected
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finding of the intramuscular concentration of leucine and isoleucine being
significantly greater in the Ala-Gin treated group. Leucine, in particular, has been
reported to stimulate rat skeletal muscle protein synthesis in vitro (Buse and Reid,
1975). Considering the data available from this study, the possibility of a similar
effect occurring in M. tibialis anterior in man, as an indirect consequence of Ala-
Gin infusion and hence increased glutamine availability, cannot be excluded.
A direct stimulatory effect of glutamine on protein synthesis has been more
readily demonstrated in in vitro studies (MacLennan et al., 1987; Wu and
Thompson, 1990). The subcellular mechanisms involved in this effect are poorly
understood. Tyobeka has shown that despite the low Km of glutamine for the
aminoacyl £-RNA transferase reaction, glutamine is able to stimulate incorporation
of labelled amino acids into protein in cell-free systems to a greater extent than
other amino acids (Tyobeka and Manchester, 1985; Tyobeka, 1983). A possible
explanation proposed by Tyobeka is that the availability of aminoacyl £-RNA
synthetases for glutamine is dependant upon the presence of glutamine and this
may be a regulatory effect.
Although there were no significant differences between the groups in whole-
body protein turnover there was nevertheless a trend toward a lowering of whole-
body protein breakdown with Ala-Gin provision. Further investigation with a
larger number of subjects is merited to establish whether or not infusion ofAla-Gin
has an acute effect on whole-body protein turnover in healthy man.
In conclusion, this study demonstrates that infusion of the dipeptide Ala-Gin
in man raises glutamine concentrations in plasma and in muscle. The increased
glutamine availability in muscle per se appears to stimulate muscle protein
synthesis, calculated on the basis of the enrichments of plasma cx-KIC. Since Ala-
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Gin infusion does not appear to affect whole-body protein turnover to any large
extent it is likely that in the absence of availability of dietary amino acids, skeletal
muscle protein synthesis is increased by glutamine at the expense of non-muscle
protein, as the muscle free amino acid pool could not sustain such an increase for
more than a few minutes. Further studies of muscle protein breakdown (e.g. by
using limb arteriovenous exchange techniques (Bennet et al., 1990) may help to
decide whether or not glutamine infusion has a net anabolic effect on skeletal
muscle protein in healthy man.
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CHAPTER 4
EFFECT OF INFUSION OF THE DIPEPTIDE L-ALANYL-L-GLUTAMINE
ON SKELETAL MUSCLE PROTEIN SYNTHESIS AND BREAKDOWN IN
HEALTHY POST-ABSORPTIVE MAN BY FOREARM
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4.1 SUMMARY
In this study the acute effects of L-alanyl-L-glutamine (Ala-Gin) dipeptide
infusion on protein synthesis and breakdown in human forearm mixed skeletal
muscle have been investigated. Fifteen healthy male post-absorptive subjects were
studied: seven subjects received an infusion of Ala-Gin (11.67 mg/kg/h) and eight
subjects received an isonitrogenous infusion of L-alanine (Ala, 4.78 mg/kg/h) plus
glycine (Gly, 8.03 mg/kg/h) (Ala+Gly). Forearm skeletal muscle protein synthesis
and breakdown were measured using a constant infusion of [15N]phenylalanine with
determination of arterialised venous plasma [15N]phenylalanine kinetics and
forearm arteriovenous exchange.
Arterialized venous blood glutamine concentration was higher during Ala-
Gin than Ala+Gly infusion (640+40 (448, 948) versus 563+22 (506, 620) /xmol/1,
respectively, meamfSEM (95% confidence intervals), p=0.03).
Forearm muscle protein synthesis as determined by [15N]phenylalanine
exchange was 16% higher in the Ala-Gin group (30.4+2 (25, 36) versus 26.1+2 (21,
32) nmol/lOOg/min) although the difference was not statistically significant. Also,
muscle protein breakdown was similar in each group (39.8+3 (33, 46) versus 35.6+3
(27, 44) nmol/lOOg/min). 3-methylhistidine balance was similar (-1.12+0.2 (-1.7, -
0.5) versus -1.27+0.2 (-1.9, -0.7) nmol/lOOg/min) between the groups.
Whole body phenylalanine flux values were similar in the two groups
(34.7+1.1 (32, 38), Ala-Gin versus 39.2+2.0 (34, 44) Ala+Gly, p.mol/kg/h), although
as with the previously described whole-body leucine flux (Chapter 3), there was a
trend toward lower values in the Ala-Gin group.
These results suggest that in healthy man increased availability of
175
glutamine, provided as the dipeptide Ala-Gin, does not acutely stimulate muscle
mixed protein synthesis, as assessed by [15N]phenylalanine arteriovenous exchange
nor does it alter the rate of protein breakdown in the post-absorptive state.
4.2 Introduction
Injury, including surgical trauma, can result in net whole-body negative
nitrogen balance. Following major surgery skeletal muscle wasting occurs,
resulting in efflux of a number of amino acids (Rennie, 1985) including glutamine,
the most abundant free amino acid in human skeletal muscle (Fiirst, 1983). This
results in a 50-60% reduction in the intramuscular free glutamine pool (Vinnars et
al., 1975; Askanazi et al., 1980a, 1980b; Roth et al., 1982; Furst, 1984) and is
associated with a fall in skeletal muscle protein synthesis as measured indirectly
using intramuscular polyribosome concentration (Hammarqvist et al., 1989). In
animal studies a positive correlation has been demonstrated between intramuscular
glutamine concentration and muscle protein synthesis (Jepson et al., 1988).
Provision of glutamine to post-surgical patients results in a diminution in the fall
in intramuscular glutamine concentration and also reduces the extent of the
negative nitrogen imbalance (Hammarqvist et al., 1989; Stehle et al., 1989).
Hammarqvist et al. (1989) have demonstrated that administration of a total
parenteral nutrition (TPN) solution supplemented by glutamine, to patients
undergoing elective abdominal surgery reduces the fall in intramuscular free
glutamine, improves nitrogen balance and counteracts the fall in muscle
polyribosome concentration. Information from both in vivo and in vitro animal
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studies would appear to suggest that glutamine inhibits protein breakdown in
cultured rat skeletal muscles (Smith, 1985) and in the perfused rat hindlimb
(MacLennan et al., 1989). In an in vitro study Wu and Thompson demonstrated
that glutamine decreases protein breakdown in chick skeletal muscle (Wu and
Thompson, 1990). Although these studies have provided valuable information in
forming a more detailed picture of glutamine's effect on skeletal muscle protein
balance no similar studies have been reported in man. Because of major differences
in skeletal muscle composition and in particular the free glutamine pool size in
man (Furst et al., 1987) information obtained from animal studies on glutamine's
role in muscle protein metabolism may have only limited application to man.
Provision of parenterally administered glutamine in a stable form as the dipeptide
L-alanyl-L-glutamine (Ala-Gin) (Stehle et al., 1984; Furst et al., 1987; Albers et al.,
1988; Albers et al., 1989) increases glutamine availability, reduces post-operative
muscle loss of alanine and glutamine (Roth etal., 1988) and whole-body N-excretion
(Stehle et al., 1989).
From our previous study (see Chapter 3) although Ala-Gin appears to have
a small but significant stimulatory effect on skeletal muscle protein synthesis in
healthy post-absorptive man as determined by tracer Ll-13C]leucine incorporation
studies, such an investigative approach is unable to provide information on muscle
protein breakdown. We have therefore investigated the possible acute effects of
Ala-Gin infusion on muscle protein synthesis and breakdown in 15 healthy male
post-absorptive subjects using a forearm arteriovenous phenylalanine exchange
method with [15N]phenylalanine as tracer.
This technique may be used to measure arteriovenous uptake and release
of phenylalanine across a limb (Gelfand and Barrett, 1987; Thompson et al., 1989;
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Cheng et al., 1985), which predominantly contains skeletal muscle (Haggmark et
al., 1978). In skeletal muscle the only metabolic fates of phenylalanine are
incorporation into protein and release from protein; catabolism of phenylalanine to
tyrosine occurs predominantly in liver and does not occur in muscle. Uptake and
release of phenylalanine by the limb are therefore, indices of protein synthesis and
breakdown respectively. The 15N enrichment of arterial and venous plasma
phenylalanine, during a primed continuous infusion of [15N (phenylalanine, and
plasma concentrations may be used to calculate phenylalanine exchange by limb
tissue from the degree of dilution of the tracer in the venous outflow in comparison
with the arterial inflow.
4.3 METHODS
4.3.1 Subjects
The present studies were performed concurrently with the studies described
in Chapter 3 and the same subjects were studied. As described in Chapter 3, the
fifteen healthy male subjects (age 24-52 y, weight 63.8-84.5 kg, Table 3.1, Chapter
3) were studied in the Department of Surgery, Ninewells Hospital and Medical
School, Dundee University. Each subject gave written consent after a full
explanation of the study. The protocol for the study was approved according to the
Declaration of Helsinki guidelines by the Dundee General Hospitals Committee on
Medical Ethics of the Tayside Health Board.
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4.3.2 Study Design
Subjects were randomised to receive either Ala-Gin infusion (n=7) or
isonitrogenous L-alanineplus glycine (Ala+Gly, n=8). After an overnight 15 h fast,
subjects were studied in the supine position in a thermoneutral environment (25-
27°C). No food or water was given to the subjects until the study was complete.
Whole-body tracer phenylalanine turnover and forearm muscle protein balance as
determined by [15N|phenylalanine arteriovenous exchange were investigated over
an 8 h period in each group.
4.3.3 Materials
Solutions of L-[[15N]phenylalanine (99 atoms %, Tracer Technologies Inc.,
Newton, MA, U.S.A.) were prepared under aseptic conditions in sterile, pyrogen-
free 0.9% (150 mmol/1) sodium chloride solution (Baxter Healthcare Ltd, Thetford,
Norfolk, U.K.). The solutions were sterilized by filtration through 0.22 pm filters
(Millipore SA, Molsheim, France). Solutions were similarly prepared of the
dipeptide Ala-Gin (Kabi-Pfrimmer, Erlangen, Germany) and a mixture of the
unlabelled amino acids L-alanine and glycine (Sigma Laboratories, U.K.).
4.3.4 Study Details
Arterialized venous blood ('arterial' blood) sampling was carried out via a 1.7
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mm outer diameter cannula (Venflon, Viggo AB, Helsingborg, Sweden), placed
retrogradely in a dorsal hand vein and maintained patent by slow infusion of 150
mmol/1 NaCl solution. Before each sampling the hand was warmed for 10 min by
insertion in a thermostatic chamber heated to 65"C (Abumrad, et al., 1981). A
second cannula was placed antegradely in an antecubital vein of the ipsilateral arm
for tracer amino acid and dipeptide infusions. The third cannula was inserted
retrogradely in an antecubital vein of the contralateral forearm for venous blood
sampling. Priming doses of L-[15N]phenylalanine (0.5 mg/kg) were administered
(Matthews et al., 1980; Nair, et al., 1988) followed by a constant infusion of tracer
L-[15N]phenylalanine (0.5 mg/kg/h) with Ala and Gly (4.78 and 8.03 mg/kg/h
respectively, control group) or L-[10N]phenylalanine with Ala-Gin (11.67 mg/kg/h,
study group) maintained and delivered over 8 h with an IMED 928 volumetric
infusion pump (IMED Ltd, Abington, U.K.). Forearm blood flows were measured
by venous occlusion mercury-in-silastic strain-gauge plethysmography (Medimatic,
Denmark) at regular intervals throughout the study period, on each occasion 2
minutes prior to blood sampling. During flowrate measurements as well as during
blood sampling, a paediatric sphygmomanometer cuff was inflated to above systolic
pressure at wrist level of the study forearm to temporarily occlude and exclude the
hand circulation from measurements (Jackson et al., 1987). Paired arterialised
venous and venous blood samples were taken before the start of the tracer infusion
and at intervals throughout the study (30, 90, 150, 240, 330, 420, 480 min) for
blood gas analysis (Pcos, Po2, Sa02% - Corning 178 Blood Gas Analyzer, CIBA
Corning Diagnostics, Essex, U.K.), amino acid concentrations and for determination
of [15N] enrichment of (plasma) phenylalanine.
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4.3.5 Analysis of Amino Acid Concentrations and Phenylalanine [15N]
Enrichment
The methods of analysis used in the present study have been detailed in
Chapter 2. Plasma [15N] enrichment of phenylalanine was determined by gas
chromatography-mass spectrometry (Hewlett-Packard Ltd., Cheadle Heath, U.K.)
(Rocchiccioli et al., 1981). Free amino acid concentrations were determined in
plasma following sulphosalicylic acid extraction with an amino acid analyzer
(LC5000, Biotronik GmbH, Munchen, Germany) using ion-exchange
chromatography and fluorometric detection of o-phthaldehyde derivatives with
norvaline as internal standard.
4.3.6 Calculations
The 15N enrichment of arterial and venous plasma phenylalanine during the
primed continuous infusion of [lsN]phenylalanine and plasma concentrations of
phenylalanine were used to calculate phenylalanine exchange by limb tissue from
the degree of dilution of the tracer in the venous outflow in comparison with the
arterial inflow. The equations used are detailed in Chapter 2. The components of
plasma phenylalanine turnover were calculated from the mean arterialised venous
and venous phenylalanine enrichment and concentration from 330 to 480 min.
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4.3.7 Statistical Analysis
Intergroup differences in results were analyzed with the Student's £-test for
non-paired data (two-tailed, except where otherwise stated) whilst comparison of
intra-group differences were made using Student's £-test for paired data (two-tailed,
except where otherwise stated). 95% confidence intervals are also given in the
table and in the text.
4.4 RESULTS
4.4.1 Plasma Concentration and [ir>N] Enrichment of Phenylalanine
Plateau was attained for the enrichment of arterial plasma phenylalanine
during the period 90-480 min of each study (Figure 4.1). There were no significant
differences in enrichment of phenylalanine in the period 90-480 min between the
two groups in either arterial (APE: 7.10+0.3 (6.4, 7.8), Ala+Gly versus 7.86+0.3 (7.2,
8.5), Ala-Gin) or venous (APE: 5.87+0.3 (5.1, 6.6), Ala+Gly versus 6.13+0.3 (5.3, 6.9),
Ala-Gin) plasma.
4.4.2 Plasma Free Amino Acid Concentrations
The concentrations of free amino acids in arterial plasma, and the changes
in their concentrations from their basal values to values attained at plateau in
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Figure 4.1 Plasma arterial (O) and venous (•) enrichment of free phenylalanine
in the Ala+Gly group (top graph) and Ala-Gin group (bottom graph).
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either the Ala+Gly group or the dipeptide infused group are discussed in part in
chapter 3. The basal arterial plasma glutamine concentration in the Ala+Gly group
was 555+22 (498, 611) p.mol/1 (mean+SEM (95% CI)) and 563+22 (506, 620) ju.mol/1
during the period 90 to 480 min, thus showing little change during the study period
(Table 3.2 and Figure 3.1 , Chapter 3). In the Ala-Gin group the basal glutamine
concentration was 566+36 (476, 651) /rmol/1, rising (p=0.03) to a plateau
concentration of 640+43 (534, 746) pmol/1, between 90 to 480 min. The
concentrations of the amino acids L-leucine, L-tyrosine and L-glutamic acid also
changed from their basal values in both groups, although there was no significant
difference in the values between the two groups. The plasma concentration of
phenylalanine was stable during the period 90 to 480 min in each group (Figure
4.2). The basal arterial plasma phenylalanine concentration in the Ala+Gly group
was 50.6+4 (41, 60) p.mol/1 rising slightly to 52.8+4 (44, 61) pmol/l (p=0.07) during
the period 90 to 480 min. In the Ala-Gin group the basal phenylalanine
concentration was 49.5+2 (44, 55) /rmol/1, showing a small rise of 7% to 52.9+2 (46,
59) p.mol/1 between 90 to 480 min. There were small statistically insignificant falls
in the concentrations of 3-methylhistidine in each group from basal to plateau
values (4.84+0.6 (3.3, 6.4) to 4.15+0.5 (3.0, 5.3) pmol/1 Ala+Gly group; 5.25+0.6 (3.8,
6.7) to 4.14+0.4 (3.1, 5.2) /xmol/1 in the Ala-Gin group), the 90-480 min values being
identical between the two groups.
4.4.3 Forearm Amino Acid Balance


























































Figure 4.2 Plasma arterial (O) and venous (•) concentrations of free
phenylalanine in the Ala+Gly group (top graph) and Ala-Gin group
(bottom graph).
185
Ala+Gly group at plateau were -11.5+3 (-24, -5) and -12+3 (-20, -5) nmol/lOOg/min
respectively (Table 4.1). The corresponding efflux values for phenylalanine and
tyrosine in the Ala-Gin group were similar at -11.4+2 (-15, -8) and -16+3 (-25, -7)
nmol/lOOg/min. The efflux of 3-methylhistidine from the forearm during 90-480
min was 13% higher in the Ala-Gin group (-1.27+0.2 (-1.9, -0.7) versus -1.12+0.2 (-
1.7, -0.5) nmol/lOOg/min respectively), although this difference was not statistically
significant, suggesting that there was no significant difference in the rates of
myofibrillar protein breakdown between the two groups.
4.4.4 Forearm Protein Turnover by [15N]Phenylalanine Arteriovenous
Exchange
Forearm mixed protein breakdown, assessed by [15N]phenylalanine exchange,
was 35.6+4 (27, 44) nmol/lOOg/min in the Ala+Gly group. Although the rate was
higher in the Ala-Gin group at 39.8+3 (33, 46) nmol/lOOg/min the difference was
not significant (p=0.603) (Figure 4.3 ). Forearm protein synthesis was 26.1+2 (21,
32) nmol/lOOg/min in the control group and was 16% higher at 30.4+2 (25, 36)
nmol/lOOg/min (p=0.09, 1-tailed) in the Ala-Gin group. The balance between
protein synthesis and protein breakdown was very similar between the two groups
at -11.5+3 (-24, -5) (Ala+Gly) and -11.4+2 (-15, -8) (Ala+Gln) nmol/lOOg/min.
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Muscle Protein Turnover by
Forearm Phenylalanine Exchange
SYNTHESIS BALANCE BREAKDOWN
■ Ala+Gly □ Ala-Gin
Figure 4.3 Components of forearm phenylalanine metabolism in the Ala+Gly
group (solid bars) and Ala-Gin group (hatched bars).
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4.4.5 Calculated Forearm Skeletal Muscle Fractional Protein Synthetic
Rate
With the information that muscle contains 18% protein, protein contains
4% phenylalanine (Gelfand and Barrett, 1987), and assuming on the fat content
of the subjects, and that the forearm is representative of the whole-body
(Maughan et al., 1984), that 75% of forearm blood flow is distributed to muscle
at rest, the fractional protein synthetic rate may be calculated as 0.048+0.004
(0.038, 0.058) %/h in the control group (Figure 4.4 ) and 0.052+0.005 (0.039,
0.065) %/h (p<0.09, 1-tailed) in the Ala-Gin group and this difference between
the two groups was not significant.
4.4.6 Whole-body Phenylalanine Kinetics
There were no significant differences between the two groups in whole-
body phenylalanine kinetics (Figure 4.5 ). Whole-body phenylalanine flux was
39.2+2 (34, 44) pmol/kg/h in the Ala+Gly group and was 11% lower in the Ala-
Gin group at 34.7+1 (32, 38) gmol/kg/h (p=0.105). Whole-body protein
breakdown was 36.2+2 (31, 41) gmol/kg/h in the control group and was 12%

















Figure 4.4 Skeletal muscle fractional mixed protein synthesis in the Ala+Gly









Figure 4.5 Whole-body phenylalanine kinetics (flux and breakdown) in the
Ala+Gly group (solid bars) and Ala-Gin group (hatched bars).
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4.5 DISCUSSION
In this study, parenteral administration of the dipeptide Ala-Gin, raised
arterialized venous blood glutamine concentration in the study group by 18 %
(p<0.05) and this latter value was also significantly higher (p=0.03) than during
Ala+Gly infusion. Thus, for the first time, we were able to evaluate the effects
of glutamine provision on muscle protein synthesis and breakdown in healthy
post-absorptive man. There is good evidence from previously reported studies
(Albers et al., 1986; Albers et al., 1988), that in healthy subjects there is both
rapid and complete hydrolysis of the dipeptide Ala-Gin once infused, releasing
the free amino acids alanine and glutamine. Also, a similar finding has been
reported in post-operative patients (Stehle et al., 1989) in whom there was no
detectable Ala-Gin dipeptide (as determined by high performance liquid
chromatography) in the arterial plasma during constant infusion of the
dipeptide in amounts equivalent to the dose used in the present study. In the
present study, therefore, as both groups received equivalent amounts of alanine,
the comparison between the groups, in essence, was between glutamine and
glycine, with glycine being used as the control amino acid. The alanine and
glycine mixture was given in isonitrogenous amounts to the Ala-Gin dipeptide
to eliminate the effect of the variable total amino-nitrogen on muscle protein
synthesis.
In designing the study, without prior information available as to the
likely possible effect, either qualitatively or quantitatively, of glutamine on
muscle protein synthesis and breakdown in man, two separate subject groups
were used. The subject numbers are relatively small and the practical
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difficulties of recruiting and performing fairly invasive and long metabolic
studies as described have placed some constraint on the subject numbers.
Ideally, if such constraints were not in place, it may have been possible and
desirable to repeat the studies in each subject in a 'cross-over' manner so that
the control subjects, receiving Ala+Gly, would receive Ala-Gin in the second
study and vice versa. Such a study design, with the subjects being self-
controlled, would have made statistical comparison more powerful by minimising
the considerably greater effects of biological variation in response to nutrient
provision observed in man in comparison to laboratory animals.
The infusion rate of Ala-Gin chosen for this study (11.67 mg/kg/h) was
the highest that had previously been shown to be safe and effective in raising
plasma Gin concentrations in man (Stehle et al., 1989). However, in that study,
performed in post-operative subjects, this dose was calculated to replace the
expected post-operative loss of nitrogen. This dose was therefore in the
pharmacological range and by using a similar dose in healthy man in the
present studies we were in effect investigating the effects of supra-physiological
glutamine provision in the post-absorptive state.
An additional variable in this present study was the effect of blood flow
measurements on the calculated values of amino acid exchange. Small changes
in blood flow can significantly affect the measured net balance of a metabolite
across a limb. Consequently, errors in blood flow measurement may contribute
the largest proportion to the overall error of arteriovenous exchange
methodology (Butler and Home, 1987; also, see equation, Chapter 2, section
2.5.2) and every effort was made to minimise error and maintain consistency in
technique by using an identical method to measure blood flow in all subjects.
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The laboratory analytical techniques used for measurement of plasma
amino acid concentrations and [15N]phenylalanine enrichment were already well-
established in our centre and reported elsewhere (Bennet et al, 1989J and were
felt to be appropriate for this study. Previously established analysis protocols
were strictly adhered to in order to minimise laboratory error.
The rates of forearm muscle protein synthesis and breakdown in the
Ala+Gly (control) group are of a very similar order to previously published
values from our centre, for skeletal muscle synthesis (29+5 nmol/lOOg/min) and
breakdown (42.8+4 nmol/lOOg/min), in post-absorptive healthy subjects (Bennet
et al., 1989) using identical tracer methodology (i.e. using the arteriovenous limb
exchange of [15NJphenylalanine), although the leg preparation was used for those
studies rather than the forearm as described here. Thompson and colleagues
(Thompson et al., 1989), using deuterated phenylalanine and the forearm
preparation, have also reported similar values for synthesis (37 nmol/lOOg/min)
and breakdown (46 nmol/lOOg/min). Gelfand and Barrett (1987) have used the
tracers tritiated phenylalanine and [14C ]leucine and the forearm preparation to
determine values of 43 and 57 nmol/lOOg/min for synthesis and breakdown
respectively with the former tracer and much higher values of 113 and 126
nmol/lOOg/min respectively with the latter tracer. Cheng and colleagues (Cheng
et al., 1987) have also used the forearm preparation but have used the stable
isotope tracer [13C, 15N]leucine to obtain values of 70 and 98 nmol/lOOg/min
respectively for muscle protein synthesis and breakdown.
In the post-absorptive state in healthy man, glutamine provision, in the
form of the dipeptide Ala-Gin, does not appear to reduce the rate of muscle
protein breakdown. This result is at variance with that of others who have
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reported an inhibitory effect of glutamine on muscle protein breakdown
(MacLellan et al., 1989; Wu and Thompson, 1990). This may be explained in
large part by i) the different methodologies employed, with use by McLelland et
al., (1989) of an isolated perfused rat hindlimb and the use of isolated chick
muscle by Wu and Thompson (1990). Also, interspecies differences in muscle
protein metabolism particularly and their bearing on muscle glutamine
metabolism are incompletely understood; they may also account for the different
response to glutamine provision in muscle protein breakdown observed in man
in the present study.
In this study, we were unable to demonstrate a statistically significant
effect on protein synthesis of Ala-Gin administration, as determined by
arteriovenous [15N (phenylalanine forearm exchange, in contrast to the earlier
study (described in Chapter 3) where protein synthesis was higher in the Ala-
Gin group. In part this is likely to be explained by the different muscles under
study i.e., M. tibialis anterior in the incorporation study and the muscles of the
forearm in the [15N (phenylalanine exchange study. It is known that skeletal
muscles differ in their rates of protein synthesis (Smith and Rennie, 1990) and
the variation in the acute response of skeletal muscle protein synthesis to Ala-
Gin provision seen in these studies may well in part be accounted by this factor
alone. Additionally, the forearm exchange method for determining rates of
protein synthesis is possibly less sensitive than the tracer incorporation method
and any actual small difference between the two groups would arguably be more
likely to be detected by the latter method than the former (Biolo et al., 1995).
Protein synthesis was higher in the dipeptide-infused group and although
the difference was not statistically significant, qualitatively the difference is
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similar in direction to that observed in the previous study on the effect of Ala-
Gin on muscle protein synthesis as determined by [l-13C]leucine incorporation.
The findings of this study, taken in consideration with those of the earlier study,
would appear to suggest a possible mild acute stimulatory effect of glutamine
provided as the dipeptide on skeletal muscle protein synthesis but with no effect
on muscle protein breakdown, in healthy post-absorptive man.
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5.1 SUMMARY
The aim of this study was to investigate the acute effects of L-alanyl-L-
glutamine (Ala-Gin) dipeptide supplementation of conventional TPN on skeletal
muscle protein synthesis in post-surgical patients receiving conventional glutamine-
free total parenteral nutritional support after major surgery. Sixteen patients
received a constant infusion of non-glutamine containing TPN from the first post¬
operative day up to and including the third post-operative day when muscle protein
synthesis was investigated over an eight hour period using a primed constant
infusion of [l-13C]leucine with determination of plasma leucine-C flux and assay of
[l-13C]leucine incorporation into mixed anterior tibial muscle protein sampled by
biopsy. The effects of TPN alone were studied in eight of sixteen patients (cross-
sectional study of Ala-Gin supplementation); the remaining eight patients were
studied over two 4-hour periods (longitudinal study of Ala-Gin supplementation).
In the first, TPN was supplemented with a primed constant infusion of L-alanine
plus glycine (Ala+Gly) as a control mixture isonitrogenous with the primed constant
infusion of Ala-Gin given in the second period.
The mean basal (-30 to 0 min) plasma arterial glutamine concentration in
the cross-sectional study was 332+17 (287, 377) pmol/1 (mean+SEM, (95% confidence
intervals)) and remained unchanged during 90-480 min at 340+11 (311, 370)
pmol/1. The mean basal plasma arterial glutamine concentration in the
longitudinal study was 330+16 (281, 364) pmol/1 and 314+16 (274, 355) /xmol/1
during infusion with Ala+Gly, rising by 29% to 404+30 (316, 471) pmol/1 (p<0.05)
with the infusion of Ala-Gin. The intramuscular concentration of glutamine fell by
51% from the pre-operative value of 62+4 (51, 72) pmol/g protein to a post-operative
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value of 30+3 (24, 37) gmol/g protein at the end of the Ala+Gly supplementation
period (p<0.0005), rising by a small but significant amount to 34+3 (26, 42) pmol/g
at the end of Ala-Gin infusion (p<0.03, 1-tailed).
For both plasma leucine and a-ketoisocaproate, plateau enrichment was
attained during the last 180 min of each phase of the longitudinal study and during
the last 390 min of the cross-sectional study. In the longitudinal study, the
intracellular leucine enrichment remained unchanged (3.21+0.17 (2.8, 3.6) APE,
Ala+Gly versus 3.24+0.11 (3.0, 3.5) APE, Ala-Gin). The fractional rates of protein
synthesis in M. tibialis anterior with TPN alone, during TPN + Ala+Gly and during
TPN + Ala-Gin, calculated on the basis of each of the two different surrogate
precursor pools plasma a-ketoisocaproate and intracellular leucine were
respectively: plasma a-ketoisocaproate: 0.031+0.003 (0.026, 0.036) %/h, 0.025+0.003
(0.016, 0.034) %/h, 0.047+0.006 (0.031, 0.062) %/h (p=0.0052, TPN + Ala-Gin versus
TPN + Ala+Gly; p=0.049, TPN + Ala-Gin versus TPN alone); intracellular free
leucine: 0.049+0.005 (0.037, 0.061) %/h, 0.039+0.003 (0.032, 0.047), 0.075+0.008
(0.055, 0.096) (p=0.0095, TPN + Ala-Gin versus TPN + Ala+Gly; p=0.04, TPN + Ala-
Gin versus TPN alone). Whole-body leucine kinetics were similar during TPN alone
and during TPN + Ala+Gly and TPN + Ala-Gin, although there was a trend
towards lower values for leucine flux with TPN + Ala-Gin. These results suggest
that short-term Ala-Gin supplementation ofTPN in post-operative patients results
in a modest repletion of the intramuscular free glutamine pool and acutely
stimulates skeletal muscle mixed protein synthesis, assessed by [l-13C]leucine
incorporation into muscle protein, irrespective of the surrogate precursor pool (for
i)RNA) used to calculate protein synthesis.
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5.2 Introduction
Following surgery particularly major surgery, or following trauma and sepsis
intramuscular free glutamine falls by up to 60% (Vinnars et al., 1975; Askanazi et
al., 1980a; Askanazi et al., 1980b). Negative nitrogen balance occurs, associated
with muscle wasting. Muscle wasting is likely to be significant in adding to post¬
operative mortality and morbidity, particularly in increasing complications such as
chest infections, deep vein thrombosis and slow mobilisation. About 50% of
patients undergoing major surgery are malnourished (Bistrian et al., 1975).
Complications associated with peri-operative malnutrition are compounded by a
pre-operative malnutritional state. Malnutrition may result in delayed wound
healing, increased frequency of wound infections, decreased vital organ function,
decreased immunocompetence, increased occurrence of sepsis, prolonged ileus and
more frequent pulmonary infections and pulmonary insufficiency (Mullen et al.,
1979; Reinhardt et al., 1980; Seltzer et al., 1979). Severe malnutrition is likely to
occur in patients who have been unable, for a number of reasons, to maintain an
adequate diet over a prolonged period of time pre-operatively. The malnourished
state may be compounded in the post-operative period, particularly in patients with
upper gastrointestinal pathology requiring major oesophageal and gastric surgery
and who may be unable to take adequate nutrition orally, either through a clinical
requirement to protect gastrointestinal anastomoses or because of post-operative
small intestinal ileus. Conventional parenteral nutrition was established by the
pioneering work of Dudrick et al. (1967, 1968). Although parenteral nutrition has
not been shown to be of value in normally nourished or mildly nourished patients
(Detsky et al., 1987) it has shown been shown that perioperative TPN confers
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significant benefits in terms of reducing post operative morbidity and mortality
(Mullen et al., 1980). However, conventional TPN, comprising a mixture of amino
acids, carbohydrates (glucose) and lipids, does not appear to reverse post-operative
negative nitrogen balance nor does it prevent post operative muscle wasting.
The observed post-operative fall in intramuscular glutamine is associated
with a fall in skeletal muscle protein synthesis (Hammarqvist et al., 1989). A
positive correlation has been demonstrated between intramuscular free glutamine
and muscle protein synthesis by Jepson et al. (1988). Provision of glutamine by the
parenteral route appears to reduce the extent of the post-operative negative
nitrogen balance (Stehle et al., 1989). Although conventional TPN did not
significantly alter post-operative muscle protein synthesis when compared to pre¬
operative values, studied using the flooding dose technique (Essen, 1991),
glutamine supplementation appeared to raise post-operative muscle glutamine
concentration and reduce the extent of the post-operative fall in muscle protein
synthesis as assessed indirectly from the intramuscular polyribosome concentration
as an index of protein synthesis (Hammarqvist et al., 1989) in muscle. Because of
reported potential problems with the solubility and possibly the stability of free
glutamine solutions for heat sterilisation and storage (Stehle and Furst, 1987) we
have used the dipeptide L-alanyl-L-glutamine (Ala-Gin). This peptide has greater
solubility and stability and upon intravenous infusion in man is rapidly hydrolysed
to release the free amino acids alanine and glutamine (Albers et al., 1988, 1989).
The aim of this present study was to measure directly, using a primed
constant infusion of [l-13C]leucine and determination of its incorporation into
muscle protein, the acute effects of conventional TPN supplemented by Ala-Gin in
patients undergoing major elective upper gastrointestinal surgery. Comparison was
205
made first with the effect on muscle protein synthesis (in the same patients! of
provision of TPN supplemented by isonitrogenous amounts of the free amino acids
L-alanine and glycine and secondly with the effects of TPN alone in a different
group of patients.
5.3 Methods
5.3.1 Place of Study
All studies were performed in the intensive care unit of Ninewells Hospital
and Medical School, Dundee.
5.3.2 Patients
16 patients were studied over a period of 8 h on the third post-operative day:
8 patients according to a longitudinal study protocol comparing the effect of TPN
supplemented by L-alanyl-L-glutamine on skeletal muscle mixed protein fractional
synthetic rate with the effect on protein synthesis of TPN supplemented with an
isonitrogenous solution of L-alanine and glycine (see protocol 3, Chapter 2). The
remaining 8 patients were studied as a control group (cross-sectional study) to
determine the rates of protein synthesis with provision of TPN alone (see protocol
2, Chapter 2). All patients had localised carcinoma of the lower third of oesophagus
and had been admitted electively into one of the general surgical wards for curative
206
oesophagogastrectomy (Chapter 2). This particular patient group was selected for
study because the planned surgery was major and perceived as likely to cause
significant perturbation of whole-body protein metabolism. Also, for a variety of
clinical reasons (e.g. the need to avoid the oral route post-operatively to protect
intestinal anastomotic suture lines in the early post-operative period and post¬
operative ileus) as well as on nutritional grounds, this group of patients would
routinely receive post-operative parenteral nutrition. Details of the patients' age,
morphological data and pre-operative plasma albumin and total protein are
provided in Table 5.1a. Details of the length of operation, operative blood loss and
blood replacement required by transfusion are given in Table 5.1b. All patients
were evaluated on admission to ICU to allocate an APACHE II score (Acute
Physiology and Chronic Health Evaluation, second modification (Knaus et al.,
1985)), thus making a formal assessment of the severity of the acute systemic
pathophysiological disturbance resulting from the trauma of surgery, on a
background of their long-term health status. The mean APACHE II scores are
given in Table 5.1b.
5.3.3 Ethical Approval and Informed Consent
Study protocols were reviewed and approved by the Tayside Ethical
Committee for Medical Research. Potentially suitable patients were initially
approached on their admission to hospital. During a 2 hour interview, the purpose
of the research project and the proposed study details were discussed in detail and
patients were also familiarised with the various study instruments and equipment
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All patients received parenteral nutrition from the first post-operative day.
The nutrition solution consisted of a 50:50 mixture of two commercially available
mixed amino acid solutions (Synthamin 9, 500 ml and Synthamin 14, 500 ml, from
Baxter Healthcare, Thetford, UK) providing 11.5 g nitrogen (Table 2.3, Chapter 2).
In addition, 7532 kJ were provided as 450 g glucose, electrolyte replacement as 70
mmol Na+ and 80 mmol K+, all in a total volume of 1.5 1 water per 24 h. Patients
therefore received a combined total of a 2.5 1 bag of TPN solution over 24 h,
provided at a constant rate by volumetric infusion pump.
5.3.4.2 Alanine, Glycine and Ala-Gin
Pre-sterilised solutions (prepared in the Department ofPharmacy, Ninewells
Hospital and Medical School, Dundee) of the free amino acids L-alanine and glycine
(Kabi-Vitrum, Sweden), in 250 ml 0.9% saline (Baxter Healthcare, Thetford,
England) were infused via a 0.22 p,m filter (Millipore SA, Molsheim, France) at
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constant rates of 4.8 mg/kg/h and 8.0 mg/kg/h respectively (after priming bolus
doses of 4.8 mg/kg and 8.0 mg/kg respectively in a volume of 20 ml 0.9% saline),
providing a total of 2.25 mg amino-N/kg/h, for 4 h during the first half of the 8 h
tracer infusion study. A sterile solution of the dipeptide L-alanyl-L-glutamine (Ala-
Gin, Kabi-Pfrimmer, Germany) in 250 ml 0.9% saline (Baxter Healthcare, Thetford,
England) was infused at a constant 11.7 mg/kg/h (after a priming bolus of 11.7
mg/kg in 20 ml 0.9% saline), providing 2.25 mg amino-N/kg/h, for 4 h during the
second half of the 8 h tracer infusion study.
5.3.4.3 Stable Isotope Tracers
The stable isotope labelled amino acid L-[l-13C]leucine (99% 13C) and sodium
[13C]bicarbonate were purchased from Tracer Technologies Incorporated, Newton,
MA, U.S.A. L-| l-13C|leucine was mixed in sterile pyrogen-free sodium chloride
(NaCl) solution (Baxter Healthcare, Norfolk, U.K.) immediately prior to
administration using an aseptic technique and was sterilised by passage through
a 0.22 pm filter (Millipore SA, Molsheim, France). The tracer infusate was
subsequently diluted to a total volume of 500 ml in sterile pyrogen-free NaCl
solution (Baxter Healthcare, Norfolk, U.K.) and was infused at a constant rate via
a second 0.22 pm filter at a rate of 1.0 mg/kg/h over 8 h by volumetric pump. L-[l-
13C]leucine (1 mg/kg) and sodium [13C]bicarbonate (0.24 mg/kg) used for priming
were prepared and administered in similar careful fashion except that the volume
of 0.9% NaCl solution used was 20 ml and it was given as a bolus over 3 min.
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5.3.5 Placement of Cannulas
A triple lumen cannula was inserted antegradely into the internal jugular
vein by the anaesthetist in charge at the time of surgery. This was initially used
in the first 24-48 hours to monitor central venous pressure and to administer
intravenous medication as required. Cannula patency was maintained by the slow
infusion of 0.9% saline (Baxter Healthcare, Norfolk, 500 ml per 24 h). Also, from
the first post-operative day, one channel was used to deliver TPN. The remaining
channels were used on the day of the metabolic study for constant infusion of
labelled amino acids as well as the dipeptide and control solutions.
Deep venous blood was obtained from the "study" forearm from a cannula
inserted retrogradely into the median cephalic or basilic ante-cubital vein. Arterial
blood was obtained from an intra-arterial cannula sited in the radial artery (at the
wrist) for routine post-operative monitoring of mean arterial blood pressure. Blood
samples were obtained for determination of plasma amino acid and glucose
concentrations, free leucine and a-ketoisocaproate (a-KIC) concentrations and 13C
isotope enrichment and hormonal (C-peptide, insulin, glucagon, IGF-I) profiles.
5.3.6 Muscle Biopsies
Three leg muscle (tibialis anterior) biopsies were carried out using
conchotome forceps (Chapter 2): i) at the time of surgery for baseline sample for
isotope enrichment and free amino acid concentration ii) on the third post-operative
day, at the end of the first 4 h period of isotope infusion whilst the patients
212
received TPN and Ala+Gly and iii) at the end of the second 4 h period of isotope
infusion whilst receiving TPN and Ala-Gin infusion. Muscle samples were blotted
dry to remove any blood; also, any evident fatty tissue was removed prior to
immersion and subsequent storage in liquid nitrogen at -196"C.
5.3.7 Blood and Breath Samples
Blood samples were obtained for amino acid and a-KIC concentrations, a-
KIC and 13C-leucine enrichment and hormone profiles (C-peptide, insulin, glucagon
and IGF-I). Attempts were made to collect breath samples for C02 production rate
by Douglas bag and 13C enrichment of expired C02 (according to Protocols 2 and
3, Chapter 2) in order to measure leucine oxidation; however most patients were
unable to tolerate breath collections so soon after major upper gastrointestinal
surgery using a thoracic approach and so collections were abandoned.
5.3.8 Laboratory Analysis
The laboratory analytical techniques used in this study are described in
Chapter 2, section 2.17. Additionally, muscle water content was determined for the
longitudinal study samples by separating and weighing a portion of each biopsy
sample (approximately 10%, by wet weight) then freeze-drying this portion to a
constant weight. The change in weight, related to the wet weight, was expressed
as percentage muscle water content.
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5.4 Results
5.4.1 Arterial Plasma Free Amino and Keto Acid Concentrations
In the longitudinal study, the mean plasma arterial glutamine concentration
(Figure 5.land Table 5.2) was 330+16 (281, 364) /xmol/1 (mean+SEM, 95% confidence
intervals) from the period -30 min to 0 min, falling slightly to 314+16 (274, 355)
/xmol/1 during infusion with Ala+Gly, although this change was not statistically
significant; with the infusion of Ala-Gin, the glutamine concentration rose by 29%
to 404^30 (316, 471) /xmol/1 (p<0.05). This latter value was also higher than the
value of 340+11 (311, 370) /xmol/1 (p<0.04, 1-tailed) for the concentration of
glutamine between 90 to 480 min in the cross-sectional study (Table 5.3). In the
longitudinal study, the concentration of alanine rose from a basal value of 187+32
(92, 259) /xmol/1 to a value of 243+26 (173, 306) /xmol/1 during Ala+Gly infusion
(p<0.03, 1-tailed) remaining stable at 235+22 (179, 291) /xmol/1 with Ala-Gin
infusion. The concentration of glycine rose by 57% from the basal value with
Ala+Gly infusion, from 147.3 + 11 (103, 158) /xmol/1 to 231 + 11 (191, 247) /xmol/1, in
the longitudinal study, falling back to a near-basal level of 127+7 (105, 142) /xmol/1
with Ala-Gin infusion. The plasma concentration of leucine was stable during each
phase of the longitudinal study (Figure 5.2 ). The mean leucine concentrations in
the longitudinal study for the basal, Ala+Gly and Ala-Gin periods were 123 + 13 (90,
156) /xmol/1, 121 + 11 (93, 150) /xmol/1 and 119+7 (102, 136) /xmol/1 respectively and
there were no statistical differences between these values. The corresponding basal
value and the value during 90-480 min for the cross-sectional study group were
similar at 96+20 (48, 144) /xmol/1 and 123+9 (101, 146) /xmol/1 respectively. The
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Figure 5.1 Free glutamine concentrations in arterial plasma representing basal
(dark grey stippled bar) and plateau (90-480 min, unfilled bar)
values for the patient group receiving TPN alone; basal, (light grey
stippled bar) and values at plateau for patients receiving TPN
supplemented with Ala+Gly (60-240 min, filled bar) and TPN
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Plasma arterial (□) and venous (■) concentrations of free leucine in
the patient group receiving TPN alone (90-480 min; top graph) and
the group receiving TPN supplemented by Ala+Gly (60-240 min) and
Ala-Gin (300-480 min; bottom graph).
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Table 5.3 Plasma arterial free amino acid concentrations (cross-sectional




acid ,umol/l CI /+mol/l CI
ALA 174.9 + 20 (124, 226) 176.8 + 16 (134, 221)
ARG 51.7 + 4 (43, 61) 54.5 + 4 (44, 65)
ASP 3.7 + 0.6 (2.2, 5.3) 3.7 + 0.4 (2.6, 4.7)
ASN 32.3 + 5 (19, 46) 27.7 + 3 (20, 35)
GLU 40.6 + 6 (24, 57) 40.2 + 5 (26, 54)
GLN 331.9 + 17 (287, 377) 340.4 + 11 (311, 370)
GLY 189.7 + 17 (146, 234) 238.7 + 34 (148, 329)
HIS 59.5 + 3 (51, 68) 65.8 + 6 (49, 83)
3-MH 3.80 + 0.6 (2.4, 5.4) 3.75 + 0.6 (2.2, 5.4)
ISOLEU 57.8 + 7 (40, 76) 54.8 + 7 (35, 74)
LEU 95.6 + 20 (48, 144) 123.4 + 9 (101, 145)
LYS 157.7 + 11 (130, 186) 147.9 + 13 (113, 183)
MET 39.2 + 8 (18, 60) 29.3 + 3 (22, 37)
PHE 118.3 + 9 (98, 139) 115.5 + 8 (97, 134)
SER 78.1 + 5 (66, 91) 79 + 6 (63, 95)
TAU 36.3 + 2 (31, 42) 29.8 + 2 (26, 34)
THR 87.1 + 7 (70, 105) 90.9 + 6 (75, 106)
TYR 66.5 + 4 (57, 76) 65.1 + 4 (55, 75)
TRY 36.8 + 4 (26, 48) 43.1 + 7 (24, 62)
VAL 175.6 + 13 (140, 211) 179.7 + 8 (158, 201)
BCAA 329.0 + 23 (269, 388) 357.9 + 24 (295, 421)
concentration of 3-methylhistidine was lower during TPN + Ala-Gin infusion than
during TPN + Ala+Gly, the respective values being 3.00+0.4 (1.7, 4.1) /xmol/1 and
3.57+0.3 (3.0, 4.9) pmol/1.
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5.4.2.1 Intramuscular Water Content
Data was available for the longitudinal study only (Figure 5.3 ). The pre¬
operative muscle water content was 69.9+2 (66, 74) %, rising to 76.8+0.7 (75, 78)
% with TPN + Ala+Gly and remaining at the same value at 76.8+0.4 (76, 78) %
with TPN + Ala-Gin infusion.
5.4.2.2 Intramuscular Free Amino Acid Concentrations
The intramuscular concentration of free amino acids in the two groups in
the pre- and both post-operative muscle biopsy samples are shown in Tables 5.4a
and 5.5. In the longitudinal study, the intramuscular concentration of glutamine
fell by 51% from the pre-operative value of 62+4 (51, 72) pmol/g protein to the post¬
operative value of 30+3 (24, 37) pmol/g protein at the end of the Ala+Gly infusion
period (p<0.0005), rising by a small (13%) but significant amount to 34+3 (26, 42)
pmol/g protein at the end of the Ala-Gin infusion (p<0.03, 1-tailed) (Table 5.4b and
Figure 5.4 ), although this value was still 45% lower than the pre-operative value.
The pre-operative and end-of-study post-operative intramuscular glutamine
concentrations in the cross-sectional study group were 60+5 (48, 72) and 28^4 (19,
37) /xmol/g protein (falling by 53%), similar to the corresponding pre-operative and
M2 (end of Ala+Gly infusion) values in the longitudinal study. In the longitudinal
study, there were falls in the concentrations of arginine, histidine, lysine and
tyrosine from pre-operative values and corresponding rises in concentrations of the




Figure 5.3 Intramuscular water content, expressed as a percentage of initial
muscle sample wet weight, in the longitudinal study group: pre¬
operative sample, stippled bar; sample at end of Ala+Gly
supplementation of TPN, filled bar; sample at end of Ala-Gin
supplementation of TPN, hatched bar.
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Figure 5.4 Intramuscular free glutamine concentrations. Represented on the
left are pre-operative (dark grey stippled bar) and post-operative
values (at 480 min, unfilled bar) for the patient group receiving TPN
alone; on the right are pre-operative (light grey stippled bar), end of
period of TPN + Ala+Gly (at 240 min, filled bar) and TPN + Ala-Gin
(at 480 min, hatched bar) values in the longitudinal study group.
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in the concentration of BCAA's between the Ala+Gly period and Ala-Gin period.
5.4.3 Plasma Hormones and Substrates
The concentrations of plasma C-peptide, insulin, glucagon, IGF-I and of
blood D-(-)-3-hydroxybutyrate were stable within each study period in the split
period study (Table 5.6). Neither supplementation of TPN by the Ala+Gly mixture
nor by Ala-Gin dipeptide significantly altered the concentrations of these hormones
and metabolites from their pre-study basal values on TPN alone. The basal plasma
glucose concentration, in the cross-sectional study group was 8.3+0.4 (7.3, 9.2)
mmol/1, and remained unchanged at 8.5+0.7 (6.9, 10.0) mmol/1 during the period
90-480 min. The basal value in the longitudinal study was 9.5 (7.6, 11.4) mmol/1,
and did not change significantly between the TPN + Ala+Gly (9.0+0.7 (7.2, 10.7)
mmol/1) and TPN + Ala-Gin (8.8+0.6 (7.5, 10.2) mmol/1) periods.
5.4.4 Plasma and Muscle Free Leucine Pool Enrichments
For both plasma leucine and a-ketoisocaproate, plateau enrichment was
attained during the last 180 min of each phase of the longitudinal study and
during the last 420 min of the cross-sectional study (Figures 5.5 and 5.6 and Table
5.7). Also, the plasma concentration of a-ketoisocaproate was stable during each
phase of the longitudinal study (Figure 5.7 ) and plateau concentrations were
attained and maintained in the period 60-480 min of the cross-sectional study
(Figure 5.7 ). In longitudinal study, there was a rise in plasma leucine enrichment
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Figure 5.5 Plasma arterial (A) and venous (▼) enrichment of a-ketoisocaproate
in the group of patients receiving TPN alone (90-480 min, top graph)
and the patients receiving TPN supplemented by Ala+Gly (0-240
min) and Ala-Gin (240-480 min; bottom graph).
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Figure 5.6 Plasma arterial (□) and venous (■) enrichment of free leucine in the
patient group receiving TPN alone (90-480 min; top graph) and the
group receiving TPN supplemented by Ala+Gly (0-240 min) and Ala-
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Figure 5.7 Plasma arterial (A) and venous (▼) concentrations of a-
ketoisocaproate in the patient group receiving TPN alone (90-480
min; top graph) and the group receiving TPN supplemented by
Ala+Gly (60-240 min) and Ala-Gin (300-480 min; bottom graph).
227
Table 5.4b Intramuscular free glutamine concentrations (pmol/g protein;
individual patients'values: longitudinal study). CI = 95% confidence
intervals.
Subject Pre-op (Ml) Post-op (M2) Post-op (M2)
ju,mol/g pmol/g fimol/g
1 54.8 30.7 31.4
2 75.2 37.5 50.1
3 46.6 29.0 28.5
4 55.4 20.0 22.8
5 71.8 25.4 25.4
6 49.6 27.9 31.6
7 81.1 25.9 35.2
8 58.9 45.0 46.7
Mean+SEM 61.7+4.2 30.2+2.6 33.9+3.2
CI (51.1,72.4) (23.7,36.7) (25.8,42.1)
from 5.05+0.2 (4.4, 5.7) APE to 5.49+0.6 (4.0, 7.0) APE and there was also a rise
in plasma a-ketoisocaproate enrichment from 4.75+0.3 (4.0, 5.5) APE during
Ala+Gly infusion to 6.11^0.6 (4.7, 7.5) APE during Ala-Gin infusion. Neither
change reached statistical significance (p=0.30 and p=0.066, respectively). The
intracellular leucine enrichment remained unchanged (3.21+0.2 (2.8, 3.6) versus
3.24+0.1 (3.0, 3.5) APE). The 13C intracellular leucine enrichment was 63% of that
of plasma leucine during Ala+Gly infusion, remaining at a similar value of 59%
during Ala-Gin infusion. The 13C intracellular leucine enrichment was 68% of that
of plasma a-ketoisocaproate duringAla+Gly infusion, falling to 53% during Ala-Gin
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infusion.
5.4.5 Muscle Protein Synthesis
In the longitudinal study, the fractional rate of protein synthesis in T.
anterior muscle during Ala+Gly infusion, calculated on the basis that the mean 13C
enrichment in plasma cx-ketoisocaproate (Table 5.7) should most closely the
precursor synthetic pool of dR.NA and provide the best estimate of protein
synthesis, was 0.025+0.003 (0.016, 0.034) %/h; the rate increased during Ala-Gin
infusion by 88% to 0.047+0.006 (0.031, 0.062) %/h (p=0.0052) (Figures 5.8 and 5.9
). The fractional rate of protein synthesis with TPN infusion alone, also using a-
ketoisocaproate as the 'surrogate' precursor, was 0.031+ 0.003 (0.026, 0.036) %/h,
not significantly different from the rate observed in the longitudinal study during
Ala+Gly infusion but significantly lower than the rate observed during the Ala-Gin
period (p<0.05). These values may be considered as the best estimates of protein
synthesis. For the longitudinal study, when calculating the protein synthetic rate
on the basis of the 13C enrichment of the muscle intracellular free leucine pool, a
value (the probable upper limit) of 0.039^0.003 (0.032, 0.047) was obtained during
the Ala+Gly infusion period, rising by 92% to 0.075+0.008 (0.055. 0.096) %/h
(p=0.0095) during Ala-Gin infusion. The rate of protein synthesis in the cross-
sectional group, calculated on the same basis, was 0.049+0.005 %/h (0.037, 0.061),
and this value was not significantly different to the corresponding value in the
longitudinal study group during the Ala+Gly infusion, but significantly slower than
that obtained during Ala-Gin infusion (p=0.04).
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TPN+Ala+Gly TPN+Ala-GIn
Figure 5.8 Fractional muscle protein synthesis rate by [l-13CJleucine
incorporation, calculated using plasma a-ketoisocaproate as the
precursor pool, in the group receiving TPN supplemented by Ala+Gly
(on the left) and Ala-Gin (on the right). The hatched bar connects the
points representing the mean synthetic rates for each period.
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Muscle Protein Synthesis with
Two Different Precursor Pools
0.10
TPN alone TPN+Ala+Gly TPN+Ala-GIn
Figure 5.9 Skeletal muscle fractional mixed protein synthesis, calculated
separately using the surrogate precursor pools (for the true
precursor, £RNA) for protein synthesis, of a-ketoisocaproate (unfilled
bar) and intracellular (intramuscular) free leucine (hatched bar), in
the patient group receiving TPN alone and the group receiving TPN
supplemented by Ala+Gly and Ala-Gin.
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Table 5.5 Free intramuscular amino acid concentrations (/rmol/g protein; cross-
sectional study).
Pre-Op (Ml) Post-op (M2)
Amino
acid p,mol/g CI ixmol/g CI
ALA 10.8 + 0.7 (9.0, 12.5) 12.6 + 0.4 (11.5, 13.6)
ARG 5 + 0.5 (3.8, 6.3) 1.5 + 0.4 (0.6, 2.5)
ASP 5.1 + 0.6 (3.5, 6.8) 4.2 + 0.3 (3.4, 4.9)
GLU 10.5 + 0.9 (8.2, 12.8) 13.2 + 1 (10.7, 15.7)
GLN 60 + 4.6 (47.8, 72.3) 27.8 + 3.5 (18.6, 36.9)
GLY 6.7 + 0.4 (5.6, 7.7) 6.6 + 0.5 (5.2, 8.0)
HIS 1.6 + 0.2 (1.2, 2.1) 0.9 + 0.0 (0.8, 1.0)
ISO 0.3 + 0.0 (0.2, 0.4) 0.3 + 0.1 (0.2, 0.5)
LEU 0.9 + 0.1 (0.6, 1.3) 0.8 + 0.1 (0.6, 0.9)
LYS 16.3 + 2.8 (8.4, 24.1) 3.2 + 0.8 (1.0, 5.4)
PHE 0.4 + 0.0 (0.2, 0.7) 0.7 + 0.1 (0.6, 0.8)
SER 2.2 + 0.2 (1.8, 2.6) 2.9 + 0.2 (2.4, 3.4)
TAU 27.1 + 3.5 (17.8, 36.4) 81.7 + 3.9 (70.7, 92.7)
THR 3.1 + 0.2 (2.6, 3.5) 2.9 + 0.2 (2.3, 3.4)
TRY 33.9 + 5.2 (20.7, 47.0) 40.2 + 4.4 (29.2, 51.2)
TYR 0.5 + 0.0 (0.4, 0.6) 0.5 + 0.1 (0.4, 0.6)
VAL 2 + 0.2 (1.4, 2.6) 1.6 + 0.1 (1.2, 2.0)
BCAA 3.2 + 0.3 (2.5, 3.9) 2.6 + 0.3 (1.7, 3.5)
5.4.6 Whole-body Leucine Kinetics
Although plasma leucine flux was lower during TPN + Ala-Gin infusion
than during TPN + Ala+Gly infusion i.e. 128.7+4 (118, 140) /xmol/kg/h versus
141.7+8 (123, 161) /xmol/kg/h, the difference did not reach statistical significance
at the 5% level (Figure 5.10). Similarly, the rate of appearance of endogenous
leucine, a measure of protein breakdown, was lower, but not by a significant
amount, during Ala-Gin infusion, 102.3+5 (91, 114) /xmol/kg/h versus 115.3+6 (101,
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Table5.6Pl smaarteri lhormonendetaboliteconcentrat onsdur ngthp ri dTPN+Ala+Gly(60-240i ) +Ala-Gin,(300-480min). HormoneP e-opBasalCITPN+Ala+GlyCI
TPN+Ala-Gln
CI
C-peptide (nmol/1) Insulin (mU/1) IGF-1 (Mg/1) Glucagon (Mg/1) B-hydroxy- butyrate (pmol/1)
0.75+0.071.51+0.20 8.0+2.126.7+4.5 150.1+28.497.0 11.2 0.09+0.010.17+0. 2 13.4+5.3
(1.00,2.03) (15.4,38.1) (68.6,125.4) (0.10,0.23) (-7.5,34.3)
1.73+0.12(1.48,.99)1.61+0.12( .35,8 ) 29.4+2.3 95.8+6.2 0.2+0.02 29.6+12.2(24.3,3 .5)24.6+2.6 (74.4,117.1)93.4+5.0 (0.13,0.28).24+0.04 (-11.0,70.3)15.2+4.
(18.8,30.4) (76.0,110 9) (0.09,0.39) (-0.50,3 9)















Figure 5.10 Whole-body leucine flux and breakdown for the patient group
receiving TPN alone (unfilled bar) and the group receiving TPN
supplemented by Ala+Gly (filled bar) and Ala-Gin (hatched bar).
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129) p,mol/kg/h. The rates of plasma leucine flux and whole-body protein
breakdown with TPN alone were 142^13 (113, 172) and 115^12 (86, 144)
/xmol/kg/h, respectively, these values being identical to the values observed
during the Ala+Gly infusion period of the longitudinal study.
5.5 Discussion
As all the clinical studies of post-operative patients reported here were
carried out in the ICU, the study environment was entirely different to that in
which the volunteer studies were carried out. There were many expected
interruptions during the course of each study with patients requiring the
attentions of attending nursing and medical staff as well as ancillary staff such
as physiotherapists and phlebotomists and it was sometimes difficult to stick
rigidly to the blood sampling times as per protocol. Nevertheless, where
sampling times differed from intended times, actual times were carefully
recorded and taken into account in subsequent calculations.
The laboratory analytical techniques used in this study are well
established (Bennet et al, 1989) and were felt to be appropriate. Previously
established analysis protocols were strictly adhered to in order to minimise
laboratory error.
In designing these studies it was considered important to have an
isocaloric, isonitrogenous control amino acid solution against which to compare
the effects of Ala-Gin supplementation of TPN on protein turnover in patients
and the initial rationale for the use of amino acids alanine and glycine was that
this mixture had previously been reported to have been safely and effectively
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used as a control solution in post-operative patients for studies of Ala-Gin
supplementation on nitrogen balance (Stehle et al., 1989). Also, prior to its use
in patients, it was used without any side-effects in our studies on the effects of
Ala-Gin on muscle protein synthesis and breakdown in healthy subjects
(Chapters 3 and 4). Alanine was effectively given in the same amounts during
each of the four hour periods, assuming near-complete hydrolysis of Ala-Gin
(Albers et al., 1988). Therefore glycine was effectively the control amino acid
against which glutamine was compared. To our knowledge there is no evidence
that glycine has any significant effect on muscle protein turnover. Indeed, in the
rat, no correlation was found between intramuscular glycine concentration and
muscle protein synthesis (Jepson et al., 1988); however, as this may not
necessarily apply in man, the safeguard used in the present studies was to
incorporate into the protocol design a study group receiving TPN alone, for
which, if the assumption that glycine has a neutral effect on protein turnover is
correct, the synthesis and breakdown rates should not be significantly different
from that observed during alanine and glycine supplementation of TPN. This
was indeed observed and although the protein synthetic rates were generally a
little higher with TPN alone than during TPN supplemented by alanine and
glycine, the differences were not significant.
The calculations of muscle protein synthesis are based upon an
assumption of attainment of steady state. A time period of 1-1.5 hours is usually
required for plasma a-KIC 13C enrichment to reach plateau values during tracer
infusion (see Figure 1.5, Chapter 1). Four hours should theoretically, therefore,
be an adequate time period for each part of the longitudinal study and this
appears to have been the case (see Figure 5.4), since a-KIC enrichment and
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concentrations attained, and were maintained, at plateau during the
measurement periods 90-240 min and 330 to 480 min of each 4 h study period.
Leucine 13C enrichment and leucine concentration similarly reached plateau and
were maintained thus over the same time intervals. A similar 4 h / 4 h
longitudinal study design was successfully used by Bennet and colleagues to
demonstrate the effects of insulin with mixed amino acid infusion on skeletal
muscle protein synthesis in both healthy subjects (Bennet et a.l., 1989) and also
in insulin dependant diabetic patients (Bennet et al., 1990).
Nevertheless there were potentially conflicting factors which required
consideration prior to adopting the 4 h/ 4 h longitudinal study design in
investigating post-surgical patients. Although an ideal protocol may have
incorporated longer study periods, e.g. 8 h or 6 h rather than 4 h, a single group
of relatively unwell patients would have been unlikely to be able to tolerate 2
such studies 'back-to-back'. However, the use of 2 different patient groups
introduces additional variables i.e. surgery and anaesthesia (Rennie and
MacLennan, 1985; Carli et al., 1989; Essen, 1991; Essen et al., 1992a), post¬
operative analgesia (Kehlet, 1984), post-operative TPN (Moller-Loswick et al.,
1991; Carli et al., 1990; Essen et al., 1993). The potential heterogeneity in the
pathophysiological responses to such intervention could possibly make it harder
to determine the additional effect of a further intervention i.e. glutamine
provision, without the use of larger patient numbers in each group.
As an alternative to the primed constant infusion technique, Garlick and
colleagues have applied the 'flooding dose' technique, (Garlick et al., 1989), to
measure rates of protein synthesis, by tracer incorporation, in healthy subjects
to investigate the effect of feeding (McNurlan et al., 1993) and insulin (McNurlan
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et al., 1992) and in patients to determine the effects of anaesthesia (Essen et al.,
1992), surgery (Essen, 1991) and post-operative TPN (Essen et al., 1993). The
technique aims to flood all rapidly exchanging leucine pools to the same level of
labelling with tracer, by administration of a large dose of leucine (0.05 g/kg body
weight), of a relatively low level of labelling (20%) over a period of a few minutes.
Muscle is sampled after 90 min by biopsy and analysed by the usual methods.
The enrichment is related to the average of the tracer-labelling of venous blood
cx-KIC. Although the flooding dose method has the obvious attraction when
applied in patient studies in requiring less time for completion for each
individual study, there is now good evidence that this method may itself
stimulate muscle protein synthesis (Smith et al., 1992, 1993) and so may be
unable to detect additional or further effects of other interventions of interest.
The post-operative falls in intramuscular free glutamine of 51% and 53%
in the two groups in this study are almost identical in extent to those previously
reported following surgical injury (Vinnars et al., 1975; Carli et al., 1990).
Recently, Hammarqvist and colleagues (Hammarqvist al., 1989) reported a fall
in intramuscular free glutamine of 39% in patients undergoing elective
cholecystectomy. This lower value may reflect the relatively minor nature of
surgery undertaken and consequently the metabolic response was likely to have
been less severe than after oesophagogastrectomy, although no formal
assessment (by 'injury score') of severity of surgical injury is reported in
Hammarqvist's study. In the same study, Hammarqvist and colleagues
compared the intramuscular glutamine concentration in the patients receiving
conventional TPN with that in another group receiving glutamine-enriched TPN.
The 17% observed attenuation in the extent of the post-operative intramuscular
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glutamine concentration fall (Hammarqvist et al., 1989) is of a similar order to
the 13% rise in intramuscular glutamine with short-term Ala-Gin
supplementation in our study, achieved in association with a 14% rise in plasma
glutamine concentration. It is surprising that in Hammarqvist's study, the
attenuation of the post-operative muscle free glutamine concentration fall was
achieved inspite of a reduction in the post-operative plasma free glutamine
concentration with glutamine provision; yet interestingly, the control group
receiving conventional TPN showed no significant change in their post-operative
plasma glutamine concentration.
It did not prove possible in these studies to determine pre-operative values
for rates of muscle protein synthesis against which to compare the effect of
surgery. A number of studies have now been reported from our centre in the use
of the percutaneous conchotome biopsy technique of the muscle tibialis anterior
in the investigation of muscle protein synthesis under a variety of circumstances.
Bennet and colleagues (Bennet et al., 1989) reported a mean protein synthetic
rate in tibialis anterior of 0.055 %/h in healthy young post-absorptive men, rising
to 0.074 %/h with a mixed amino acid infusion of Synthamin (Baxter Healthcare,
Norfolk, UK). More recent reported work from the same centre, using similar
methodology, indicates a slightly lower mean value for tibialis anterior protein
synthetic rate of 0.045 %/h in healthy post-absorptive man (Smith et al., 1992).
The post-operative rates for protein synthesis in the same muscle, in the present
study, were 31-44% lower in post-operative patients inspite of receiving
nutrition, i.e., intravenous amino acids in TPN with Ala+Gly or in TPN alone.
The higher mean value of 0.047 %h with Ala-Gin supplementation was very
similar to the value for post-absorptive man (Smith et al., 1992), mid-way
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between the values observed in healthy post-absorptive man receiving Ala+Gly
alone (0.042 %/h) or receiving Ala-Gin alone (0.051 %/h) (Chapter 3), and 36%
lower than post-absorptive subjects receiving mixed amino acids (0.074 %/h,
Bennet et al., 1989). However comparisons such as these can only be made with
caution and no firm conclusions can be drawn as the characteristics of the
subjects were different (healthy versus elderly cancer patients) and the study
environments were entirely different.
Although it was my original intention to investigate the effects of Ala-Gin
supplementation on whole-body protein turnover by determining whole-body
leucine kinetics, a major component of this, whole-body leucine oxidation, could
not be measured or calculated as the great majority of patients were unable to
tolerate the use of a Douglas bag so soon after their major surgery (particularly
as a thoraco-abdominal incision was often used). No portable ventilated hood
equipment was available during the time period of these studies and thus the
opportunity to investigate this particular aspect of the effect ofAla-Gin could not
be taken.
From these findings, the low post-operative intramuscular glutamine
concentration does appear to be associated with a reduced muscle protein
synthetic rate. Provision of TPN alone or provision of TPN supplemented by a
control isonitrogenous solution of Ala+Gly does not raise intramuscular free
glutamine nor does it increase the muscle protein synthetic rate. However Ala-
Gin supplementation of conventional TPN acutely raises intramuscular free
glutamine concentration by a small but significant amount although a longer
period of Ala-Gin provision would probably be necessary to raise glutamine
concentrations further. Ala-Gin supplementation also appears to raise muscle
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protein synthetic rate (by 88%), although absolute values only approach the
range seen in healthy fasted man (see Chapter 3) and still remain below values
observed (by historical comparison) when a physiological mixture of amino acids
similar to that used in the present studies was administered to healthy subjects
(Bennet et al., 1989). In this study no correlation could be demonstrated between
intramuscular glutamine concentration and muscle protein synthetic rate.
However, it should be noted that the overall subject numbers used in this
calculation of correlation in man were small in comparison to the large numbers
used in a previous animal study demonstrating a significant positive correlation
(Jepson et al, 1988).
The mechanism by which glutamine supplementation exerts its observed
effect in raising muscle protein synthesis in post-operative patients is unknown.
Nor has it been possible to determine whether the effect is a direct effect at
cellular level or indirectly mediated. However, the possible hormonal agents
which may play a role in any indirect effect glutamine may have on protein
synthesis and which were monitored in the present studies were unchanged in
their plasma concentrations between the two phases of the longitudinal study.
Branched chain amino acids and leucine in particular, previously reported to
have a regulatory role in muscle protein metabolism (Buse and Reid, 1975) also
do not appear to play a significant part as concentrations were similar with or
without Ala-Gin infusion. Glutamine appears to be conditionally essential for the
maintenance of muscle protein synthesis in post-operative patients and the
overall amelioration in whole-body nitrogen balance observed in previous studies
of Ala-Gin provision (Stehle et al., 1989; Hammarqvist et al., 1989) to post¬
operative subjects may in part be explained by a stimulatory effect which
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increased glutamine appears to have on muscle protein synthetic rate. However
tracer incorporation methodology as used in the present study can only provide
partial information and it would be essential to carry out further studies of
arteriovenous tracer exchange for a more complete understanding of glutamine's
net effect on post-operative muscle protein balance.
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CHAPTER 6
THE EFFECT OF L-ALANYL-L-GLUTAMINE SUPPLEMENTATION OF
CONVENTIONAL TPN ON SKELETAL MUSCLE PROTEIN SYNTHESIS IN
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6.1 SUMMARY
The acute effects of L-alanyl-L-glutamine (Ala-Gin) dipeptide
supplementation of conventional TPN on skeletal muscle protein synthesis and
breakdown have been investigated in post-operative patients. Sixteen patients
received a constant infusion of non-glutamine containing TPN from the first post¬
operative day up to and including the third post-operative day when muscle protein
synthesis and breakdown were measured over an eight hour period using a primed
constant infusion of [15N]phenylalanine with determination of forearm
arteriovenous plasma phenylalanine balance and 15N enrichment. The effects of
TPN alone were studied in eight of sixteen patients ('cross-sectional' study of Ala-
Gin supplementation); the remaining eight patients were studied over two 4-hour
periods ('longitudinal' study of Ala-Gin supplementation). In the first period, TPN
was supplemented with a primed constant infusion of L-alanine plus glycine
(Ala+Gly) as a control mixture isonitrogenous with the primed constant infusion
of Ala-Gin given in the second period.
The mean plasma arterial glutamine concentration between 90-480 min in
the cross-sectional study was 340+11 (311, 370) pmol/1 (mean+SEM, (95% confidence
intervals)). In the longitudinal study the mean glutamine concentration during
infusion with TPN + Ala+Gly was 314+16 (274, 355) pmol/1, rising by 29% to
404.4+30 (316, 471) pmol/1 (p<0.05) with the infusion of TPN + Ala-Gin. Forearm
mixed protein breakdown in the cross-sectional study patients was 32.8_+5 (21, 44)
nmol/lOOg/min; the values remained similar during Ala+Gly and Ala-Gin
supplementation at 37.6+11 (9, 67), 36.7+9 (14, 59) nmol/lOOg/min respectively. 3-
methylhistidine efflux in the cross-sectional group was -0.24+0.5 (-1.5, 1.0)
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nmol/lOOg/min. Efflux of 3-methylhistidine was -0.6+0.2 (-1.2, 0.1) nmol/lOOg/min
during Ala+Gly supplementation, increasing with Ala-Gin infusion to -0.9+0.3 (-2, -
0.1) nmol/lOOg/min (p<0.02). Forearm protein synthesis was 19.1+3 (12, 26)
nmol/lOOg/min in the cross-sectional study, similar to the rate of 17.8+2 (12, 23)
nmol/lOOg/min during Ala+Gly infusion, increasing to 23.4+2 (18, 29)
nmol/lOOg/min (p<0.03, 1-tailed) during the Ala-Gin period. The net negative
protein balance decreased by 32.5% from the Ala+Gly to the Ala-Gin period (-20+5
(-33, -7) versus -13.5+5 (-27, 0.4) nmol/lOOg/min), although this change did not
reach significance at the 5% level. In the cross-sectional study whole body
phenylalanine flux and protein breakdown were 62+4 (52, 72) and 45.8+4 (37, 54)
pmol/kg/h respectively. Whole-body phenylalanine flux was 63.5+2 (58, 69)
/xmol/kg/h, TPN + Ala+Gly, decreasing slightly to 60.5+4 (52, 69) pmol/kg/h, TPN
+ Ala-Gin. Whole-body protein breakdown decreased slightly but not significantly
from the period of Ala+Gly supplementation (47.7+2 (43, 52) pmol/kg/h), to the
period of Ala-Gin supplementation (44.7+3 (37, 52) pmol/kg/h). These results
suggest that Ala-Gin supplementation of TPN in post-operative patients increased
availability of glutamine and acutely stimulated muscle mixed protein synthesis,
assessed by [15NJphenylalanine arteriovenous exchange, without altering the rate
of mixed protein breakdown. Increased 3-methylhistidine efflux with Ala-Gin
supplementation appeared to indicate that the rate of myofibrillar protein
breakdown was increased by glutamine dipeptide supplementation in these patients
following major elective surgery, in whom both muscle protein synthesis and
protein breakdown are usually reduced from pre-operative values. However the
likelihood of trans-stimulation of the 3-methylhistidine transporter by the large




Studies ofprotein balance in man, using techniques involving measurement
of arteriovenous exchange of amino acids across limbs, indicate that following
injury (including surgical injury), trauma and sepsis, there is a net efflux from
skeletal muscle of certain amino acids, chiefly the gluconeogenic amino acids
glutamine and alanine (Aulick and Wilmore, 1979; Clowes et al., 1980). There is
also efflux of the amino acid 3-methylhistidine from skeletal muscle myofibrillar
protein, and this has been used as the basis of a quantitative assessment of
myofibrillar protein breakdown (Ballard and Tomas, 1983). Conventional TPN
does not appear to reverse the typically negative post-operative nitrogen balance
and is unable to increase post-operative muscle protein synthesis as determined by
the 'flooding dose' technique (Essen, 1991). Also, it does not appear to improve
amino acid and protein balance as measured by limb arteriovenous exchange
(Moller-Loswick, et al., 1991). Various methods of nutritional and hormonal
supplementation of conventional TPN have been advocated and investigated to
establish a possible role for such agents in augmenting the efficacy of TPN in
improving peri-operative whole-body nitrogen and protein balance. Human
recombinant growth hormone has been shown to improve post-operative nitrogen
balance and to stimulate post-operative muscle protein synthesis as determined by
[1,3C]leucine tracer incorporation studies (Ponting et al., 1988). Branched chain
amino acid-enriched TPN however did not improve post-operative muscle protein
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synthesis when assessed indirectly by the semi-quantitative method of muscle
polyribosome concentration determination (Hammarqvist et al., 1988). Glutamine
supplementation of conventional TPN did improve post-operative nitrogen balance
and reduced the extent of the post-operative fall in intramuscular free glutamine
concentration and the associated fall in muscle protein synthetic rate determined
by intramuscular polyribosome concentration (Hammarqvist et al., 1989). However,
to our knowledge, no studies have been reported to date which have sought to
establish by direct methodology the effect of glutamine provision on muscle protein
balance, i.e. synthesis and breakdown, in post-operative patients. Although tracer
incorporation studies using [13C]leucine and tissue biopsy can be used to measure
protein synthesis, they do not provide information on protein breakdown.
Information on both protein synthesis and breakdown is required to assess the net
effect of glutamine, administered either in free form or as the dipeptide Ala-Gin,
on muscle protein balance and to formulate an explanation for the mechanisms by
which the previously reported net improvement in nitrogen balance occurs.
The amino acid L-phenylalanine is neither synthesised nor metabolised by
skeletal muscle. Stable isotope labelled [15N]phenylalanine is therefore an ideal
tracer for use in the investigation of muscle protein synthesis and breakdown. 3-
methylhistidine (i.e. A^-methylhistidine) is an amino acid produced by post-
translational methylation at the 1ST position of histidine-73 of the actin chain
(Vanderkerckhove and Webster, 1984). When released by the breakdown of
myofibrillar proteins actin and myosin, 3-methylhistidine is not reincorporated into
protein by protein synthesis and does not undergo intermediary metabolism (Young
et al., 1971). Actin and myosin together constitute 50% of muscle protein and
release of 3-methylhistidine therefore provides a specific index of breakdown of
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these myofibrillar proteins. The arteriovenous balance of 3-methylhistidine across
the forearm has been measured in this study to determine the effect of Ala-Gin
provision on post-operative myofibrillar protein breakdown.
6.3 Methods
6.3.1 Place of Study
All studies were performed in the intensive care unit of Ninewells Hospital
and Medical School, Dundee.
6.3.2 Patients
The present studies were performed concurrently with the studies of [1-
13C]leucine tracer incorporation described in Chapter 5 and the same patients were
investigated for each study i.e. 8 patients for the 4 h - 4 h longitudinal study ofAla-
Gin supplementation of TPN and 8 patients for the 8 h (TPN alone) cross-sectional
study. All patients had undergone potentially curative upper gastrointestinal
surgery for carcinoma of the oesophagus and were studied on their third post¬
operative day. Their ages, morphological data and operative details are as detailed
in Tables 5.1a and 5.1b, Chapter 5.
Ethical approval for these studies was obtained from the Tayside Committee
on Ethics in Medical Research. Written informed consent was obtained from each
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patient after a 2 hour interview and provision of a written information sheet.
6.3.3 Study Protocol
The overall design used for the studies described here is as described in
Protocol 2 and 3, Chapter 2.
6.3.4 TPN Solution
From the first post-operative day till the third post-operative day when the
metabolic studies described here were performed, patients received TPN in the
form of a 2.5 1 bag of solution per 24 h. The solution comprised a mixture of two
commercially available mixed amino acid solutions: 500 ml of Synthamin 14 (14 g
amino-N per litre) and 500 ml of Synthamin 9 (9 g amino-N per litre) (Baxter
Healthcare, Thetford, England), providing 11.5 g amino-N, 1500 ml glucose 30%
(Baxter Healthcare, Thetford, England) providing 7532 kJ, and replacement
electrolytes (70 mmol Na+, 80 mmol K+).
6.3.5 Tracer Solution
A pre-sterilised solution of [15N (phenylalanine (99 atom%, Tracer
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Technologies, U.S.A.), in 0.9% saline (Baxter Healthcare, Thetford, England) was
infused as a primed constant infusion at a rate of 0.5 mg (amino acid)/kg body
weight/hour respectively, after a 0.5 mg/kg priming dose.
6.3.6 Study Solutions
Pre-sterilised solutions (prepared in the Department of Pharmacy, Ninewells
Hospital and Medical School, Dundee) of the free amino acids L-alanine and glycine
(Kabi-Vitrum, Sweden), in 250 ml 0.9% saline (Baxter Healthcare, Thetford,
England) were infused at 4.8 mg/kg/h and 8.0 mg/kg/h respectively (after priming
bolus doses of 4.8 mg/kg and 8.0 mg/kg respectively in a volume of 20 ml 0.9%
saline), providing a total of 2.25 mg amino-N/kg/h, for 4 h during the first half of
the 8 h tracer infusion study. A sterile solution of the dipeptide L-alanyl-L-
glutamine (Ala-Gin, Kabi-Pfrimmer, Germany) in 250 ml 0.9% saline (Baxter
Healthcare, Thetford, England) was infused at 11.7 mg/kg/h (after a priming bolus
of 11.7 mg/kg in 20 ml 0.9% saline), providing 2.25 mg amino-N/kg/h, for 4 h during
the second half of the 8 h tracer infusion study.
6.3.7 Siting of Cannulas
Deep venous blood was obtained from the "study" forearm from a 18 gauge
cannula (Venflon, Viggo, Sweden) inserted retrogradely into the median cephalic
or basilic ante-cubital vein. A paediatric sphygmomanometer cuff was applied to
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the wrist and inflated to above systolic pressure for one minute prior to blood
sampling in order to minimise the variable effects of the cutaneous circulation,
minimising the admixture of deep venous blood (draining predominantly the
forearm muscle bed) with cutaneous blood from the hand. Before commencing the
main study, confirmatory evidence that this venous cannula was indeed draining
the deep tissues i.e. the muscle bed of the forearm, was obtained by measurement
of blood gases of blood sampled from the cannula. A 02 saturation value of 50% or
below was assumed to indicate the presence of blood draining the deep tissues
(Jackson et al., 1987). Arterial blood was obtained from an intra-arterial cannula
(Viggo, Sweden) sited in the radial artery (at the wrist) for routine post-operative
monitoring of mean arterial blood pressure. A triple lumen catheter was inserted
in the internal jugular vein at the time of surgery by the senior anaesthetist in
charge. This cannula was used initially for monitoring of central venous pressure
and for administration of inotropic drugs if required as well as for TPN infusion.
On the study day one lumen was used for the infusion of the study (amino acid and
dipeptide) solutions.
6.3.8 Blood Flow Measurement
Blood flow was measured in the study forearm using venous occlusion strain
gauge plethysmography using a commercially available machine (Medimatic,
Denmark) regularly maintained and calibrated by the Vascular Laboratory,
Ninewells Hospital and Medical School, Dundee and kindly lent for the present
metabolic studies. Appropriate precautions were taken according to guidelines
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outlined by Jackson and colleagues (Jackson et al., 1987) with, in particular, a
paediatric wrist cuff being applied, as described above, prior to blood flow
measurement in order to stabilise the measured blood flow by minimising the
variable effects of the cutaneous circulation on flow.
6.3.9 Calculations
The 15N enrichment of arterial and venous plasma phenylalanine during the
primed continuous infusion of [15N|phenylalanine and plasma concentrations of
phenylalanine were used to calculate phenylalanine exchange by limb tissue from
the degree of dilution of the tracer in the venous outflow in comparison with the
arterial inflow. The equations used are detailed in Chapter 2.
6.4 RESULTS
6.4.1 Arterial Plasma Amino Acid Concentrations
The concentrations of free amino acids in arterial plasma, and the changes
in their concentrations from basal values to values attained during TPN infusion
alone or TPN supplemented by either an L-alanine plus glycine mixture or by L-
alanyl-L-glutamine are detailed and discussed in part in the previous chapter
(Chapter 5, section 5.4.1 and Tables 5.2, 5.3). In particular, in the longitudinal
study, the mean plasma arterial glutamine concentration (Chapter 5, Figure 5.1
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and Table 5.2) was 329.5 + 16 (281, 364) /xmol/1 (mean+SEM, 95% confidence
intervals) from the period -30 min to 0 min, falling slightly to 313+16 (274, 355)
/xmol/1 during infusion with Ala+Gly, although this change was not statistically
significant; with the infusion of Ala-Gin, the glutamine concentration rose by 23%
to 404.4+30 (316, 471) /xmol/1 (p<0.05). The plasma concentration of phenylalanine
was stable during each phase of the longitudinal study (Figure 6.1). The mean
phenylalanine concentrations in the longitudinal study for the basal, Ala+Gly and
Ala-Gin periods were stable at 98+7 (79, 116) /xmol/1, 93+5 (80, 106) /xmol/1 and
96+4 (82, 110) /xmol/1. The corresponding basal and 90-480 min values for the
cross-sectional study group, comparing with the basal and Ala+Gly periods of the
longitudinal study, were higher at 118+9 (98, 139) /xmol/1 and 115+8 (97, 134)
/xmol/1 respectively, although the differences were not significant. The mean basal
tyrosine concentration in the longitudinal study was 54.3+7 (34, 71) /xmol/1 (p<0.02),
falling by 10% during Ala+Gly infusion to 48.6+6 (32, 64) /xmol/1 and by a further
5% during the Ala-Gin period to 46.3+5 (30, 60) /xmol/1). The basal and 90-480 min
tyrosine concentrations in the cross-sectional study group, compared with the basal
and Ala+Gly periods of the longitudinal study, were similar at 67+4 (57, 76) /xmol/1
and 65+4 (55, 75) /xmol/1 respectively. The mean basal 3-methylhistidine
concentration in the longitudinal study was 3.71+0.4 (2.8, 5.1) /xmol/1, 3.57+0.3 (3,
4.9) /xmol/1 during Ala+Gly infusion and 3.0+0.4 (1.7, 4.1) /xmol/1 during the Ala-Gin
period. There were no significant differences in the corresponding basal and 90-480
min values for the cross-sectional study group, which were similar at 3.88+0.6 (2.4,
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Figure 6.1 Plasma arterial (O) and venous (•) concentration of free
phenylalanine in patients receiving TPN alone (90-480 min, topgraph) and in patients receiving TPN supplemented by either
Ala+Gly (60-240 min) or Ala-Gin (300-480 min, bottom graph).
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6.4.2 Forearm Amino Acid Balance
In the longitudinal study the net effluxes from the forearm of phenylalanine
and tyrosine (Table 6.1a) during the Ala+Gly period were -20+5 (-33, -7) and -
16.7+4 (-29.5, -4) nmol/lOOg/min respectively. The phenylalanine efflux decreased
to -13.5+5 (-27, -0.4) nmol/lOOg/min during the Ala-Gin period. The tyrosine efflux
did not significantly change at -20.1+4 (-33.5, -6.5) nmol/lOOg/min. In the cross-
sectional study, net effluxes of phenylalanine and tyrosine between 90-480 min
(Table 6.1a) were -13.6+4 (-23, -4) and -18.6+7 (-36, -2) nmol/lOOg/min respectively:
these values, also, were not significantly different to the values observed during
either of the Ala-Gin or the Ala+Gly infusion periods in the longitudinal study.
The efflux of 3-methylhistidine from the forearm increased with Ala-Gin infusion,
from -0.6+0.2 (-1.2, 0.1) nmol/lOOg/min (with Ala+Gly) to -0.9+0.3 (-2, -0.1)
nmol/lOOg/min (p<0.02) which would appear to suggest that the rate of myofibrillar
protein breakdown was increased by glutamine dipeptide supplementation. In
comparison to 3-methylhistidine efflux during the Ala+Gly period the corresponding
value at plateau in the cross-sectional study (Table 6.1a) was not significantly
different at -0.24+0.5 (-1.5, 1.0) nmol/lOOg/min.
Total amino acid efflux increased slightly from -618+111 (-838, -398)
nmol/lOOg/min with TPN + Ala+Gly to -643+115 (-870, -416) nmol/lOOg/min with
TPN + Ala-Gin. The total efflux of essential amino acids fell from -206.1+43 (-292,
-398) nmol/lOOg/min with TPN + Ala+Gly to -180.6+31 (-243, -118) nmol/lOOg/min
with TPN + Ala-Gin. The total efflux of non-essential amino acids increased
from -411.5+62 (-310, -62) nmol/lOOg/min with TPN + Ala+Gly to -462+110 (-
682, -243) nmol/lOOg/min with TPN + Ala-Gin. However, excluding the
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supplemental amino acids Ala, Gin and Gly, the total efflux of the remaining non¬
essential amino acids fell from -70.7+30 (-131, -11) nmol/lOOg/min with TPN +
Ala+Gly to -40.3+25 (-90, -9) nmol/lOOg/min with TPN + Ala-Gin.
6.4.3 Plasma Hormones and Substrates
The concentrations of plasma C-peptide, insulin, glucagon, IGF-I and of
blood D-(-)-3-hydroxybutyrate were stable within each study period in the
longitudinal study (Chapter 5, Table 5.6).
6.4.4 Plasma [15N] Enrichment of Phenylalanine
Plateau was attained for the enrichment of plasma phenylalanine during the
final periods of each study (Figure 6.2) and in particular, during each phase of the
longitudinal study. In the latter study, arterial plasma phenylalanine enrichment
(APE) was 4.2+0.2 (3.7, 4.7) during the Ala+Gly period, rising to 4.5+0.3 (3.8, 5.1),
p<0.05, during Ala-Gin infusion.
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Figure 6.2 Plasma arterial (O) and venous (•) enrichment of free phenylalanine
in patients receiving TPN alone (90-480 min, top graph) and in
patients receiving TPN supplemented by either Ala+Gly (0-240 min)
or Ala-Gin (240-480 min, bottom graph).
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6.4.5 Forearm Protein Balance by [l5N]phenylalanine Arteriovenous
Exchange
In the longitudinal study forearm mixed protein breakdown, assessed
by[15N]phenylalanine, was similar during the Ala+Gly and Ala-Gin periods at
37.8+7 (20, 55) nmol/lOOg/min versus 36.9+7 (22, 51) nmol/lOOg/min respectively
(Figure 6.3). The protein breakdown rate in the cross-sectional study was also
similar at 32.8+5 (21, 44) nmol/lOOg/min. Forearm protein synthesis increased
from 17.8+2 (12, 23) nmol/lOOg/min during the Ala+Gly period of the longitudinal
study to 23.4+2 (18, 29) nmol/lOOg/min (p<0.03, 1-tailed) during the Ala-Gin period
(Figure 6.4). Forearm protein synthesis in the cross-sectional study was similar to
the value during the Ala+Gly period of the longitudinal study, at 19.1+3 (12, 26)
nmol/lOOg/min. The balance between protein synthesis and protein breakdown
decreased by 32.5% from the Ala+Gly to the Ala-Gin period, although this change
did not reach statistical significance.
6.4.6 Whole-body Phenylalanine Kinetics
In the longitudinal study, whole-body phenylalanine flux (Figure 6.5) fell
from 63.5+2 (58, 69) pmol/kg/h during the Ala+Gly period to 60.5+4 (52, 69)
pmol/kg/h during the Ala-Gin period, although the change was not statistically
significant. During the same periods whole-body protein breakdown decreased
slightly but not significantly from 47.7+2 (43, 52) pmol/kg/h to 44.7+3 (37, 52)
pmol/kg/h respectively. In the cross-sectional study (Figure 6.5), whole body
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Figure 6.4 Skeletal muscle protein synthesis in the patient group receiving TPN
supplemented either by Ala+Gly (on the left) or Ala-Gin (hollow
















Figure 6.5 Whole-body phenylalanine flux and breakdown for the patient group
receiving TPN alone (unfilled bar) and the group receiving TPN
supplemented by Ala+Gly (filled bar) and Ala-Gin (hatched bar).
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phenylalanine flux and protein breakdown during 90-480 min were similar at 62+4
(52, 72) gmol/kg/h and 45.8+4 (37, 54) gmol/kg/h respectively.
6.5 DISCUSSION
The potential pitfalls of a 4 h - 4 h periods longitudinal study design have
been discussed in Chapter 5 with particular reference to the Ll-13C]leucine
incorporation method for studying protein synthesis by the primed constant
infusion technique. When studying muscle protein turnover by the
[15N [phenylalanine arteriovenous exchange method it is equally important to attain
steady states of tracer enrichment during each study period, as the model used for
calculating protein synthesis and breakdown presupposes such steady states.
Steady states were indeed achieved for [15N] enrichment of phenylalanine and also
of phenylalanine concentration during both 4 hour periods of the longitudinal study
and also during the 8 hour cross-sectional study. The principal advantage of the
longitudinal study protocol, i.e. using individual patients as their own control in
order to minimise the effects of variables on protein synthesis such as the
heterogenous pathophysiological response to surgery, anaesthesia and TPN, is
particularly pertinent to the present study where the methodology itself is subject
to the influence of additional important variables e.g. the measured blood flow in
the forearm muscle bed and the fluctuations in the venous drainage from this
muscle bed (Butler and Home, 1987). Thus the coefficients of variation of the
measures of protein turnover were larger with the use of the [ 15N]phenylalanine
arteriovenous exchange method than the variation observed for muscle protein
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synthesis calculated from tissue enrichments in samples obtained by biopsy. This
was probably due to errors compounding in the calculations based on small
arteriovenous differences and to the inter-individual variation in blood flow
measurements, a major component in the calculation of protein turnover by the
limb exchange method.
Although the clinical investigative methodology used in the present studies
is well established and has been previously used and adapted at our centre by
Bennet and colleagues (Bennet et al., 1990) to investigate the effects of insulin and
mixed amino acid provision on skeletal muscle protein synthesis and breakdown,
Bennet's studies were performed on healthy volunteers and fully ambulant diabetic
patients. The present studies were carried out on non-ambulant post-operative
patients in the intensive care unit. These patients are at increased risk of deep
venous thrombosis (DVT) (Barua, 1992) and it was therefore felt that femoral vein
cannulation to obtain venous samples draining the lower limb muscles (Bennet et
al., 1990), would be wholly inappropriate, particularly for research purposes, as
even relatively minor local endothelial injury at the site of cannulation could
augment the risk of DVT. The forearm was therefore used for these studies as
described by Cheng and colleagues (Cheng et al., 1985). A potential disadvantage
of using the forearm preparation however is that protein turnover values are
determined for a much smaller muscle mass, possibly introducing greater error
when extrapolating to calculate changes in protein turnover for the whole-body
muscle mass.
The values of post-operative forearm arteriovenous balance of the amino
acids alanine, glutamine, methionine and phenylalanine in the longitudinal and
cross-sectional study groups are broadly in the same range as, but not identical to,
268
the values reported (with these amino acids alone being quoted) in a study
investigating post-hysterectomy patients on TPN (Carli et al., 1990). Although the
forearm preparation has been used in both studies, the differences which exist in
the amino acid balance results between the studies may be accounted for by
differences in the patient groups (age, disease and nutritional state), the nature of
surgical intervention and the subsequent metabolic response and the composition
of the intravenous nutrition provided.
Muscle protein synthesis was significantly higher during the Ala-Gin period
(p<0.03, paired t-test, 1 tailed) in comparison with the Ala+Gly supplementation
period. Interestingly, the absolute values for muscle protein synthesis with TPN
alone or Ala+Gly supplementation of TPN in post-operative patients were lower
than that observed in the post-absorptive healthy subjects receiving the control
solution of Ala+Gly, (19.1+3 (12, 26) and 17.8+2 (12, 23) versus 26.1+2 (21, 32)
nmol/lOOg/min) in the study described in chapter 4, and only approached parity
with Ala-Gin supplementation (23.4+2 (18, 29) versus 26.1+2 (21, 32)
nmol/lOOg/min), suggesting the presence, in post-operative patients, of a significant
degree of residual resistance to the observed stimulatory effect of intravenous
nutrition with TPN in healthy subjects (Bennet et al., 1989). There was no
significant difference in muscle protein breakdown between the first and second
periods of the longitudinal study and this suggests that Ala-Gin supplementation
of TPN does not alter mixed muscle protein breakdown in patients undergoing
major surgery.
In relation to the arteriovenous balance of amino acids, one concern is that
the observed increase in protein synthesis with Ala-Gin provision, without any
significant increase in breakdown, does not appear to be reflected in a
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corresponding decrease in total amino acid efflux. Although the reason for this
apparent disparity is not self-evident, a number of factors can be considered which
may be contributory. The co-efficient of variation in the measurement of
arteriovenous differences was large and in this study this method is unlikely to
have been sensitive for indirectly assessing quantitative changes in protein balance.
The concentrations of phenylalanine, used in the calculations of balance and
protein synthesis, were determined with mass spectrography methodology using
true internal standards and in general are likely to have been more accurate than
the concentrations of other amino acids determined by amino acid analyser with
external standard. Also, the dipeptide Ala-Gin is metabolised in muscle to release
into venous blood free Ala and Gin (Fiirst, 1989), hence increasing 'production' and
net efflux of these amino acids from muscle. Glycine provision was withdrawn in
the TPN + Ala+Gln period and this could explain the increase in the net negative
balance during this period. Excluding these three amino acids, the total efflux of
non-essential amino acids fell by 43% with Ala-Gin supplementation and the total
efflux of essential amino acids fell by 12%. Neither change, however, reached
statistical significance.
The finding that the average muscle protein synthesis increased with Ala-
Gin supplementation of TPN, by use of the [15N]phenylalanine forearm
arteriovenous exchange method, is in agreement with the results from a previous
study in which protein synthetic rate was determined by [l-13C]leucine tracer
incorporation into percutaneous muscle biopsy samples (Chapter 5). The present
findings show the effect of Ala-Gin supplementation of TPN to be in the same
direction, although quantitatively to a lesser degree, as observed in data obtained
by the tracer incorporation method. The quantitative difference could be accounted
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for in part by differences between the two methodologies used, involving the use of
two different stable isotope tracers. Also, the limb arteriovenous amino acid
exchange method used in the present study may underestimate the actual
intracellular values of protein synthesis and breakdown, as a fraction of the
intracellular amino acids resulting from protein breakdown is directly
reincorporated into protein without entering the plasma amino acid pool (Biolo et
al., 1995).
The processes which regulate muscle protein breakdown in patients
undergoing elective surgery do not appear to be acutely influenced by provision of
glutamine in the form of Ala-Gin. There is evidence that in certain conditions
including elective surgery which involve acute muscle wasting, both the
mechanisms of muscle protein synthesis and breakdown are depressed (Rennie,
1985), with synthesis being depressed to a greater extent than breakdown,
resulting in net negative protein balance. In these circumstances, intervention
such as glutamine provision may have a net anabolic effect on protein balance by
a possible combination of stimulation, inhibition or sparing of the processes of
synthesis and breakdown, with the net effect favouring synthesis over breakdown.
The evidence from the present study would appear to suggest that glutamine
provision does stimulate protein synthesis in post-operative patients. Also, in
contrast to the situation reported in perfused murine skeletal muscle (McLelland
et al., 1988), where glutamine provision inhibited protein breakdown, it does not
appear to alter mixed protein breakdown in post-operative man. The efflux of 3-
methylhistidine increased with Ala-Gin supplementation. This observation appears
to suggest that myofibrillar protein breakdown increased in these patients with
glutamine provision. However the possibility exists that significant trans-
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stimulation of the 3-methylhistidine transporter (Hundal et al., 1987 ) occurred with
the large amount of administered glutamine, thereby increasing 3-methylhistidine
efflux, making interpretation of myofibrillar protein breakdown unreliable, as efflux
of this amino acid in these circumstances would not necessarily reflect the rate of
myofibrillar protein breakdown.
Whole-body phenylalanine flux was not significantly different in each of the
study periods in the longitudinal study group in comparison with values observed
in the cross-sectional study group. Qualitatively, however, there was a trend
towards a reduction in whole-body flux with the dipeptide supplementation, as
previously observed using [l-13C]leucine tracer (see Chapter 5). Information on
whole-body protein synthesis was unavailable as tyrosine flux was not measured
in this study (see Chapter 2 for discussion).
The net skeletal muscle protein balance remained negative and this result
is in concordance with nitrogen balance studies of glutamine provision, either as
Ala-Gin (Stehle et al., 1989) or as free glutamine (Hammarqvist et al., 1989) where
it has been reported that although glutamine supplementation of TPN improved
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7.1 SUMMARY
The acute effects of L-alanyl-L-glutamine (Ala-Gin) dipeptide
supplementation of conventional TPN on albumin synthesis have been investigated
in patients undergoing major curative surgery for oesophageal carcinoma. Eight
patients received a constant infusion of non-glutamine containing TPN from the
first post-operative day up to and including the third post-operative day when
albumin synthesis was measured over an eight hour period using a primed
constant infusion of [l-13C]lleucine with determination of plasma [13C]-a-
ketoisocaproate ([13C]-aKIC) enrichment and [13C]leucine incorporation into plasma
albumin. The eight patients were studied over two 4-hour periods. In the first,
TPN was supplemented with a primed constant infusion of L-alanine plus glycine
(Ala+Gly) as a control mixture isonitrogenous with the primed constant infusion
of Ala-Gin given in the second period. The mean plasma arterial glutamine
concentration was 314+16 (274, 355) /xmol/1 (mean+SEM (95% confidence intervals))
during infusion with Ala+Gly, rising to 404+30 (316, 471) /+mol/l (p<0.05) with the
infusion ofAla-Gin. There was a rise in plasma a-ketoisocaproate enrichment from
4.75+0.3 (4.0, 5.5) APE during Ala+Gly infusion to 6.11+0.6 (4.7, 7.5) APE during
Ala-Gin infusion, although this change did not reach statistical significance
(p=0.066). The [13C]leucine enrichment in plasma albumin rose from (0.039+0.001
(0.037, 0.042) to 0.088j+0.001 (0.085, 0.092), APE) during the period 60-240 min of
TPN + Ala+Gly infusion (p<0.00001) and from (0.179+0.002 (0.174, 0.185) to
0.246+0.005 (0.234, 0.258), APE) during the period 60-240 min of TPN + Ala-Gin
infusion (p<0.00001). The calculated albumin synthesis rate was 0.041+0.05 (0.29,
0.53) %/h during Ala+Gly supplementation of TPN and was 37% higher at
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0.056+0.10 (0.30, 0.82) %/h with Ala-Gin supplementation. Although this difference
was just beyond the limit of significance on analysis by the Student's paired £-test
(two-tailed), at the 5% level (p=0.058), there was nevertheless a definite trend
toward higher values of albumin synthesis with the dipeptide supplementation in
comparison to the isonitrogenous Ala+Gly mixture, indicating that short-term
glutamine provision, in the form of Ala-Gin dipeptide supplementation of TPN
appears to have an acute stimulatory effect on albumin synthesis in post-operative
patients.
7.2 Introduction
Albumin is a plasma protein of molecular weight 69,000 which is
synthesised in the liver. In healthy adult man, the plasma albumin concentration
is 35-50 g/1 and the total exchangeable albumin pool is 4.0-5.0 g/kg bodyweight. 38-
45% of this albumin is intravascular and much of the rest is in the skin (Ganong,
1981). Six to ten per cent is degraded per day and the degraded albumin is
replaced by hepatic synthesis of 200-400 mg/kg/d. Because of its relatively small
size albumin has an important role in the maintaining of plasma oncotic pressure
(James and Coward, 1981). Albumin has been reported to have scavenging
properties in relation to free radicals (Holt et al., 1984) and improves prognosis in
the sheep model of the adult respiratory distress syndrome (Emerson et al., 1988).
It also appears to have anticoagulant properties, inhibiting platelet aggregation
and enhancing the inhibition of factor Xa by antithrombin III (Jorgensen and
Stoffersen, 1980 and 1979). Albumin is also an important carrier protein in
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plasma, binding many substances, and is a useful marker of nutritional status
(Mullen et al., 1979).
It appears that albumin synthesis cannot be maintained for any length of
time with the re-direction of amino acids derived from intracellular hepatic protein
breakdown, and in vitro experiments, perfusion studies and measurements of
albumin synthesis in vitro have all demonstrated the importance of extra-hepatic
amino acids in determining the rate of albumin synthesis (Morgan and Peters,
1971; Rothschild et al., 1977). Until relatively recently, direct measurement of the
synthesis rate of albumin has only been carried out by a few investigators, e.g.
Tavill and co-workers (1968), but there is clear evidence that the provision of
amino acids by infusion will enhance synthesis (Skillman et al., 1976). The earlier
work on synthesis rate depended on inferring the rate from measurements of the
catabolic rate measured under steady state conditions. Nevertheless, it is clear
that albumin synthesis is much more sensitive to protein intake than can be
inferred simply from the plasma albumin concentration (Hoffenberg et al., 1966).
Recently, there has been increased interest in the measurement of rates of
plasma albumin synthesis and metabolism, as albumin concentration is an useful
indicator of nutritional and metabolic status, which is known to fall in critically ill
and malnourished patients (Fleck et al., 1985; Hunter et al., 1985). However
knowledge of the albumin concentration alone may be of limited value, as it is the
resultant of several processes including synthesis and breakdown, changes in
extracellular fluid volume, and losses to the extravascular space (Fleck et al.,
1985).
It is known that the rate of albumin synthesis can be regulated by dietary
protein intake (Kaysen et al., 1989), is normalised by infusion of branched-chain
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amino acid-enriched total parenteral nutrition in patients with cancer cachexia
(Hunter et al., 1989), and is sensitive to changes in insulin in diabetic rats (Peavy
et al., 1978 and 1985). There is conflicting evidence available on the effect of
insulin in type I diabetic patients, who are reported to show either a decrease
(DeFeo et al., 1991) or no change (Pacy et al., 1990) in the rate of albumin
synthesis after insulin withdrawal.
We became interested in the effect of Ala-Gin supplementation of TPN on
albumin synthesis after having completed earlier studies on the effect of Ala-Gin
supplementation of TPN on skeletal muscle protein turnover in post-surgical
patients (Chapters 5 and 6). Also, the general methodology for investigating
albumin synthesis had recently become established locally in our laboratory and
successful studies had been performed investigating a possible stimulatory role of
the flooding dose method in protein synthesis, in particular in acutely stimulating
albumin synthesis in healthy post-absorptive subjects (Smith et al., 1993). Because
plasma samples remained from the earlier studies on the role of Ala-Gin
supplementation in muscle protein turnover, we made some additional
measurements on these samples in order to complete this retrospective study on
the acute effect of short-term Ala-Gin supplementation of TPN on albumin
synthesis.
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7.3 Materials and Methods
7.3.1 Experimental Design
A detailed experimental protocol is given in the previous chapters (see
Protocol 3, Chapter 2 and Chapter 5) and the present work only describes basic
essentials and additional details.
7.3.2 Patient Details and Place of Study
Eight patients, (66-79 years, 44-85 kg, mean APACHE II score 9.13,
(Chapter 5, Table 5.1b) who had undergone curative resection for oesophageal
carcinoma, were studied postoperatively. All patients were studied on the third
post-operative day, in the intensive care unit at Ninewells Hospital and Medical
School, Dundee.
7.3.3 TPN and Infusion of Ala+Gly, Ala-Gin and Tracer Solutions
From the first postoperative day, patients were given intravenous nutrition,
consisting of a 50:50 1 litre mixture of two commercially available mixed amino
acid solutions, Synthamin 9 and Synthamin 14 (Baxter Healthcare, Norfolk,
England) providing 11.5 g N, plus 450g glucose, 70 mmol Na+ and K+, all in 2.5 1
water/24 h. The patients were studied on the third postoperative day between
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0800 h and 1600 h when they received a primed constant infusion of |T-13C]leucine.
The study protocol was divided into two four hour periods: in the first the
conventional non-glutamine containing TPN was supplemented with alanine (4.8
mg/kg/h) and glycine (8 mg/kg/h) to provide amounts isonitrogenous with the
dipeptide (Ala-Gin, 11.8 mg/kg/h) which was given in the second four hour period.
7.3.4 Blood Sampling and Storage
Blood samples were taken prior to the infusion of tracer (at -30 to 0 min)
and at frequent intervals throughout the study, according to protocol 3 described
in Chapter 2. Blood samples were immediately stored on ice prior to subsequent
cold centrifugation and separation of plasma. The plasma was stored at -80°C until
the time of analysis.
7.3.5 Laboratory Analysis
The laboratory analytical techniques used were as described by Smith et al.
(1992) and detailed in Chapter 2. Plasma was separated from the blood and used
for the determination of concentration and enrichment of [13C]leucine and a-
ketoisocaproic acid by standard methods, using gas chromatography-mass
spectrometry (Rocchiccioli et al., 1981; Schwenk et al., 1984).
Albumin was isolated from 1 ml plasma by alcoholic extraction of the
trichloroacetic acid-precipitated protein (Ballmer et al., 1990; Korner and Debro,
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1956). The alcohol was evaporated under nitrogen at 70°C using a TurboVap LV
evaporator (Zymark). Contamination of the albumin by free amino acids was
minimized by redissolving the protein in 0.3 N NaOH at 37°C for 30 min, then
reprecipitating with ice-cold 2M HC104. Measurement of the 13C labelling of
leucine in albumin was carried out by routine methods involving acid hydrolysis
of the protein, purification of the acid hydrolysate by ion-exchange chromatography,
preparative gas chromatography, and isotope ratio-mass spectrometry of carboxyl-
C02 (Smith et al., 1988).
7.3.6 Methods of Calculation
The rates of albumin synthesis were calculated by standard equations for
the constant infusion method (see Chapter 2 for details). In the calculation of
albumin synthetic rate it is essential to take into account the lag period between
the synthesis and processing of albumin by the liver and its eventual secretion into
plasma, i.e. the secretion time (ts). The relationship between precursor and product
is displaced by this secretion time, which can be calculated by plotting the
regression line of the linear portion of the [13C]leucine incorporation into albumin
and extrapolating to the basal enrichment.
Statistical analysis for hypothesis testing was by Students paired £-test,
with significance being assigned at the 5% level. Additional statistical analysis is




7.4.1 Plasma a-KIC Enrichment
Plateau enrichment was attained for plasma a-ketoisocaproate, as described
previously in Chapter 5, during the last 180 min of each 4 h phase of the 8 h study
(Chapter 5, Figure 5.1 and Table 5.7). Also, the plasma concentration of a-
ketoisocaproate was stable during each phase of the study (Chapter 5, Figure 5.3).
There was a rise in plasma a-ketoisocaproate enrichment from 4.75+0.3 (4.0, 5.5)
APE during Ala+Gly infusion to 6.1E+0.6 (4.7, 7.5) APE during Ala-Gin infusion.
However this change did not reach statistical significance (p=0.066).
7.4.2 Tracer Enrichment in Plasma Albumin
The [13C]leucine enrichment in plasma albumin (Figure 7.1) increased
linearly from 0.039+0.001 (0.037, 0.042) to 0.088+0.001 (0.085, 0.092), APE, during
the period 60-240 min of TPN + Ala+Gly infusion (p<0.00001) and from
0.179+0.002 (0.0174, 0.0185) to 0.246+0.005 (0.234, 0.258), APE, during the period
60-240 min of TPN + Ala-Gin infusion (p<0.00001). Regression analysis of the data
gave the equation for the relationship between tracer incorporation into albumin
and time as y = 0.024 x - 0.008 during the period 60-240 min of TPN + Ala+Gly
infusion (Figure 7.1 and y = 0.033 x - 0.018 during the period 60-240 min of TPN
+ Ala-Gin infusion. Extrapolation of these lines to the values for basal enrichment
indicated secretion times of 20 min and 32.7 min respectively.
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Figure 7.1 [l-13CJleucine enrichment in plasma albumin during TPN
supplementation with Ala+Gly (120-240 min) and during
supplementation with Ala-Gin (360-480 min). The equations denote
the calculated regression slopes of the curves showing linear
incorporation of the tracer in each period.
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Table 7.1 Calculated albumin synthetic rates assuming plasma a-
ketoisocaproate (a-KIC) as precursor.











CI (0.30, 0.53) (0.30, 0.82)
7.4.3 Calculated Albumin Synthetic Rate
The calculated albumin synthesis rate was 0.41+0.05 (0.290, 0.525) %/h
during Ala+Gly supplementation of TPN and was 37 % higher at 0.56+0.10 (0.304,
0.817) %/h, p=0.058, with Ala-Gin supplementation (Figure 7.2 and Table 7.1)).
The calculated daily rates were 9.8+1.2 (7.0, 13.0) %/d (Ala+Gly) and 13.5+2.5 (7.3,
19.6) %/d (Ala-Gin).
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Figure 7.2 Albumin synthesis rate by [l-13C]leucine incorporation, calculated
using plasma a-ketoisocaproate as the precursor pool, in the
longitudinal study group receiving TPN supplemented by Ala+Gly
(on the left) followed by Ala-Gin (on the right). The hatched bar




Conceptually this study was a retrospective study and was undertaken using
blood samples remaining from earlier studies investigating muscle and whole-body
protein turnover; as such it may have been susceptible to the same problems of
study design and execution, as well as incomplete data collection which may beset
such studies and disadvantage them in comparison to prospective studies.
Nevertheless we believe the present study to be of interest, as to our
knowledge, it provides the first account of an investigation into the effect of
glutamine provision (as the dipeptide Ala-Gin) on albumin synthesis in man and
in particular an evaluation of its role in this regard during TPN supplementation
in post-surgical patients.
It is arguable that the present study's design allowed for too short a period
of time, i.e. 4 h, to determine the possible acute effect of nutritional intervention.
Although, in a previous study, an acute stimulatory effect of large-dose ('flooding
dose') administration of the branched-chain amino acid leucine on albumin
synthesis was detected over a period of 90 min (Smith et al., 1993), that study was
performed however on healthy young post-absorptive subjects and it cannot be
assumed that liver albumin synthesis would show similar acute responsiveness to
additional nutrient stimulus in older post-surgical patients receiving TPN.
Measurement of protein synthesis by stable isotope tracers ideally requires
knowledge of the enrichment of the precursor pool (aminoacyl £RNA) from which
it is being synthesised. In practice it may prove difficult or impossible to obtain
tissue by biopsy sufficient to analyse this pool. Instead enrichment values of the
accessible amino acid pools, which during | l-13C]leucine infusion are 13C-leucine or
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"C-ocKIC, are commonly used. Although there is now a considerable body of
evidence to suggest that at least for the whole-body and skeletal muscle, plasma
13C-(xKIC more precisely reflects and predicts the enrichment of intracellular
leucine than plasma 13C-leucine (Matthews et al., 1982; Layman and Wolfe, 1987;
Horber etal., 1989), the question arises as to whether the same argument holds for
more rapidly turning over proteins such as albumin. Supportive evidence to
indicate an affirmative answer has come from a number of recent studies
(Schwenck et al., 1985; Layman and Wolfe, 1987; Pacy et al., 1990).
Although a large number of studies of albumin synthesis have been reported
in healthy subjects and in patients, no single study appears to provide an
appropriate 'ideal' reference range to allow comparison of the values of albumin
synthesis determined under the circumstances of the present study. Reported
values obtained for albumin synthesis in healthy subjects show a wide range,
possibly reflecting the differing investigative methods used. In healthy young
subjects they range from 6.0 %/d to 12 %/d in the post-absorptive state (Smith et
al., 1993; Olefumi et al., 1991; De Feo et al., 1991). Feeding resulted in stimulation
of albumin synthesis up to a value of 23 %/d (De Feo et al., 1991). Also,
administration of a large dose of leucine resulted in an acute stimulation of
albumin synthesis from 6.0 %/d to 10.3 %/d (Smith et al., 1993). Studies of
albumin synthesis in patients have provided a range of values for a number of
different disease conditions: 8 %/d in patients receiving a mixed solution of the
branched chain amino acids alone following gastric bypass surgery for morbid
obesity (Desai et al., 1985); 9.6 %/d in post-absorptive patients suffering from
cancer cachexia (Shaw et al., 1991) and 9.9 %/d in type 1 diabetic patients in the
fed state, whilst receiving replacement insulin (De Feo et al., 1991). The values for
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albumin synthesis observed in the present study in patients after major surgery
receiving TPN, from 9.8+1.2 %/d with Ala+Gly supplementation to 13.5+2.5 %/d
with Ala-Gin supplementation, fall within this broad reported range.
In conclusion, short-term glutamine provision, in the form of Ala-Gin
dipeptide supplementation of TPN, appears to result in acute stimulation of
albumin synthesis in post-operative patients, although in percentage terms the
stimulatory effect was smaller in degree than the effect observed on skeletal
muscle protein synthesis (Chapters 5 and 6). The values obtained are similar to
those obtained in postabsorptive healthy volunteers (De Feo et al., 1991) and
therefore may represent a degree of resistance to the effects of parenteral feeding.
Following trauma, including the trauma ofelective surgery, the reported fall
in plasma albumin concentration may be due largely to redistribution to
extravascular compartments rather than a reduction in its synthesis or increase
in breakdown (Soni, 1995), although in this study we have not investigated rates
of breakdown. Interventions aimed at ameliorating the pathophysiological effects
of trauma or sepsis on the body as a whole are therefore more likely to be effective
in restoring albumin levels to normal than interventions directed at raising
albumin concentrations in plasma per se (Soni, 1995).
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8.1 General Discussion
The studies described here are subject to a number of uncertainties and
limitations. Amongst the most important is that errors may have arisen by
calculation of indices of protein turnover and amino acid metabolism from the
tracee enrichments in the accessible vascular compartment rather than in /RNA.
The evidence supporting this approach in man is circumstantial. Qualitative
mistakes may have arisen therefore in the present studies, particularly with
overestimation of the anabolic effect of glutamine dipeptide provision on protein
synthesis.
A second source of potential error, particularly in the healthy volunteer
studies, has been the use of Ala+Gly as a control isonitrogenous solution against
which to compare the effects of Ala-Gin on protein synthesis. The use of this
solution has not yet been independently validated to have a neutral effect on
protein turnover and any depressive effect it may have on protein synthesis
(although no evidence for this has been reported) would lead to an overestimation
of the stimulatory effect of Ala-Gin on protein synthesis. In the studies in post¬
operative patients, carried out at a later time, the study design was modified
therefore to include the use of an 'independent' group of patients receiving TPN
alone against which to compare the effects on protein synthesis ofAla+Gly and Ala-
Gin supplementation.
The coefficients of variation of the measures of protein turnover were large,
particularly with the use of the forearm [15N]phenylalanine arteriovenous exchange
method. This was due to errors compounding in the calculations based on small
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arteriovenous differences and to the inter-individual variation in blood flow
measurements, a major component in the calculation of protein turnover by the
limb exchange method. The coefficients of variation for muscle protein synthesis
calculated from tissue enrichments in samples obtained by biopsy were lower than
those determined by the arteriovenous exchange technique. However, it may not
be valid to directly compare the results from the two techniques as the
arteriovenous exchange technique determines protein turnover at a point in time,
whereas the biopsy technique gives an integrated result during a period of time.
Also, in these studies different groups of limb muscles were studied by each
technique, i.e. mixed muscles of the forearm versus the M. tibialis anterior.
It is probable that the metabolic response to surgical injury in the patients
was variable, even though the nature of the surgical operation and anaesthesia was
similar for all patients. In order to minimise the effects of such a variable in
elucidating the effects of Ala-Gin supplementation on these patients, a further
modification was introduced to the study design for one patient group by dividing
the eight hour study period in two and using the patients as their own controls.
In using this modified approach, however, the time scale of the protocols may not
have been optimal to adequately show the effects of Ala+Gly and Ala-Gin
supplementation.
Despite these qualifications, the results show that provision of the dipeptide
Ala-Gin by the intravenous route resulted in significant rises in plasma and
intramuscular free glutamine in healthy post-absorptive man. In comparison with
a control group provided with an isonitrogenous solution of Ala+Gly, fractional
muscle protein synthesis was significantly higher in the Ala-Gin subjects, as
determined by [l-13C |leucine incorporation into muscle protein. The rate of protein
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synthesis was also higher in the Ala-Gin subjects when calculated by forearm
arteriovenous exchange of [15N]phenylalanine, although the difference was smaller.
These findings suggest a small stimulatory effect on muscle protein synthesis of
parenteral glutamine provision in dipeptide form in healthy post-absorptive man.
It is possible that the stimulation in protein synthesis was mediated by the
observed rise in the intramuscular free glutamine, although in the small group of
subjects studied no significant positive correlation was found between the
intramuscular glutamine concentration and the fractional muscle protein synthetic
rate. Further studies are required on larger subject groups to validate the above
findings and demonstrate conclusively whether any correlation exists in healthy
man between intramuscular glutamine concentration and muscle protein synthesis,
of a kind which has already previously been described in animal studies (Jepson
et al., 1988). Glutamine provision, as the dipeptide Ala-Gin, did not have any
significant effect on the rate of skeletal muscle protein breakdown, as determined
by forearm arteriovenous exchange of [15N Iphenylalanine, in contrast to the finding
in perfused rat skeletal muscle, where it has been shown to inhibit breakdown
(MacLennan et al., 1988). Also, although whole-body protein breakdown, as
determined by |I:!C [leucine and [15N]phenylalanine plasma kinetics, was lower in
the Ala-Gin subjects in comparison with the group provided with Ala+Gly, the
difference was not statistically significant.
Although the work described in chapters 3 and 4 provides for the first time
information on the relationship between glutamine provision and protein synthesis
(by direct measurement) and protein breakdown, respectively, in healthy man it is
not possible from these studies alone to draw firm general conclusions as to what
physiological role glutamine may have in modulating skeletal muscle protein
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turnover and further studies to investigate the effect of glutamine provision,
perhaps administered in a wider range of doses, in healthy man in the fed state
would seem desirable to facilitate a more complete understanding.
Major surgery resulted in a significant fall in intramuscular free glutamine
(> 50%), in keeping with previously reported findings (Vinnars et al., 1975; Fiirst
et al., 1984) inspite of the provision of parenteral nutrition in the form of a
commercially available mixture of amino acids from the first post-operative day. It
would appear therefore that conventional TPN is not capable of reversing the
expected post-operative depletion of the free intramuscular glutamine pool. Also,
fractional muscle protein synthetic rates remained depressed (in comparison to
literature values of muscle protein synthesis rates in healthy man) when patients
were studied on their third post-operative day.
Ala-Gin supplementation of conventional TPN in post-operative patients
resulted in significant rises in the plasma and intramuscular free glutamine
concentrations, in comparison (within the same group of patients) to
supplementation of TPN by an isonitrogenous control solution of Ala+Gly and also
in comparison to a separate group of patients provided conventional TPN alone.
Ala-Gin supplementation also resulted in a significant rise in the fractional muscle
protein synthetic rate, as determined by fl-iaC]leucine incorporation into tibialis
anterior muscle protein, regardless of calculation based on two different surrogate
precursor pools for leucyl-^RNA: a-ketoisocaproate and intramuscular free leucine.
The rate of protein synthesis was also significantly higher with Ala-Gin
supplementation when calculated by forearm arteriovenous exchange of
[15N Iphenylalanine, although the difference was smaller. In absolute terms, the
rates of muscle protein synthesis in this group of parenterally fed patients only just
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approached the values observed for muscle protein synthesis in the post-absorptive
healthy volunteers. This latter comparison can only be made with great care as
there are many other variables separating the two groups, including age (patients
were older) and pre-study general state of health (patients suffered from
oesophageal carcinoma). Nevertheless the present study appears to demonstrate
that although glutamine dipeptide supplementation of conventional TPN in
patients undergoing major surgery partly repletes their intramuscular glutamine
pool and raises the muscle protein synthetic rate, there may be some residual
'resistance' to a return to normal muscle protein homoeostasis inspite of what
would appear to be adequate nitrogen and energy provision.
8.2 Future work
The results of glutamine provision as Ala-Gin in healthy subjects are
intriguing and raise questions regarding the physiological basis for glutamine's role
in modulating muscle protein balance in health in man. Further work, at both
cellular and tissue level, needs to be undertaken to elucidate the mechanism(s) by
which glutamine stimulates muscle protein synthesis.
With respect to post-operative patients, in the present studies information
on whole-body breakdown only was obtained as these particular patients were
unable to tolerate our method for collection of expired breath by Douglas bag.
Further studies need to be undertaken therefore to investigate the effect ofAla-Gin
on whole-body protein turnover, using commercially available portable 'metabolic
carts' to measure C02 output accurately. In order to answer the question as to
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whether improving muscle protein balance by glutamine provision is associated
with concomitant improvement in post-operative skeletal muscle strength/function,
it would be desirable to study this separately, perhaps as part of a prospective
randomised, controlled metabolic and clinical study (see below) and establish if
there is any correlation between improved muscle protein balance and muscle
strength/function, as determined for example by dynamometry (Jeejeebhoy, 1986)
and electromyographic studies as well as respiratory function tests.
8.3 Clinical Implications
Recently, in growing recognition of the important role of glutamine in the
nutritional care of the critically ill, a number of commercially available glutamine-
enriched products for enteral feeding have become available (e.g. Alitraq, Ross
Products Division, Abbott Laboratories, England). Based on the findings of this
work, considering alone the potential benefits to skeletal muscle physiology in the
post-operative patient, it would seem that there is some evidence to support the
routine inclusion of glutamine or a glutamine dipeptide such as Ala-Gin in
commercial TPN solutions. However before this approach can be advocated, a
number of other questions regarding glutamine supplementation of TPN, such as
its effect on the immune system, would need to be answered. O'Riordain and
colleagues (O'Riordain et al., 1994), have recently investigated the role of glutamine
supplemented TPN on T-lymphocyte response in surgical patients undergoing
colorectal surgery. There was a significant rise in T-cell DNA synthesis (p<0.05)
over the pre-operative values with glycyl-glutamine dipeptide supplementation in
comparison to the group receiving conventional TPN. Interestingly, in contrast to
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earlier investigators, they additionally found no significant improvement in
nitrogen balance with glutamine supplementation. Pre- and post-operative plasma
and intra-muscular free glutamine concentrations as well as tissue and whole-body
protein turnover were not studied and patients were not assigned injury scores.
Nevertheless this study highlights the need for exercising caution in extrapolating
the findings of earlier studies on the effect of glutamine supplementation on
nitrogen balance to all catabolic patients regardless of the severity of the 'injury'.
It is possible that in this study, as the authors have suggested, the patients were
only mildly catabolic and glutamine supplementation may not have been able to
further improve their nitrogen economy as they were already in neutral nitrogen
balance. Petersson and colleagues (Petersson et al., 1994) have also recently
reported a similar finding of a failure of glutamine supplemented TPN in altering
whole-body nitrogen economy in post-operative patients undergoing elective (open)
cholecystectomy, although the post-operative decline in muscle protein synthesis
(as assessed indirectly by total ribosome concentration) observed in the control
group did not occur in the glutamine supplementation group.
In a wider context, using prospective randomised controlled clinical trials
with larger cohorts of patients, parameters such as hospital stay, complication
rates (infection, respiratory, delayed wound healing) and overall mortality and
morbidity would need to be investigated in detail to assess the likely cost-benefits
of glutamine supplementation. Such a long-term study is being undertaken by
Griffiths and colleagues on intensive care patients (Rennie, 1993). It is possible
that such general clinical studies, with a much broader outlook than allowed by the
limited scope (essentially biochemical/metabolic) of the present work, may also
reveal unexpected and untoward 'side-effects' of glutamine supplementation.
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